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Abstract 
Posttranscriptional processes increase protein diversity by expanding the 
information content of the transcriptome and thus contribute to the tremendous 
complexity of higher organisms. One widespread posttranscriptional modification is the 
selective deamination of adenosines (A) to inosines (I) in RNA. In protein-coding 
transcripts, the edited codon can alter the protein‟s amino acid sequence, which quite 
often has critical consequences on protein stability, localization, and/or functional 
properties. The production of several protein isoforms in the same cell increases 
proteome diversity from a limited number of genes. This recoding process is necessary 
for the proper development and physiological functions of higher eukaryotes, 
underscoring the importance of editing in higher organisms. The goal of this thesis was to 
identify previously unknown A-to-I RNA recoding events and characterize their 
implications for the alternative protein variants.  
Only few protein-coding RNA editing sites were known in 2006, most of which 
had been identified by chance. However, their often dramatic impact on protein function 
warranted a genome-wide search strategy to systematically identify previously unknown 
A-to-I RNA editing recoding targets and evaluate their prevalence in the human 
transcriptome. Here, we experimentally validate several novel A-to-I RNA recoding 
targets identified by bioinformatics screening methods as potential candidate sites. From 
these, we selected several targets to assess consequences of the elicited amino acid 
changes on protein function using molecular and protein biology methods tailored to the 
respective targets. We show that A-to-I RNA editing has significant and biologically 
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relevant consequences for at least one protein. Finally, we analyzed the regulatory aspects 
of A-to-I RNA editing in a specific target that is promiscuously edited in the pre-
messenger RNA, but shows no editing in the spliced, mature RNA. This thesis work 
underscores the importance of post-transcriptional A-to-I RNA editing on proteome 
diversity in higher organisms and uncovers a previously undescribed mechanism of 
regulation that opens up a new area of research. 
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1 Introduction 
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1.1 RNA versatility 
RNA may well be the most underrated biological molecule of the 20th century. 
Apart from being extensively studied for its central roles in spliceosomes and ribosomes 
during transcriptional processing and translation, respectively, it has by and large led a 
wallflower existence in the wider research community. For a long time, the main function 
of RNA was thought to be serving as intermediary between DNA and protein, facilitating 
the portability and translation of genetic information. However, this view has been 
revised in recent years and the prominence of RNA, particularly within regulatory 
networks, has started to surface (Mercer et al., 2009; Hung & Chang, 2010). In fact, RNA 
is extraordinarily well suited to serve as regulatory molecule, since it can provide both 
exquisite one-dimensional sequence-specificity and versatile tertiary structures that can 
either be recognized by proteins or have catalytic activity themselves (Hung & Chang, 
2010). RNA therefore resembles a converter of digital to analog signals, directly bridging 
two worlds, that of informational content stored in DNA and the functional output 
embodied by proteins (Kohler et al., 1993; Mattick, 2004; St Laurent & Wahlestedt, 
2007). Classic examples of RNAs with these properties are tRNAs, whose tertiary 
structures interact selectively with both aminoacyl tRNA synthetases and ribosomes, 
while specifically base-pairing to the respective codons of an mRNA. The versatility of 
functional RNAs, such as ribozymes, enables them to catalyze enzymatic reactions and 
allows for certain long non-coding RNAs (ncRNAs) to nucleate and propagate epigenetic 
silencing across chromatin (Forster & Symons, 1987; de la Pena & Garcia-Robles, 2010; 
Hung & Chang, 2010).  
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Another layer of versatility is added by the hydrolytic deamination of adenosine 
to inosine (Figure 1), or A-to-I RNA editing, of nuclear-encoded RNAs of metazoa, 
which enables a cell to change genetic information at the post-transcriptional level (Bass, 
2002). Since inosine base-pairs with cytosine, this deamination effectively results in a 
change in sequence with potential consequences for downstream events, as most enzymes 
recognize inosine as guanosine (Bass, 2002). For instance, if this sequence change takes 
place within the coding region of a pre-mRNA, it can result in a codon change which 
subsequently leads to production of a protein with a different amino acid sequence 
(Figure 2).  
The first of a number of accounts of such RNA editing recoding events was 
reported twenty years ago (Sommer et al., 1991). Fast excitatory glutamate receptor 
channels in the brain were found to contain either an arginine or a glutamine residue at a 
critical position in the channel-forming segment, with profound effects on ion flow. 
Intriguingly, the genomic sequence only encoded a glutamine, and thus the research 
Figure 1: Adenosine-to-inosine RNA editing 
Hydrolytic deamination of adenosine yields inosine. Inosine forms Watson–Crick 
base-pairing with cytidine, analogous to guanosine and inosine appears as a 
guanosine in cloned cDNA. Figure from Godfried Sie & Kuchka, 2011. 
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group proposed the existence of an RNA editing machinery that modifies the glutamine 
to an arginine codon. This was confirmed when a previously identified protein with 
„double-stranded (ds) RNA unwinding activity‟ (Bass & Weintraub, 1987) was found to 
have deaminase activity and was therefore named adenosine deaminase acting on RNA 
(ADAR1) (Kim & Nishikura, 1993). A homologue was later cloned (Melcher et al., 
1996), and termed ADAR2. ADAR3 and TENR (testis nuclear RNA binding protein) 
complete the family in humans. However, ADAR3, which is solely expressed in the 
brain, and TENR, expressed exclusively in testis and essential for proper spermatogenesis 
(Connolly et al., 2005), do not seem to have deaminase activity (Chen et al., 2000).  
  
Figure 2: Schematic representation of the flow of genetic information and RNA 
editing  
Double-stranded structures of a certain length formed by RNA (shown here is pre-
mRNA) are potential substrates for the enzymes mediating A-to-I RNA editing, the 
ADAR family of proteins. 
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1.2 ADARs 
1.2.1 ADAR family members are essential for higher organisms 
All types of RNA transcripts can be subject to modification by A-to-I editing, 
which converts adenosine (A) to inosine (I) through hydrolytic deamination in double-
stranded RNA (dsRNA). Inosine preferentially base-pairs with cytidine and is thus 
interpreted as guanosine in most cases (Figure 1). Consequently, editing provides a 
means by which cells can manipulate primary sequence readouts as well as higher order 
RNA structures. Editing is catalyzed by members of the ADAR family of proteins, which 
are found in most metazoans, but have not been detected in plants, yeast, and fungi (Jin et 
al., 2009). There are four ADAR family members in mammals (ADAR1-3 and TENR = 
testis nuclear RNA binding protein), one in Drosophila (dADAR) and two in 
Caenorhabditis elegans (adr-1 and adr-2). ADAR deficiencies lead to a wide range of 
phenotypes, particularly with effects on functions of the central nervous system, which 
underlines their importance for proper development and behavior in different species. 
The dADAR
–/–
 Drosophila show incapacitated coordination of locomotion and abnormal 
behavior (Palladino et al., 2000). Homozygous deletion of ADARs in C. elegans results 
in defective chemotaxis (Tonkin et al., 2002). ADAR2
–/–
 mice die within three weeks 
post natum, after repeated episodes of epileptic seizures (Higuchi et al., 2000), and 
ADAR1
–/–
 mice have an embryonically lethal phenotype associated with liver 
disintegration and defects in hematopoiesis (Wang et al., 2000; Hartner et al., 2004; 
Hartner et al., 2009; XuFeng et al., 2009). 
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1.2.2 ADAR domain structure  
All ADARs share a similar domain structure, with one to three double-stranded 
RNA binding motifs (DRBMs) and a C-terminal deaminase domain (Figure 4). However, 
of the four mammalian ADAR family members, only ADAR1 and ADAR2 have a 
catalytically active deaminase, while ADAR3 and TENR (also called ADAD1 = 
adenosine deaminase domain containing 1) are presumed to be deamination deficient as 
catalytically critical residues are not conserved and the enzymes are unable to modify any 
of the known substrates (Lai et al., 1995; Mian et al., 1998; Chen et al., 2000). 
Sometimes ADAR1 and ADAR2 have overlapping target-specificity, but more often an 
adenosine within a given sequence is primarily edited by one or the other (Lehmann & 
Bass, 2000; Wong et al., 2001). Preliminary evidence suggested that this target-
specificity can mostly be credited to the respective deaminase domains (Wong et al., 
2001). However, editing specificity is mediated to a considerable extent also by the 
DRBMs, as shown by hydroxyl radical footprinting (Yi-Brunozzi et al., 2001; Stephens 
et al., 2004) and recently confirmed by the crystal structure of DRBMs 1 and 2 of 
ADAR2 bound to a pre-mRNA target (Stefl et al., 2010). There are at least two types of 
ADAR substrates – dsRNAs of 50 or more base pairs that are promiscuously edited, and 
partially double-stranded RNAs with loops and bulges that are edited at specific 
adenosines only (Lehmann & Bass, 1999; Bass, 2002). In the former, nonspecific editing 
occurs because ADARs bind long dsRNA via their DRBMs without sequence preference. 
The presence of loops and bulges in the dsRNA, conversely, mediates the defined 
positioning of the active site on the substrate through sequence-specific interactions of 
the DRBMs and provides for precise targeting of one or few adenosines within the 
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tertiary RNA structure (Enstero et al., 2009; Stefl et al., 2010). Thus, DRBMs and active 
sites unite to promote exquisitely controlled editing in some contexts, while allowing 
promiscuous editing in others.  
Both deaminase domains and DRBMs contribute to preferences for certain 
nucleotides that adjoin the edited adenosine. Such nearest-neighbor preferences were first 
observed in editing of Alu repeat elements (Athanasiadis et al., 2004) and were 
subsequently analyzed in a more quantitative manner (Lehmann & Bass, 2000; Dawson 
et al., 2004; Eggington et al., 2011). Nearest-neighbor preferences of human ADAR1 and 
ADAR2 are shown in Figure 3. 
 
1.2.3 Regulation of ADARs 
Our understanding of how ADAR activity is regulated is still incomplete, but new 
findings continue to paint an increasingly complex picture. ADARs are expressed in a 
large number of tissues but editing is most abundant in the central nervous system (CNS) 
(Paul & Bass, 1998). ADAR expression and editing activity are regulated in a tight 
spatio-temporal manner and generally increase during development (Rula et al., 2008; 
Figure 3: Nearest-neighbor preferences of 
human ADAR1 and ADAR2 
Schematic displaying enriched bases above 
top line and depleted bases below bottom line 
on both sides of the central edited adenosine 
determined among 406 adenosines. Level of 
enrichment/depletion shown by letter heights 
with reference to scale on the left. Figure 
taken and adapted from Eggington et al., 
2011.  
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Jacobs et al., 2009; Wahlstedt et al., 2009). On the other hand, a decrease of editing is 
seen in specific subsets of ADAR targets during differentiation of human embryonic stem 
cells into the neural lineage (Osenberg et al., 2010). Several lines of evidence thus point 
toward complex and precise regulation of editing. 
Drosophila expresses different ADAR isoforms through alternative splicing of 
one ADAR transcript. Substrate dsRNA induces cooperative interaction between two 
dADAR monomers to promote dimerization and heterodimerization of different dADAR 
isoforms, which affects editing efficiency (Gallo et al., 2003). Homodimerization of 
ADAR1 or ADAR2 in human is also required for enzymatic activity (Cho et al., 2003), 
but heterodimerization between ADAR1 and ADAR2 was not detected. However, this 
analysis did not take into account heterodimerization between alternative splice isoforms 
of ADAR1 and ADAR2, respectively (Figure 4), creating a possible regulatory 
mechanism that remains to be explored. 
Transcription from alternative promoters leads to the expression of variant ADAR 
isoforms, as indicated in Figure 4. Aside from allowing regulation of protein levels in 
response to external stimuli, transcription from alternative promoters can result in 
different translation start sites and produce proteins with additional domains and/or 
untranslated regions (UTRs). ADAR1, for example, exists in two isoforms. The 
constitutive ADAR1p110 harbors a nuclear localization signal (NLS) within the DRBM3 
and is thus mostly nuclear (Eckmann et al., 2001). In contrast, ADAR1p150 is 
transcribed from an interferon-inducible promoter (George & Samuel, 1999b, a; George 
et al., 2008) and not only contains an additional Z-DNA binding domain, but also a 
nuclear export signal (NES), which allows its nucleocytoplasmic shuttling (Eckmann et 
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al., 2001; Poulsen et al., 2001; Strehblow et al., 2002; Fritz et al., 2009). Of course, both 
alterations in functional domains and cellular localization allow ADARs to access 
different sets of substrates, and so it is believed that the main targets of ADAR1p150 are 
dsRNA from viral infections present in the cytoplasm (Samuel, 2011). Furthermore, 
Figure 4: Adenosine Deaminases acting on RNA family of proteins 
Hydrolytic deamination of adenosines is catalyzed by the ADAR family of proteins. 
ADARs are probably regulated on many different levels such as use of alternative 
promoters, alternative splicing, regulation of sub-cellular localization, and post-
transcriptional modifications. ADAR2 is known to edit its own transcripts in a 
negative feedback loop. The deaminase domains of ADAR3 and TENR are believed to 
be non-functional as positions important for catalytic activity are not conserved 
(Chen et al., 2000; Saunders & Barber, 2003). For more detailed information, see 
text. Abbreviations: Z and Z Z-DNA binding domains; R1-R3, double-stranded 
RNA binding motifs; NES, nuclear export signal; NLS, nuclear localization signal; 
NoLS, nucleolar localization signal; Sumo, sumoylation site; P, phosphorylation site; 
AluJ, AluJ alternative cassette; NLS
#
 overlaps with NoLS. Figure from Godfried Sie 
& Kuchka, 2011. 
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ADAR1 dynamically associates with the nucleolus due to the presence of a nucleolar 
localization signal (NoLS), which overlaps with the NLS (Desterro et al., 2003).  
Besides subcellular localization, ADAR1 is likely regulated on a number of 
additional levels as well. Alternative splicing of ADAR1 leads to differential spacing 
between DRBMs and the deaminase domains (marked with an asterisk * in Figure 4), 
potentially altering target specificity and/or activity of homodimers. Post-translational 
modifications also play a role as sumoylation of K418 reduces editing activity, possibly 
due to stereochemical inhibition of dimerization (Desterro et al., 2005). And finally, 
ADAR1 has several phosphorylation sites, but their functional relevance is currently 
unknown.  
ADAR2 is apparently also subjected to regulation on multiple levels, which is not 
yet fully understood. Two autoinhibitory mechanisms allow partial regulation of enzyme 
activity. First, the N-terminal DRBM ensures binding of ADAR2 to dsRNA of a certain 
length by inhibiting binding to shorter dsRNAs that cannot accommodate interactions 
with both DRBMs (Macbeth et al., 2004). Second, ADAR2 editing of its own pre-mRNA 
creates a 3-acceptor site, adding a 47 nucleotide insertion to the 5‟ end of the second 
coding exon. This leads to a frameshift and the creation of a premature termination 
codon, providing for a negative autoregulatory mechanism (Rueter et al., 1999). 
Additional regulatory mechanisms include alternative splicing, which results in the 
insertion of an AluJ cassette into the deaminase domain, reducing enzyme activity 
approximately two-fold (Gerber et al., 1997). Use of an alternative promoter extends the 
N-terminus with a NLS, which may also function as single-stranded (ss)RNA binding 
domain  (Maas & Gommans, 2009). ADAR2 is primarily nuclear and like ADAR1 
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dynamically associates with the nucleolus due to the presence of a NoLS (Desterro et al., 
2003). One phosphorylation site with unknown function is present. Considering the 
controlled spatio-temporal regulation, tissue-specificity, and responsiveness to 
environmental cues, ADAR activity must undergo tight regulation.  
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1.3 Consequences of editing 
1.3.1 Pre-mRNA editing in coding sequences 
As mentioned earlier, site-specific editing in coding regions was first discovered 
in brain-specific mRNAs, where the resulting codon changes lead to the expression of 
protein isoforms with altered amino acid sequences, as inosine is interpreted as guanosine 
by the translational machinery (Sommer et al., 1991; Burns et al., 1997; Berg et al., 
2001). One editing site of the glutamate receptor 2 (GluR2) changes a glutamine to an 
arginine codon (Q/R site), which renders the channel Ca
2+
-impermeable (Sommer et al., 
1991). This is also the only site known to date to undergo 100% editing in mammals. In 
fact, the lethal ADAR2
–/–
 phenotype has been entirely ascribed to the lack of editing at 
the GluR2 Q/R site (Higuchi et al., 2000). Another thoroughly studied editing target is 
the G-protein coupled serotonin receptor (5HT2cR), where editing occurs at five 
adenosines that change the coding of three amino acids. These are located in the second 
intracellular loop, important for receptor activity, and the combinatorial editing of these 
five adenosines alters G-protein interaction, agonist affinity, and receptor trafficking 
(Burns et al., 1997; Herrick-Davis et al., 1999; Berg et al., 2001; Marion et al., 2004). 
Glutamate and serotonin receptor pre-mRNA editing have been extensively 
studied, but much still needs to be learned about the regulation and consequences of 
editing in these complex targets. The profound effects of editing on the functions of these 
two exemplary frontrunners have inspired the intensive search for additional recoding 
sites (Clutterbuck et al., 2005; Eisenberg et al., 2005a; Levanon et al., 2005; Gommans et 
al., 2008; Li et al., 2009).  
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The most recent recoding target for which a functional consequence has been 
established is NEIL1. NEIL1 is a DNA repair enzyme that catalyzes the cleavage of 
oxidized base lesions (David et al., 2007). It can remove a wide array of modified DNA 
bases that arise from oxidative stress during inflammation, radiation, or after exposure to 
toxic agents and endogenous metabolic activity (Neeley & Essigmann, 2006). NEIL1 was 
found to be edited, changing codon 242 from lysine (K) to arginine (R) (Li et al., 2009). 
The recoding site is located in its lesion recognition loop. Indeed, the two variants of the 
NEIL1 protein have distinct enzymatic properties with changes observed for both 
glycosylase activity and lesion specificity (Yeo et al., 2010). Most notably, NEIL1 
mRNA recoding is regulated by interferon through upregulation of ADAR1, suggesting a 
unique regulatory mechanism for DNA repair.  
Only few examples of edited targets that produce an alteration in protein function 
are known (Table 1). A comprehensive list of all currently known recoding targets has 
recently been discussed by Pullirsch and Jantsch (Pullirsch & Jantsch, 2010). Recoding 
editing sites that are edited to high levels are relatively rare. In many cases, however, 
editing seems to occur at low levels. This speculation was based on limited dataset 
analyses, and has recently been more strongly substantiated by deep-sequencing results 
(Clutterbuck et al., 2005; Levanon et al., 2005; Gommans, 2008; Li et al., 2009; Pullirsch 
& Jantsch, 2010). It has been proposed that editing of many targets at low levels may 
provide a mechanism for the continuous probing of potentially advantageous editing 
events, without compromising the genomic information content (Gommans et al., 2009). 
Such a mechanism would manifest itself in the observed low levels of editing in many 
transcripts. The fluctuating nature of pre-mRNA secondary structure may allow such  
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continuous probing of potentially beneficial editing sites. Accordingly, an editing event 
could become engraved if it conferred an adaptive advantage under a given selection 
pressure, and only then would be edited at relatively high levels (Gommans et al., 2009).  
Table 1: Editing events leading to codon changes 
List of editing events that lead to codon changes and where a functional impact has 
been determined. Table from Godfried Sie & Kuchka, 2011. 
Gene 
name 
Function AA change Functional impact of 
editing 
References 
GluR-2 Glutamate-gated 
ion channel 
subunit 2 
Q606R,  
R763G 
Decreased Ca
2+
 
permeability (Q606R); 
faster recovery from 
desensitization (R763G) 
(Sommer et al., 
1991; Lomeli et 
al., 1994) 
GluR-3 Glutamate-gated 
ion channel 
subunit 3 
R775G Faster recovery from 
desensitization 
(Lomeli et al., 
1994) 
GluR-4 Glutamate-gated 
ion channel 
subunit 4 
R765G Faster recovery from 
desensitization 
(Lomeli et al., 
1994) 
GluR-5 Glutamate-gated 
ion channel 
subunit 5 
Q621R Variation in ion 
permeability 
(Sommer et al., 
1991) 
GluR-6 Glutamate-gated 
ion channel 
subunit 6 
I567V,  
Y571C,  
Q621R 
Q621R: increased Ca
2+
 
permeability if I/V and 
Y/C are edited. 
(Sommer et al., 
1991) 
5HT2cR G-protein 
coupled 
serotonin 
receptor 
I156V/M,  
N158S/D/G,  
I160V 
Altered G-protein 
coupling, agonist 
affinity, receptor 
trafficking 
(Burns et al., 
1997) 
 
KCNA1 Voltage-gated  
potassium 
channel 
I400V Increased recovery rate 
from inactivation 
(Bhalla et al., 
2004) 
Gabra-3 -aminobutyric 
acid gated 
chloride channel 
subunit 
I342M Altered receptor 
sensitivity and 
deactivation rate  
(Rula et al., 
2008; Nimmich 
et al., 2009) 
ADAR2 Adenosine 
deaminase 
acting on RNA 
creates 3‟ 
splice 
acceptor site 
in intron 
Frameshift, premature 
termination codon, 
negative feedback 
(Rueter et al., 
1999) 
NEIL1 DNA repair 
enzyme 
K242R Changes lesion 
specificity  
(Li et al., 2009; 
Yeo et al., 2010) 
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The observed tissue-specificity (He et al., 2011), developmental regulation 
(Wahlstedt et al., 2009) and responsiveness to certain environmental cues (Gan et al., 
2006; Yeo et al., 2010) may be a further impediment to arrive at a better appreciation of  
the prevalence of recoding editing events that have functional consequences for the 
resulting protein variant(s). However, the impact of editing on the regulation and 
functionality of known targets calls for efforts to uncover novel recoding editing sites on 
a genome-wide scale. The vastness of the transcribed genome makes such an undertaking 
the literal equivalent of searching for a needle in the haystack and thus necessitates a 
systematic and well-directed approach. Our laboratory employed such a systematic 
search and was able to find new editing recoding sites, as discussed in Chapters 2 and 3. 
1.3.2 Pre-mRNA editing in non-coding sequences 
While the number of high-level, site-selective recoding editing sites appears to be 
relatively low, bioinformatic screenings of human sequence databases have revealed that 
most (>85%) pre-mRNAs are edited at least at one position. However, in primates the 
bulk of editing takes place in Alu repeat elements within introns and untranslated regions 
(UTRs) (Athanasiadis et al., 2004; Blow et al., 2004; Kim et al., 2004; Levanon et al., 
2004). Alu elements belong to the short interspersed nuclear elements (SINE) family of 
transposable elements and comprise about 10% of the human genome (International 
Human Genome Sequencing Consortium, 2004). They are approximately 300 nucleotides 
long and are found in gene rich regions. Due to their high copy number, they are often 
present multiple times in one transcript, sometimes in opposite orientation to one another. 
Alu elements have a conserved sequence owing to their relatively recent expansion in the 
primate genome (Batzer & Deininger, 2002). Therefore, transcribed oppositely oriented 
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Alu elements form long dsRNA structures and are potent substrates for ADARs and are 
edited promiscuously, i.e. at multiple adenosines within the dsRNA structure. Alu 
elements appear to be evolutionarily important for primates, especially in conjunction 
with A-to-I RNA editing (Eisenberg et al., 2005b; Hasler & Strub, 2006; Hasler et al., 
2007; Chen & Carmichael, 2008; Mattick & Mehler, 2008). This notion has been 
supported by the finding that editing can lead to the exonization of an Alu element by 
changing an AA dinucleotide into an AG 3 acceptor splice site (Lev-Maor et al., 2007; 
Moller-Krull et al., 2008).  
RNA editing in introns and UTRs also appears to affect transcripts in other ways, 
such as retention in the nucleus, altered stability, and inhibition of transcription and 
translation, although conflicting results foretell multi-layered regulatory mechanisms 
involved in determining the fate of inosine-containing pre-mRNAs (Zhang & 
Carmichael, 2001; Prasanth et al., 2005; Scadden & Smith, 2001; Chen et al., 2008; 
Scadden, 2007; Chen et al., 2008; Hundley & Bass, 2010; Morse & Bass, 1999; Hundley 
et al., 2008).  
Evidently, A-to-I RNA editing has been shown to effectuate a wide range of 
consequences for pre-mRNAs, and it is expected that additional functions remain to be 
discovered. Figure 5 summarizes known and potential ways A-to-I RNA editing may 
influence pre-mRNA fate.  
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Figure 5: Possible effects 
of editing on pre-mRNA 
Effects which have been 
demonstrated in vivo are 
underlined (for references 
see text), while the other 
indicated consequences 
are hypothetical 
(Godfried Sie & Kuchka, 
2011). 
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1.4 Editing and the microRNA pathway, a lesson about impact of 
editing on RNA fate 
MicroRNAs (miRNAs) are a class of small non-coding RNAs of approximately 
22 nucleotide length. A single miRNA can regulate the expression of dozens or even 
hundreds of genes by repressing translation or promoting transcript destabilization 
(Djuranovic et al., 2011). MiRNAs have important roles in development, differentiation, 
proliferation, and apoptosis. The miRNA database [www.mirbase.org (Griffiths-Jones et 
al., 2008)] currently reports 1424 miRNAs in human, which together regulate thousands 
of protein-coding genes (Friedman et al., 2009). MiRNAs are usually produced from long 
primary miRNAs (pri-miRNAs) by two processive steps (for review see Bartel, 2004). In 
the nucleus, a protein complex containing Drosha and DGCR8 recognizes characteristic 
hairpin structures within the pri-miRNAs and cleaves them at the base, resulting in stem-
loop precursor miRNAs (pre-miRNAs) of about 70 nucleotide length. Pre-miRNAs are 
transported by exportin-5 and RanGTP into the cytoplasm, where they are further 
processed by the Dicer/TRBP-containing protein complex into 22-bp miRNA/miRNA 
duplexes consisting of 5 (miR-5p) and 3 strands (miR-3p). The strand of the duplex with 
lower base-pairing stability at the 5-end selectively associates with one of the Argonaute 
(AGO) proteins, which are part of the multi-protein microRNA-induced silencing 
complex (miRISC). The charged miRISC complexes are guided by the seven nucleotide 
“seed” region of the miRNA located at its 5-end to partially complementary sequences 
most commonly located in the 3-UTRs of target mRNAs, where they direct translational 
repression and/or mRNA degradation (Djuranovic et al., 2011). Transcriptional 
regulation can only partly determine miRNA levels, as pri-miRNAs are often transcribed 
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in clusters or as part of introns and UTRs of protein-coding genes. Their expression is 
therefore governed by the promoter activity of other genes (Baskerville & Bartel, 2005; 
Miyoshi et al., 2010). The multi-step maturation path provides several focal points where 
regulatory mechanisms find leverage to stop or divert production, and/or adjust the 
amount of final product (Slezak-Prochazka et al., 2010). 
The stem–loop structures of both pri- and pre-miRNAs are targets for editing. Pri-
miRNAs have been shown to undergo editing, often at more than one adenosine (Luciano 
et al., 2004; Yang et al., 2006; Kawahara et al., 2007a; Kawahara et al., 2007b; Kawahara 
et al., 2008). Yang and coworkers analyzed editing in eight randomly chosen pri-
miRNAs, and found that four were edited. Notably, editing at two adenosines close to the 
Drosha cleavage site (positions +4 and +5 from the 5-end of pri-miR-142) inhibits 
processing of pri- to pre-miR-142. Inhibition also occurs when these positions are 
mutated to guanosines, showing that Drosha/DGCR8 recognizes AG and AI changes 
alike. Surprisingly, the authors could not detect an increase of edited pri-miR-142 in this 
cell culture system, but pri-miR-142 with adenosines mutated to guanosines accumulated. 
Therefore, inosine-containing pri-miR-142 RNAs are short-lived, whereas pre-edited pri-
miR-142 (with guanosines at positions +4 and +5) is stable and accumulates. Tudor-
staphylococcal nuclease (Tudor-SN) has been identified as a ribonuclease, or a critical 
component thereof, that is specific to inosine-containing dsRNA in vitro (Scadden & 
Smith, 1997; Scadden, 2005). Higher levels of editing in pri-miR-142 render them 
progressively sensitive to Tudor-SN, and as such edited pri-miR-142 accumulates in cells 
treated with a Tudor-SN specific inhibitor. Moreover, endogenous miR-142 levels are 
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increased in ADAR null mice, underscoring that ADAR activity significantly modulates 
proper miR-142 output. 
Drosha cleavage is not the only miRNA biosynthesis step that can be modulated 
by editing. Editing in pri-miR-151 at a position close to the Dicer cleavage site is 
accomplished in a tissue-specific manner (Kawahara et al., 2007a). Detailed analysis of 
the editing levels in human pri-, pre-, and mature miR-151 revealed that in this case, 
processing by Dicer, but not Drosha, is inhibited by editing of miR-151 precursors. 
Unlike inosine-containing pri-miR-142, high levels of editing are detected in pre-miR-
151, indicating that the presence of inosine in pre-miR-151 does not render it unstable, in 
contrast to what happens to pri-miR-142. 
A systematic interrogation of editing of known pri-miRNA across different tissues 
was first performed by Blow et al. (Blow et al., 2006). Medium to high (10-70%) levels 
of editing that varied across tissues were observed in six out of 99 analyzed pri-miRNAs. 
The authors caution that low editing levels escape detection by their analysis, and thus 
their findings may underestimate the number of edited pri-miRNAs. Another study found 
that 16% (47 of 209) of pri-miRNA in human brain are edited to 10-100% at 86 sites 
(Kawahara et al., 2008). Editing in the seed sequences of mature miRNA was only 
detected in four cases. It was observed that the fraction of edited miRNA is lower than 
that of edited pri-miRNA. This reveals that editing almost always inhibits miRNA 
maturation, which was confirmed by in vitro processing analysis of a subset of edited pri-
miRNA. Interestingly, in two of the six analyzed pri-miRNAs, editing increases Drosha 
cleavage rate as much as twofold, thus promoting processing. 
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Deep sequencing studies corroborate the findings that editing can rarely be 
detected in mature miRNAs (Schulte et al., 2010). In just one case so far it has been 
shown that editing can change the target specificity of a miRNA: ADAR2 re-directs the 
edited miR-376a2-5p to a different set of targets. At the same time ADAR2 binding to 
pri-miR-376a2 also specifically competes with Drosha processing, independent of its 
editing activity (Heale et al., 2009). Predominantly, however, ADARs seem to modulate 
miRNA biogenesis and steady-state levels. The fact that 16% of pri-miRNAs are edited 
demonstrates the relevance of posttranscriptional A-to-I modification on miRNA-based 
silencing in human. This impact may be extended even further when considering that 
binding alone of pri- or pre-miRNAs by ADAR, without the actual editing event taking 
place, can interfere with Drosha or Dicer processing due to substrate competition. 
Deaminase-independent effects and degradation of inosine-containing RNAs thus 
probably further increase the percentage of miRNAs affected by ADARs compared to 
what has been reported so far. 
Taken together, since editing of miRNA precursors can modulate miRNA fate, it 
thus functions as a regulatory step in the miRNA pathway. Editing can have one of 
several effects on the quality and/or quantity of the functional mature miRNA. Working 
on a case-by-case basis, editing can either lead to destabilization and degradation of pri-
miRNA by Tudor-SN, inhibition or promotion of cleavage by Dicer or Drosha, change of 
strand-selection or re-direction to a distinct set of target mRNAs. Furthermore, binding of 
ADAR alone can interfere with the components of the miRNA pathway and thus affect 
miRNA levels. 
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1.5 Biocomputational analysis methods for the identification of novel 
A-to-I RNA editing targets 
As discussed, ADAR binding and editing can have a strong impact on the fate and 
functionality of diverse RNA species and/or the resulting proteins. This thesis work 
focuses on examples of editing that lead to non-synonymous codon changes in protein-
coding transcripts, so-called recoding events. A number of reasons contribute to the 
elusiveness of A-to-I RNA recoding events. First, there is no primary sequence signature 
that is targeted by ADARs. In fact, recognition primarily relies on intramolecular double-
stranded secondary structure of RNA, which is formed between partially complementary 
sequences that may be several kilobases apart. Second, comparison of annotated mRNA 
or EST sequence data with the genomic counterpart identifies A/G discrepancies (inosine 
appears as a guanosine in cloned cDNA). However, these may also be due to genomically 
encoded SNPs. Third, editing has in many cases been shown to be tissue-specific and 
temporally regulated and thus may evade identification due to limitations in the sampling 
spectrum. The first recoding events were all chance discoveries. Yet, the significant 
impact on the affected proteins of non-synonymous amino acid changes attributable to 
editing justify a more systematic and directional approach to uncover further editing 
events that lead to recoding. Advances on different fronts have made it possible to 
attempt such studies: the complete sequencing of the human genome and the collection of 
a vast amount of expression data provide the basis for genome-wide analysis (Lander et 
al., 2001; International Human Genome Sequencing Consortium, 2004); the speed of data 
processing achieved in recent years by advancements in computer technology grants the 
necessary horse-power to plow through immense databases at a manageable rate; and the 
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accumulation of data for the statistical analysis of the inclinations of ADARs toward 
certain sequence signatures such as nearest-neighbor preferences may streamline the 
biocomputational analyses sufficiently to achieve a viable signal-to noise ratio in the 
predictions, enabling the discovery of novel A-to-I RNA editing recoding targets. 
Furthermore, with the ever-increasing amount of data available from a number of species, 
it is possible to analyze conservation of potential editing target sites and, most 
importantly, the partially complementary sequence often present in adjoining introns, the 
so-called editing complementary sequence (ECS). High conservation of sequences within 
introns suggests the presence of functional information, which could be due to 
conservation of an ECS in order for the transcript to retain the capacity of being 
recognized by ADARs.  
Double-strandedness is an essential feature for ADAR-targets; however, other 
determinants are less well defined, which makes the search for site-selective editing 
targets particularly elusive (Seeburg, 2002). Notwithstanding, several groups attempted to 
identify novel editing targets in coding regions either experimentally (Ohlson et al., 2005; 
Pokharel & Beal, 2006) or by first scanning the human genome database in search of 
candidate genes and then verifying in vivo targets experimentally (Blow et al., 2004; 
Bundschuh, 2004; Levanon et al., 2004; Clutterbuck et al., 2005; Eisenberg et al., 2005a; 
Levanon et al., 2005). Alas, these screens missed several of the already known targets, 
reflecting the difficulty of the task. Furthermore, the candidate lists overlap little between 
studies and there was invariably a high background with only few novel bona fide editing 
targets actually being discovered. The bioinformatics approaches apply algorithms that 
allow filtering of the candidate genes to exclude genomically encoded SNPs and zero in 
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on true editing targets. ADARs show some selectivity with respect to nearest neighbor 
nucleotides and, of course, the ability of the RNA to form double-stranded structures of a 
certain length. This permits, on the one hand, the reduction of the number of candidate 
genes in the output list and, on the other hand, the ranking of the remaining putative 
targets as true in vivo substrates for ADARs. However, even though novel targets were 
found using strategic approaches, the significant amount of work invested does not seem 
to justify the low success rate. Alternative and more versatile algorithms with learning 
capabilities may be required for a systematic and directional approach for the 
identification of novel recoding events. One avenue exploring such an approach was 
implemented by our lab and is discussed in Chapters 2 and 3. 
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1.6 Identification and characterization of site-directed A-to-I RNA 
editing targets 
The specific aims outlined at the beginning of the thesis research were aimed at 
answering two questions. First, can we identify previously unknown recoding editing 
events using algorithms based on the cumulative predictive force of known features of 
such recoding events? Second, do specific recoding events have functional consequences 
for the resulting protein isoforms(s)?  
Our lab employed a two-stage approach in an effort to identify novel ADAR 
targets to answer the first question. In a pilot-study outlined in Chapter 2, we 
implemented and experimentally validated a filter algorithm that allowed for the 
identification of recoding editing within a subset of human genes, those present in the 
SNP database. This search algorithm was then used as basic principle in a fully 
automated computer program that allowed for a genome-wide analysis, as discussed in 
Chapter 3. Again, we were able to identify previously undetected A-to-I RNA editing 
events, validating and corroborating the basic principle of the approach. Such a global 
analysis, coupled with high-throughput sequencing technology to analyze different 
tissues and developmental time points, could greatly advance our understanding of the 
extent and prevalence of the “inosinome”. 
Three A-to-I RNA editing targets were then selected to determine whether the 
elicited codon change(s) have consequences on protein function in these cases. Several 
tools were employed to answer this question. For example, evolutionary conservation is a 
strong indication for the relevance of a recoding event in terms of functionality. Tissue-
specific regulation of editing levels may be yet be another sign of additional capacity that 
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editing confers upon a certain target. And finally, well-directed functional protein assays 
based on information reported in the literature about the protein can directly answer 
whether an editing event is likely to be physiologically relevant or not. In Chapter 4, the 
evolutionary conservation of A-to-I RNA editing of the Complement component 1, q 
subcomponent-like 1 (C1QL1) mRNA was assessed by analyzing the predicted RNA 
folds and editing in diverse species. In Chapter 5, we discuss functional effects editing 
could have on FilaminA (FLNA). Editing in this target has previously been shown to be 
evolutionary conserved. Here we analyzed the effect of editing on the protein-binding 
capacity of FLNA. And in Chapter 6 we characterized both evolutionary conservation 
and tissue-specificity of editing of insulin-like growth factor binding protein 7 (IGFBP7). 
This study was complemented by a functional protein assay that showed differences in 
proteolytic processing of IGFBP7 editing isoforms with possibly significant 
physiological effects. The characterization of these A-to-I RNA editing targets showed 
that editing has an effect on protein function, possibly with dramatic consequences in 
vivo. 
Finally, the predicted candidate ranked highest in the genome-wide analysis 
screen (Chapter 3) was shown not to be edited. Based on our current knowledge of 
editing targets, this observation was intriguing. In fact, the lack of editing in this Serpin 
peptidase inhibitor clade A, member 3 (SerpinA3) presented an opportunity to unveil 
possible regulatory mechanisms that prevent editing, a question that has heretofore not 
been addressed in the literature. We therefore sought to better understand the reasons for 
the lack of editing in this highly predicted target using minigene constructs and 
appropriate editing assays and concluded that editing does occur, yet it affects pre-mRNA 
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stability. This finding is unanticipated and opens new doors through which we can pursue 
to enhance our understanding on regulatory mechanisms that intersect with and modulate 
the A-to-I RNA editing pathway.  
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2 Screening of human SNP database identifies 
recoding sites of A-to-I RNA editing 
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2.1 Abstract 
Single nucleotide polymorphisms (SNPs) are DNA sequence variations that can 
affect the expression or function of genes. As a result, they may lead to phenotypic 
differences between individuals, such as susceptibility to disease, response to 
medications, and disease progression. Millions of SNPs have been mapped within the 
human genome providing a rich resource for genetic variation studies. Adenosine-to-
inosine RNA editing also leads to the production of RNA and protein sequence variants, 
but acts on the level of primary gene transcripts. Sequence variations due to RNA editing 
may be mis-annotated as SNPs if this annotation is based solely on expressed sequence 
data instead of genomic material. In this study, the human SNP database was screened for 
potential cases of A-to-I RNA editing that cause amino acid changes in the encoded 
protein. The search strategy scores candidate sites with regard to five molecular features 
displayed by known editing sites. It identifies all previously known cases of editing 
present in the SNP database and successfully uncovers novel, bona fide targets of 
adenosine deamination. Our approach sets the stage for effective and comprehensive 
genome-wide screens for A-to-I editing targets. 
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2.2 Introduction 
This chapter is part of the publications by Gommans, W.M. et al, RNA (2008), 
14:2074–2085, describing a study undertaken by our lab, and Sie, C.P. and Maas, S. 
FEBS Letters (2009) (Gommans et al., 2008; Sie & Maas, 2009). At the time of the study, 
the total number of single nucleotide polymorphisms (SNPs) reported in public databases 
exceeded 9 million (Sherry et al., 2001), making SNPs the most frequently occurring 
genetic variation in the human genome, appearing every 100 to 300 bases in coding and 
non-coding regions of the genome. SNPs are DNA sequence variations that occur when a 
single nucleotide in the genome sequence differs between members of a biological 
species. For a variation to be considered a SNP, it must occur in at least 1% of the 
population. Many SNPs have no effect on cell function, but some are important 
molecular markers that link sequence variations to phenotypic differences. The 
characterization of these SNPs advances the understanding of human physiology and the 
molecular bases of diseases (Taylor et al. 2001). Furthermore, SNPs that involve an 
amino acid change (recoding SNPs) are of interest for clinicians and researchers, since 
they often strongly influence the function of the resulting gene product.  
It is imperative to distinguish DNA-based single nucleotide variations (true SNPs) 
from sequence alterations in gene products (RNA or protein) caused by editing events. 
SNPs are generally annotated based on the sequence analysis of chromosomal DNA from 
many individuals and subsequent determination of the ratio of the alleles within the 
population for each site. However, among the millions of validated genomic SNPs, some 
polymorphisms have been annotated based solely on the analysis of expressed sequences 
derived from mRNA (Buetow et al., 1999; Irizarry et al., 2000). In the absence of 
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additional genomic confirmation, it is possible that such sequence variations may not 
represent true SNPs, but instead are a result of RNA editing. Indeed, a few previously 
annotated SNPs located within non-coding sequences were recently shown to be single 
nucleotide sequence variations caused by RNA editing (Eisenberg et al., 2005a). 
Eisenberg and co-authors identified these editing sites because they coincide with Alu 
repeat elements that had previously been shown to undergo RNA editing at other 
positions (Athanasiadis et al., 2004; Kim et al., 2004; Levanon et al., 2004).  
In contrast to thousands of editing sites identified in Alu repeat elements (see 
“1.3.2: Pre-mRNA editing in non-coding sequences”), only a small number of site-
selective recoding events are known (Pullirsch & Jantsch, 2010), most of which were 
identified serendipitously. Only few cases of recoding in mammals were found through 
bioinformatics-driven approaches (Clutterbuck et al., 2005; Levanon et al., 2005; Ohlson 
et al., 2007). However, a major limitation of systematic searches for edited genes in 
mammals has been a low signal-to-noise ratio (Morse et al., 2002; Morse, 2004; 
Gommans, 2008). Recently, high-throughput sequencing allowed analysis of a large 
number of predicted target sites. These efforts determined that high levels of recoding 
editing are relatively rare, but can occur at low levels at many sites (Li et al., 2009). 
Despite these advancements in technology and analysis methods, scientists are still 
restricted to analyzing a pre-determined pool of candidates, requiring sophisticated 
screening to enrich this sample set with true editing sites. 
We hypothesized that a bioinformatics approach, which employs a strategic 
filtering of available databases and ranking of candidates, would increase the proportion 
of true editing targets within high-ranking putative targets. Briefly, A/G discrepancies 
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between genomic and expressed sequences that are not genomically validated SNPs are 
retrieved from available databases. These candidates are then ranked with respect to their 
compliance with key attributes of a reference set of known targets. Even though there is 
no single attribute such as a specific sequence or secondary structure that determines an 
editing site, several features combined may produce a sufficiently high signal-to-noise 
ratio in the output dataset to allow for a sophisticated sampling of the gene pool and the 
retrieval of novel bona fide editing targets. The goal of this study was to experimentally 
sample candidate lists produced by this bioinformatics approach and determine whether 
or not the employed concept provides a basis for effective and comprehensive screening 
for A-to-I RNA recoding targets on the genomic scale. 
The screening protocol was shown to identify all of the previously known editing 
targets with SNP annotations as high-scoring candidates. Furthermore, here I 
experimentally show the in vivo occurrence of recoding RNA editing in human brain 
tissue for two additional genes that are among the highest scoring candidates from our 
screen, IGFBP7 (Gommans et al., 2008) and C1QL1 (Sie & Maas, 2009). The highest-
ranking candidate, SRp25 nuclear protein isoform 3, was also shown to be edited by Dr. 
W.M. Gommans in our lab. 
Overall, the experimental analysis of 68 predicted sites from four scoring groups 
revealed a high accuracy of predicting bona fide editing sites. In the highest scoring 
group, four out of seven sites (57%) are real editing substrates. It is important to keep in 
mind that our experimental analysis is limited to one human brain cDNA and as such to 
one tissue specimen and one specific developmental time-point. It cannot be ruled out 
that candidates undergo editing in different tissues (He et al., 2011), at distinct 
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developmental time points (Rula et al., 2008), or in response to external stimuli, as 
recently shown for Neil1 (Yeo et al., 2010). Furthermore, the detection limit of the assay 
may prevent identification of bona fide targets that are edited to low levels. Despite these 
experimental limitations, the results underscore the validity of the applied search 
algorithm and ranking system. The validated algorithm was used as the underlying basis 
for the development of an automated algorithm (Chapter 3) for the genome-wide analysis 
and prediction of editing target genes.  
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2.3 Materials and Methods 
2.3.1 Databases and data analysis 
The database search and data analysis was conceived and performed by other 
members of the lab (W.M. Gommans, N. Tatalias, S. Maas). For reference and in order to 
give a complete picture of the study, the search strategy is outlined briefly here and in 
detail in Appendix A, even though my contribution was restricted to the experimental 
analysis of candidate genes. Annotations for human single-nucleotide polymorphisms 
(SNPs) from the dbSNP database (Sherry et al., 2001) build 125 were downloaded using 
the UCSC genome table browser (Kuhn et al., 2007). RNA secondary structures were 
predicted using the M-fold algorithm (Zuker, 2003) and multiple sequence alignments 
were obtained with the online program clustal W 1.8 (Jeanmougin et al., 1998).  
The dbSNP database contained a total of > 5x10
6
 mapped SNPs. Figure 6 depicts 
the subsequent filtering steps that were performed to narrow down the list of SNPs to 
only those that might represent recoding RNA editing sites within known genes. First, we 
extracted all annotations that were based solely on expressed sequence data using the 
UCSC genome table browser (Kuhn et al. 2007) to yield ~30,000 sites. Second, all 
variations other than A/G or G/A were removed. Subsequently, only the entries where 
adenosine is present in the genomic sequence at the putative SNP position were retained, 
whereas those with G in the genomic sequence were removed. Fourth, we filtered the 
sites located within the known coding sequence of genes from sites in non-coding exons, 
since we wanted to focus on recoding events. This step eliminates potential A-to-I RNA 
editing sites in small regulatory RNAs such as miRNAs and editing events affecting 5‟- 
and 3‟-untranslated regions of mRNAs (for review, see Nishikura 2006; Gommans et al. 
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2008). In the next step we removed the sites that produce synonymous changes, i.e. the 
codon changes caused by the discrepancy leaves the protein sequence unaltered. This 
narrowed the number of potential editing sites down to 984. Finally, we selected among 
these 984 positions the ones located within known genes, thus removing entries with 
„„hypothetical‟‟ and „„unknown protein‟‟ annotations. The resulting list of 863 sites 
constituted the starting point for our bioinformatics analysis to rank the entries in order to 
identify the ones that have a high probability of representing bona fide RNA editing sites. 
 
The molecular features used to rank and filter each of the 863 potential 
editing/SNP sites are derived from known properties of previously characterized 
mammalian RNA editing sites. We downloaded and evaluated the bases at the -1 and +1 
positions relative to the predicted editing site in order to score the entries according to the 
Figure 6: Filtering of data 
derived from SNP db build 125  
Sequential removal of candidates 
from list due to: 
1.  SNPs annotated based on 
genomic sequence  
2.  discrepancies other than A/G 
and G/A  
3.  genes where discrepancy 
occurs in non-coding regions  
4.  discrepancies that are silent 
codon changes  
5.  unknown genes  
6.  sequences displaying a G as 
5’-neighbor  
Figure adapted from Gommans 
et al., 2008. 
1 
2 
3 
4 
5 
6 
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main 5‟- and 3‟-base preferences of ADARs (Bass, 2002; Athanasiadis et al., 2004). First, 
since guanosine rarely if ever precedes an editing site, we removed all entries with a G at 
-1 from the list. Second, the assigned values for the -1 position are 1 for A or T, and 2 for 
C and for the +1 position 1 for G and 2 for either A, T or C. Third, we manually assigned 
a value for cross-species conservation based on the PhastCons program (Siepel et al., 
2005). The value captures how strongly the potential target site itself as well as the 
surrounding sequence is conserved (including mouse, rat, chicken and zebrafish). Only 
candidates exhibiting medium to high conservation were used for further analysis. 
Fourth, evidence for in silico editing was analyzed for each of the remaining sites, 
whereby 30nt upstream and 30nt downstream of the predicted nucleotide were blasted 
against the nucleotide (nr/nt) and human EST databases (NCBI) and the percentage of 
sequences carrying a G instead of an A was recorded. Only candidates showing ≥ 1% in 
silico editing were used for the last analysis step. Finally, up to 2.5kb of genomic 
sequence in both directions from the putative editing site were inspected for RNA 
foldback structures using M-fold (Zuker, 2003) and structural scores were determined for 
each fold. 
For each of the described features individual scores were computed using a LODs 
scoring method and combined to yield an overall score (S) (Gommans et al., 2008). For 
each feature the values of a reference set (positive control regions from known cases of 
RNA editing) were compared to the values of the sample set (all A/G discrepancies) to 
rank the sample set. For a more detailed description of the search and ranking strategy see 
“2.5: Discussion” and Appendix A. 
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2.3.2 RNA editing analysis 
For experimental validation, human brain total RNA and gDNA isolated from the 
same specimen (Biochain) were purchased and processed using standard protocols for 
reverse transcription and PCR (Appendix A). Even though ADARs are expressed in 
almost all tissues (O'Connell et al., 1995), editing levels have been shown to be highest in 
the brain. Therefore, brain cDNA was used for initial analysis even if the transcript for 
the gene in the database that carries the G was derived from another tissue. In those cases 
where candidate gene transcripts are specifically expressed in tissue other than the brain, 
tissue-specific cDNA and gDNA pairs from other human tissues were analyzed. Gene-
specific fragments of cDNA as well as genomic regions were amplified by PCR and 
subjected to dideoxy sequencing (Geneway) as described previously (Athanasiadis et al. 
2004). Sequence traces of PCR products were inspected for mixed reads, with the ratio of 
the peak heights giving a first indication of editing levels.  
2.3.3 Statistical analysis 
To determine if the chance of finding a novel recoding editing site within the 
various scoring groups was significantly different from random chance we used Fisher‟s 
exact test. 
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2.4 Results 
2.4.1 Identification of novel sites of A-to-I RNA editing among high scoring 
candidates 
Four groups of genes that span the entire spectrum of the ranked candidates were 
selected in order to estimate the signal-to-noise ratios across the whole range of the 
sample set. At least 10 individual genes from each of the four groups were 
experimentally analyzed yielding a total of 68 analyzed genes (Table 2).  
No editing was detected in any of the gene candidates from the lower three groups 
(Table 2: group 2: score ranks III–X [22 of 47 analyzed]; group 3: score ranks XI–XV 
[31 out of 83 analyzed]; group 4: score ranks XVI–XXIX [12 out of 52 analyzed]) by our 
RT-PCR and sequencing screening method. It is important to note that this does not 
prove that editing cannot or does not occur at those positions. Rather, it shows that 
 
Group Score Total n Tested 
Edited 
(% of tested) 
1 5-2.5  4  4  75 
2 2.5-0.0  47  18  (22)  0 
3 0.0-(-)2.5  83  31  0 
4 <(-)2.5  52  12  0 
Table 2: Statistical analysis of experimental validation 
Group numbers and score ranges correspond to those in Table 4. n = number of 
sites in group; tested = number of sites experimentally tested in group; edited = 
percentage of sites edited in vivo of sites tested per group. Fisher’s exact test: 
group 1 versus group 2: p = 0.0026; group 1 versus group 3: p = 0.00061; 
group 1 versus group 4: p = 0.00714. Not included in this analysis are the four 
additional genes analyzed after publication (all in group 2) (Gommans et al., 
2008). 
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editing at these positions is not detectable using the RT-PCR screening method in a 
specific tissue sample isolated at a single time point from a single individual. Neither can 
it be ruled out that editing occurs at a rate below the detection threshold of this method. 
When we analyzed the top four highest scoring sites that constitute group 1 (score ranks 
I+II), we detected RNA editing in human brain at three of the four sites. These were 
located within two genes; the splicing factor SRp25 isoform 3 (analyzed by W.M. 
Gommans) and Insulin-like growth factor binding protein 7 (IGFBP7). Therefore, within 
this highest scoring group (summary score of > 2.5) four out of seven (57%) sites are real 
positives (Table 4). Table 2 summarizes the validation data and the statistical evaluation 
of expected versus observed outcomes based on the screening results in Table 4. 
Since the apparent editing level for the SRp25 transcripts based on the RT-PCR 
sequencing assay was low, the PCR amplicon was subcloned by Dr. W. Gommans and a 
total of 100 individual clones were sequenced. This revealed that 7(±1)% of cDNAs 
carried a G instead of an A at the predicted position. In addition to the main site there 
may be additional minor editing sites within the same exon. The main editing site results 
in a lysine-to-arginine change within a basic region of the protein. Interestingly, the entire 
computer-predicted RNA fold-back structure is composed of exonic RNA sequences. 
We showed that two of three predicted positions in IGFBP7 (Figure , Table 4), all 
residing within the same exon, are true editing sites. It had previously been suggested that 
these two sites might be subject to A-to-I modification based on database evidence and 
cDNA sequencing (Eisenberg et al., 2005a), without experimental evidence of an RNA-
based mechanism. Our results from analysis of matched cDNA and genomic DNA from 
the same tissue specimen confirm that both adenosines are subject to RNA editing 
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Table 3: Screen using reference set of 15 known editing sites 
  
 Gene Sum Rank 
1 SRp25 nuclear protein isoform 3 3.963 I 
2 Insulin-like growth factor binding protein 7 3.963 
3 Bladder cancer-associated protein (Bc10) 3.963 
4 YY1 transcription factor 2.844 II 
5 Insulin-like growth factor binding protein 7 2.844 
6 Bladder cancer-associated protein (Bc10) 2.844 
7 Filamin A 2.085 III 
8 3‟-phosphoadenosine 5‟-phosphosulfate synthase 2.085 
9 Insulin-like growth factor binding protein 7 2.085 
10* C1q-related factor precursor* 2.085 
11 Glioma-associated oncogene homolog (zinc finger protein) 1.915 IV 
12 Thymidylate kinase 1.915 
13 Component of oligomeric golgi complex 1 1.915 
14 Vacuolar protein sorting 4B (yeast) 1.915 
15 RARS – arginyl-tRNA synthetase 1.915 
16 S-adenosylhomocysteine hydrolase 1.915 
17 Myxovirus resistance 1, interferon-inducible protein p78 0.967 V 
18 Neogenin homolog 1 (chicken) 0.967 
19 Actin related protein 2/3 complex, subunit 3 0.967 
20 Heme oxygenase (decycling) 2 0.967 
21 Phospholipid transfer protein 0.796 VI 
22 Pyruvate dehydrogenase complex, component X 0.796 
23 Eukaryotic translation initiation factor 2, subunit 3 gamma 0.796 
24 Similar to Proliferating-cell nucleolar antigen AK021577 0.796 
25 Amyloid beta precursor protein binding protein 2 0.796 
26 Mitochondrial ribosomal protein L28 0.796 
27 ABCD3 protein ATP-binding cassette (ABC) transporters 0.796 
28 Ubiquitin protein ligase E3 component n-recognin 1 0.796 
29 Thioredoxin-like protein p19 precursor 0.796 
30 Methionyl aminopeptidase 2 0.796 
31 Vacuolar protein sorting 29 (yeast) 0.796 
32 Excision repair cross-complementing rodent 0.796 
33 Tumor suppressor candidate 3 isoform a 0.796 
34 Signal-induced proliferation-associated 1 like 1 0.796 
35 Sterol carrier protein 2 0.796 
36 Protein phosphatase 1, catalytic subunit, gamma isoform 0.796 
37 Sorcin isoform a 0.796 
38 Tripeptidyl peptidase II 0.796 
39 Brix domain containing 1 0.796 
40 EBNA-2 co-activator variant 0.796 
41 CYFIP 0.530 VII 
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Table 4: Screen using reference set of 19 known editing sites 
 
 
 Gene Sum Rank 
1 SRp25 nuclear protein isoform 3 4.239 I 
2 Insulin-like growth factor binding protein 7 4.239 
3 YY1 transcription factor 2.776 II 
4 Insulin-like growth factor binding protein 7 2.776 
5* C1q-related factor precursor* 2.455 III 
6 3‟-phosphoadenosine 5‟-phosphosulfate synthase 2.455 
7 Insulin-like growth factor binding protein 7 2.455 
8 Glioma-associated oncogene homolog (zinc finger protein) 1.607 IV 
9 Thymidylate kinase 1.607 
10 Component of oligomeric golgi complex 1 1.607 
11 Vacuolar protein sorting 4B (yeast) 1.607 
12* RARS – arginyl-tRNA synthetase* 1.607 
13* S-adenosylhomocysteine hydrolase* 1.607 
14 Myxovirus resistance 1, interferon-inducible protein p78 0.992 V 
15 Neogenin homolog 1 (chicken) 0.992 
16 Actin related protein 2/3 complex, subunit 3 0.992 
17 Heme oxygenase (decycling) 2 0.992 
18 Phospholipid transfer protein 0.516 VI 
19 Mitochondrial ribosomal protein L52, isoform a 0.221 VII 
20 ATP synthase H+ transporting mitochondrial F1, subunit 0.221 
21 Lysozyme-2 0.221 
22 Hyaluronan synthase 1 0.221 
23 Bromodomain containing 1 0.221 
24 Male-specific leghal 3-like 1 (Drosophila) 0.221 
25 Inositol polyphosphate-5-phosphatase A 0.221 
26 Zinc finger protein 358 0.221 
27 KIAA0741 protein 0.221 
28 Glycoprotein hormones, alpha polypeptide 0.221 
29* Zinc finger protein 289, ID1 regulated* 0.221 
30 Tropomyosin-binding subunit of the troponin complex 0.221 
31 Sterol carrier protein 2 0.221 
32 Ras-related C3 botulinum toxin substrate 1 0.221 
33 Pyruvate dehydrogenase complex, component X 0.144 VIII 
34 Eukaryotic translation initiation factor 2, subunit 3 gamma 0.144 
35 Similar to Proliferating-cell nucleolar antigen AK021577 0.144 
36 Amyloid beta precursor protein binding protein 2 0.144 
37 Mitochondrial ribosomal protein L28 0.144 
38 ABCD3 protein ATP-binding cassette (ABC) transporters 0.144 
39 Ubiquitin protein ligase E3 component n-recognin 1 0.144 
40 Thioredoxin-like protein p19 precursor 0.144 
41 Methionyl aminopeptidase 2 0.144 
57* C1Q-like tumor necrosis factor 5* -0.177  
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in human brain and are not genomic polymorphisms. At site B, which is edited to 30%, 
the resulting lysine-to-arginine (K95R) amino acid substitution affects the IGFBP7 
protein sequence within a region representing a heparin binding site that also overlaps a 
protease cleavage site (Sato et al., 1999; Ahmed et al., 2003). Site A is also subject to 
RNA editing with a level of modification around 10% (Figure 7) and encodes glycine 
instead of arginine in its edited state (R78G). 
EST database analysis can provide additional insight on editing levels at a specific 
site, as it often contains large numbers of annotated expressed sequences of a given gene. 
Within the IGFBP7 gene, 36 out of 302 (12%) of human ESTs carry a G at site R78G and 
132 of 302 (=43.7%) at site K95R. Such in silico editing also suggests that position C 
may be edited, with eight of 302 ESTs (=2.6%) carrying a G at this site.  
 
Legends to Tables 3 and 4 (previous pages): 
Table 3: List of gene names, score ranks, and summary score values obtained 
after screening using the basic reference set of 15 known editing sites. Entries with the 
same summary score S are grouped together. Three sites of previously annotated SNPs 
that are known editing sites are italicized. Candidates shaded in gray are true editing 
sites as shown in this or previous studies.  
Table 4: List of genes, score ranks and summary score values obtained with the 
expanded reference set of 19 sites. Candidates experimentally tested by our lab are 
shaded: validated RNA editing sites in dark and candidates with no evidence of editing in 
light gray. Candidates that were experimentally analyzed by me are highlighted in bold. 
Asterisks indicate analysis after publication of the study by Gommans et al., 2008. 
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Figure 7: A-to-I RNA editing of IGFBP7 pre-mRNA 
a) Sequence traces obtained from amplified genomic and matching cDNA samples 
encompassing the predicted RNA editing sites R78G and K95R within the IGFBP7 
exon1 sequence. A mixed read of A and G at the same position indicates a mixed 
population of mRNAs in the cDNA samples due to post-transcriptional A-to-I RNA 
modification. Reverse complement shown. b) Schematic representation of functional 
domains of the IGFBP7 protein  The approximate positions of the two amino acid 
changes resulting from RNA editing are indicated. SS = secretion signal (aa1 1-26); 
HBS = heparin binding site (aa 89-97); cleavage = protease processing site at amino 
acid position 97. c) Predicted RNA fold encompassing IGFBP7 editing sites 
(underlined and highlighted in red) within exon 1 (Zuker, 2003). Also labeled is a third 
potential minor editing site C that did not show evidence of editing in vivo in our 
screen and might represent a true genomic SNP. Figure adapted from Gommans et al., 
2008. 
 
a) 
b) 
c) 
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Candidate position C in IGFBP7 did not show evidence of editing in our sequencing 
analysis and may therefore represent a genomic polymorphism, or RNA editing is 
restricted to specific cell types or occurs at a very low level. Inspection of mouse and rat 
mRNA and EST databases suggests that RNA editing at positions R78G and K95R also 
occurs in rodents. In mouse, 48 out of 85 ESTs (=56.5%) carry a G at position R78G, and 
a similar number carry a G at position K95R (=57.7%). In rat, 75.4% of ESTs carry a G 
at position R78G and 80% at position K95R. 
The predicted editing site on rank 5, Complement component 1, q subcomponent-
like 1 (C1QL1), changes codon 66 from glutamine to arginine (Q66R) when edited. It 
shows a high level of editing (Figure 8), but due to high background in the sequence 
track, the amplicon was subcloned for more definite determination of editing levels. This 
revealed that Q66R was edited to 56%. Furthermore, we discovered an additional editing 
site located ten nucleotides upstream of this major site, which is edited to a lower degree 
(18%), changing a threonine to an alanine codon (T63A). Interestingly, this minor site is 
always edited together with codon 66. Editing at sites located on the same face of an 
RNA duplex, as is the case here, is often coupled, whereby the site edited to a lower 
degree (termed minor site) is only edited when the major site is edited (Enstero et al., 
2009). Unfortunately, the genomic counterpart for this human specimen was not 
available, and these results were thus not included in the publication by Gommans et al. 
After validating the editing in this target, it was published in separate manuscript (Sie & 
Maas, 2009). 
Within score ranks I–VI, none of the sites lacking evidence for editing turned out 
to be genomic SNPs based on the analysis of the matched genomic DNA. The analysis of 
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genes from groups VII and VIII revealed three cases as genomic SNPs (UBE3, IP5PA, 
and AK021577). The presence of a genomic SNP does not rule out that the same position 
undergoes A-to-I editing in transcripts derived from an adenosine-bearing allele, but in 
the absence of evidence for editing after experimental validation we assume that editing 
does not occur there.  
Figure 8: Editing of human Complement component 1, q subcompononent-like 1 
(C1QL1) 
a) Schematic representation of the C1QL1 protein with the three main functional domains 
indicated. The amino acid sequence surrounding the editing site is shown, and recoding 
events are indicated both at the amino acid and at the RNA sequence level. cDNA 
sequence track is shown, but the matching genomic sample was not analyzed (see Chapter 
4 for further information). b) Predicted RNA secondary structure (Mfold) of the sequence 
encompassing the two editing sites of C1QL1 in exon1. Figure adapted from Sie & Maas, 
2009. 
a) 
b) 
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2.5 Discussion 
Toward the long-term goal of a comprehensive analysis of the prevalence of A-to-
I RNA editing in the human transcriptome, we developed a combined bioinformatics and 
experimental strategy. A critical component of such a strategy is to define selective 
criteria that capture as many of the true targets as possible while eliminating sequences 
that are not modified by ADARs in vivo. Although each individual feature does not 
strongly select for a bona fide editing target over background, the combination of scores 
using five distinct molecular determinants into a single weighted score has a much 
stronger predictive value. 
2.5.1 Bioinformatics screen for A-to-I RNA editing candidates in the human SNP 
database 
Interestingly, three out of four recently validated cases of A-to-I RNA editing 
(Clutterbuck et al., 2005; Levanon et al., 2005) affecting two genes (bladder cancer-
associated protein BC10 and Filamin A) were previously annotated as SNPs and were 
ranked very high in our analysis (Table 3, position ranks 3, 6, 7). The fourth editing site 
located in the CYFIP coding sequence was ranked at position 41. These results clearly 
indicate that our search strategy is selecting for real editing targets. Furthermore, no 
known editing site is missed in our screen since there is no other previously reported 
recoding editing site among the >30,000 entries that constituted the starting point for our 
search.  
Within the pre-filtered sample set of 554 human SNPs, all known editing sites 
previously annotated as SNPs that have been identified using various approaches were 
recaptured in our screen as high-scoring candidates. In fact, when including the novel 
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sites identified and validated in this study, 50% of candidates within the highest scoring 
ranks (I–IV) are known RNA editing targets (Table 3), whereas only a single known 
editing site (CYFIP; group VII) appears within all other tested medium and low scoring 
groups. Therefore, none of the real editing targets that have previously been characterized 
were missed or ranked lower than position 41 among the total of 554 entries of recoding, 
non-synomymous SNPs. For any of the candidates that did not show detectable editing 
activity in human brain, the occurrence of editing in brain or other tissues cannot be ruled 
out. It is in the nature of the experimental screening method applied here that editing 
events with levels below ~5% may be missed. Furthermore, to facilitate testing of large 
numbers of candidates, only one adult human specimen was analyzed. RNA editing 
events that are specific for certain cell types or developmental stages may thus also 
escape this initial screening. 
Next we moved the four known cases of A-to-I editing (two in BC10 and one 
each in FLNA and CYFIP) that were contained in our candidate list into the reference set 
(now containing 19 sites). The ranking of the resulting list of highly scored candidates 
compared with the previous one showed no changes in order of the first 18 entries (Table 
4). Apart from the sites within BC10, FilaminA, and CYFIP that we moved to the 
reference set, only minor changes with respect to the order of entries occur further down 
in the listing (Gommans et al., 2008; Supplementary Table S2). 
2.5.2 Identification of novel recoding editing sites 
Splicing factor SRp25 (also known as ADP-ribosylation-like factor 6 interacting 
protein 4), analyzed by W.M. Gommans, is a ubiquitously expressed protein of 
uncharacterized function (Sasahara et al., 2000). Because of its homology with SR-
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splicing factors, it is believed to be a nuclear protein with a role in splicing regulation 
(Sasahara et al., 2000). The amino acid substitution due to RNA editing affects a basic 
region in the protein that has not been ascribed a specific function. Based on its sequence 
characteristic it may represent a nuclear localization sequence or a domain that interacts 
with the nucleic acid backbone. The lysine-to-arginine change does not alter the overall 
charge of the molecule, and represents a conservative change that may not affect the 
protein‟s function substantially. However, lysine residues can be sites of post-
translational modification and thereby regulate protein function. For example, 
sumoylation of a specific lysine residue in tumor suppressor p53 activates its 
transcriptional response (Rodriguez et al., 1999). K-to-R mutation of this site blocks 
sumoylation of the protein while preserving the local charge in the protein (Sampson et 
al., 2001). Furthermore, another specific lysine residue in p53 has been found to be 
subject to methylation, which downregulates the protein‟s transcriptional activation 
activity (Shi et al., 2007). It will be interesting to see if the editing invoked K-to-R 
change in SRp25 also has a regulatory impact on SRp25 function. 
The second gene that was detected in this study as a target for RNA editing is 
IGFBP7. Although editing in this gene had been postulated previously for two of the 
three sites (Eisenberg et al., 2005a), we provide experimental validation that the observed 
A/G discrepancy is in fact due to RNA editing by analyzing matched cDNA and genomic 
DNA sequences from the same tissue sample. IGFBP7 was initially identified as a gene 
differentially expressed in cancerous cells, and has been implicated in various forms of 
cancer, either as putative tumor suppressor (Sprenger et al. 2002; Wilson et al. 2002; 
Mutaguchi et al. 2003) with functions in apoptosis and senescence, or as a promoter of 
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angiogenesis in human tumor endothelium (St Croix et al. 2000; van Beijnum et al. 
2006), and it is overexpressed in circulating endothelial cells (CECs) of metastatic cancer 
patients (Smirnov et al. 2006). The IGFBP7 protein has several functional domains in its 
N-terminal half, such as a leucine-rich sequence, a cysteine-rich domain (CRD), a 
heparin binding site, and a Kazal-type trypsin inhibitor domain (Collet and Candy 1998). 
The two editing sites A and B affect amino acid positions 78 (R-to-G) and 95 (K-to-R) of 
the full-length protein. Interestingly, the core sequence K89SRKRRKGK97 (edited site in 
bold) has been proposed to function as a heparin binding site (Sato et al. 1999), and it 
was observed that cell-adhesion activities of IGFBP7 are inhibited by heparin (Akaogi et 
al. 1996). IGFBP7 is proteolytically cleaved after K97, which results in a two-chain form 
of the protein cross-linked by disulfide bridges. Proteolytic processing of IGFBP7 has 
been shown to modulate its growth-stimulatory activity (Ahmed et al. 2003). 
Furthermore, the heparin-binding activity of IGFBP7 is decreased upon proteolysis. The 
main editing site (K95R) not only lies within the proposed heparin-binding site of 
IGFBP7, but is also part of the recognition sequence for proteolytic cleavage. It will be 
interesting to explore the potential functional implications of RNA editing on heparin 
binding and/or proteolytic processing and its downstream effects regarding apoptosis, 
regulation of cell growth and angiogenesis.  
The family of C1Q-domain proteins includes important signaling molecules with 
roles in inflammation, adaptive immunity and energy homeostasis (Ghai et al., 2007). 
The physiological function of C1QL1 has not been elucidated, but it is expressed highest 
within the brain and was suggested to be especially important for neurons involved in 
coordination and regulation of motor control (Berube et al., 1999). Furthermore, it may 
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be part of a neuroprotective immune response (Glanzer et al., 2007) and one study 
revealed upregulation of C1QL1 in response to kainic acid induced seizures (Hunsberger 
et al., 2005). The RNA editing sites in C1QL1 are located immediately upstream and at 
the beginning of a collagen-like domain. In other C1Q-domain proteins, such as the 
hormone adiponectin, this coincides with a region of protease-mediated processing (Waki 
et al., 2005). Future studies will show if the amino acid substitutions caused by RNA 
editing may alter post-translational processing of C1QL1, or if it affects other properties 
of the protein in vivo. 
For the transcripts of all three genes, SRp25, IGFBP7, and C1QL1, the RNA fold-
back structures that are predicted to mediate RNA editing involve solely exonic RNA 
sequences. This is in contrast to almost all other characterized recoding editing sites, 
which usually involve folds where the editing site complementary sequence is located 
within an intron. As more edited genes are identified, it will be interesting to see how 
often exon-only structures mediate editing compared to exon–intron fold-back structures, 
since it could have implications for the evolutionary mechanisms that lead to the 
emergence of novel editing sites and the changes in the extent of editing at individual 
sites over evolutionary time. Furthermore, RNAs that do not require the presence of 
intronic sequences for editing to occur could continue to undergo editing after the 
completion of nuclear pre-mRNA splicing. 
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2.6 Conclusions 
The results of our limited screen indicate that the strategy is successful in 
identifying novel recoding targets. The algorithms for deriving each individual score, as 
well as the weighted combined score value reflect the current knowledge of the A-to-I 
editing mechanism and the properties of known targets. In previous database-driven 
studies, only A/G discrepancies that appear both in human sequences of a given gene as 
well as at the same position in another mammalian species were investigated (Clutterbuck 
et al. 2005; Levanon et al. 2005b). The latter is a valuable strategy for initial screens with 
little data on known targets. However, for a more comprehensive search the approach that 
is presented here is more suitable. In particular, current cDNA databases do not cover all 
genes and often do not have sufficient coverage across editing sites to reveal low-level 
editing events. Over time, improved and extended databases as well as additional insights 
into the RNA editing mechanism will lead to a refinement of the search algorithm. 
Biochemical approaches for performing target screens (Morse and Bass 1997; Ohlson et 
al. 2005) come with their separate set of biases that may favor the identification of certain 
types of editing targets but select against others. 
At this point, the presented screen represents the most unbiased search for edited 
sequences in the human transcriptome with a reasonable signal-to-noise ratio. In the 
present study several of the selection steps were performed in a non-automated manner. 
A largely automated procedure will be needed to apply this approach to the complete 
transcriptome (Chapter 3). While such a genome-wide screening approach is expected to 
uncover more recoding RNA editing targets due to its comprehensiveness, recent 
advances suggest that many editing sites may be subjected to low levels of editing or are 
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regulated in a tissue- and time-specific manner (Li et al., 2009; He et al., 2011). 
Application of a transcriptome-wide search algorithm in conjunction with high-
throughput sequencing of different tissues would enable an in-depth assessment of the 
prevalence of A-to-I RNA editing. 
This pilot study showed that the applied filtering strategy not only identifies all 
previously known cases of editing present in the subset of genes analyzed, but also 
allowed us to identify three novel editing targets, SRp25, IGFBP7 and C1QL1. It is 
expected that application of a similar search algorithm on a much larger scale, namely in 
a genome-wide approach, would be similarly successful in identifying putative 
candidates with a high probability of being edited. Due to its scale, such an endeavor will 
need to be automated, a process which requires significant dedication of time and 
resources. However, the accomplishments of the strategy discussed in this chapter 
justified such an undertaking and therefore set the stage for effective and comprehensive 
genome-wide screens for A-to-I editing targets as outlined in Chapter 3. 
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3 Genome-wide evaluation and discovery of vertebrate 
A-to-I RNA editing sites  
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3.1 Abstract 
The search and filter strategy applied to the SNP database was successful in 
identifying novel A-to-I RNA editing sites but was restricted to a relatively small subset 
of genes. Here we administer an automated bioinformatics search strategy to the human 
and mouse genomes to explore the landscape of A-to-I RNA editing on a larger scale. In 
both organisms we find evidence for high excess of A/G-type discrepancies at non-
polymorphic, non-synonymous codon sites over other types of discrepancies such as 
G/A, T/C or C/T, suggesting the existence of several thousand recoding editing sites in 
the human and mouse genomes. We experimentally validate recoding-type A-to-I RNA 
editing in a number of human genes with high scoring positions including those encoding 
the ATPase, H+ transporting V0 subunit e2 (ATP6V0E2) and the unknown protein 
BC027448. Others in the lab further identified mRNAs encoding the coatomer protein 
complex subunit alpha (COPA), as well as cyclin dependent kinase CDK13 as novel 
editing targets. 
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3.2 Introduction 
Parts of this chapter have been published in Maas et al., 2011 (Maas et al., 2011). 
The pilot study analyzing the SNP database (Chapter 2) set the basis for a genome-wide 
application of the applied search strategy. In collaboration with Dr. D. Lopresti 
(Department of Computer Science and Engineering, Lehigh University), we developed a 
computer program (RNA Editing Dataflow System or REDS) that mines through the 
human genome, whereby it extracts genes that show A-to-G discrepancies between the 
genomic and mRNA sequences that lead to amino acid changes and that are not 
genomically validated SNPs. Furthermore, the targets are screened for possible self-
complementary sequences around the predicted editing site.  
Bioinformatic analysis methods were first capitalized on to systematically 
uncover novel A-to-I RNA editing recoding sites about eight years ago. Using the fruit 
fly as a model system, Hoopengardner and co-workers observed that sequences 
surrounding known recoding editing sites were conserved among Drosophila species 
(Hoopengardner et al., 2003). Hypothesizing that high conservation adjacent to editing 
sites arose from a selective constraint against mutations near sites of ADAR 
modification, this high degree of sequence identity among species was used as a potential 
signature of editing sites. Analysis of 914 genes encoding neurological proteins and 
transcription factors procured 41 genes with coding regions of unusually high sequence 
conservation. Editing indeed occurred in 16 of the 41 candidate mRNAs. Comparative 
genomics was therefore extraordinarily well suited for the identification of previously 
unknown editing targets in the fruit fly.  
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Three notable systematic approaches investigating the prevalence of A-to-I RNA 
editing in human were published in 2004 (Athanasiadis et al., 2004; Blow et al., 2004; 
Levanon et al., 2004). Sequences from cDNA and EST databases or from a cDNA library 
were aligned to genomic sequences using bioinformatics tools and sequences with A-to-
G discrepancies were retrieved. A major problem of such approaches is that mismatches 
between genomic DNA and expressed sequence can be due to low sequence quality, false 
alignment (for instance between pseudogene and gene), SNPs, or editing. Therefore, all 
candidate sequences underwent some sort of quality conformance test and genomically 
validated SNPs were removed. Alternatively, Levanon and co-workers restricted the 
search to potentially double-stranded regions in order to remove noise and facilitate 
identification of true editing sites. All three studies found that A-to-I RNA editing 
primarily occurred in non-coding regions, mostly in Alu repeat elements, now recognized 
as the main targets of ADARs.  
By combining a bioinformatics approach and comparative genomics, Levanon 
and colleagues then selectively directed their search toward non-synonymous A-to-I 
RNA editing sites, thereby avoiding inundation of putative candidates of editing by Alu-
repeat elements (Levanon et al., 2005). First, they obtained candidate editing sites from 
both the human and mouse genomes by aligning expressed sequences and genomic DNA 
and clearing the list of sequences with low quality. Next, mouse and human candidate 
sequences were aligned and non-synonymous nucleotide mismatches occurring at 
identical positions were identified. This approach successfully detected four previously 
unknown recoding editing targets. Interestingly, all four positions had been wrongly 
annotated in the SNP database.  
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Due to limitations of sequence coverage in the databases or restriction of the 
search dataset in order to reduce noise, the bioinformatics approaches discussed above 
failed to identify known recoding editing sites as candidates. Furthermore, they had to 
rely on web-based tools such as blastn and Mfold for data analysis. A fast program, 
specifically designed to retrieve nucleotide discrepancies between expressed and genomic 
databases, malleable to user preferences, and optimizable in accordance with novel 
findings, would be a major improvement over bioinformatics approaches employed so 
far. REDS was designed precisely to allow such plasticity in the search strategy. It can be 
applied to any database, and could also be used for other purposes owing to its many 
adjustable parameter settings. The scripting language (Tcl/Tk – Tool Command 
Language/Toolkit) allows fast processing times, which permits running it on a normal 
desktop computer or as a web-based algorithm. Here we show that with REDS we are 
able to apply our proven search strategy to the genomic scale to analyze the overall 
landscape of base discrepancies in two species followed by experimental validation of 
novel recoding editing sites in the human transcriptome. In combination with standard or 
high-throughput experimental validation, REDS would facilitate mapping the A-to-I 
RNA editing landscape and define the overall impact of editing on gene expression. 
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3.3 Materials and Methods 
3.3.1 Databases and REDS 
The REDS program was conceived by S. Maas and D. Lopresti and written by D. 
Lopresti and his students in the scripting language Tcl/Tk (Tool Command Language, 
Toolkit). Human and mouse genomic DNA sequences, mRNA data files, SNP data, as 
well as table annotations were retrieved using the UCSC genome browser ftp site 
(assembly March 2006 for human and February 2006 for mouse) (Kuhn et al., 2007). 
REDS consists of three consecutive computational stages (Figure 9). Stage 1 aligns 
expressed sequences (UCSC mRNA database) from a given species to the corresponding 
genomic sequence. Coding sequences are translated, allowing for determination of non-
synonymous codon positions within open reading frames (ORFs). According to user 
specifications (type of base difference, coding versus non-coding, synonymous versus 
non-synonymous), specific types of base discrepancies are mapped and recorded with 
chromosome location and position, mRNA accession and position, gene ID and 
description and affected amino acid. Previously known RNA editing sites are flagged. 
Stage 2 compares the list of base discrepancies to the species-specific SNP database 
(Sherry et al., 2001) and all positions that correspond to genomically validated SNPs are 
filtered out. 
The third stage of the computational pipeline evaluates RNA folding 
characteristics for each of the remaining sites. The user defines several parameters: a first 
sequence window determines how much of the genomic sequence upstream and 
downstream of the putative editing site is analyzed. A second sequence window selects a 
small gene section surrounding the candidate site, for which the algorithm generates the 
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reverse complement sequence with which to scan window 1 for matches (including G-T 
wobble base pairs and allowing for single, symmetric mismatches). Next, the cut-off 
value for the number of consecutive base pair matches within the RNA secondary 
structure are required to pass the filter and finally a minimum value for the length of the 
intervening sequence between the base-pairing sections are determined. 
A multi-segment heuristic combines pairs of base-pairing segments within the 
sequence that may be part of one composite RNA secondary structure. A score is 
assigned to this composite structure, whereby base-pairs involving nucleotides within the 
inner window 2 are weighted more strongly according to a user-defined value (please see 
Appendix A for more detailed explanation). This biases the search for bona fide editing 
targets since base-paired segments of an RNA fold that supports editing include, or are in 
Figure 9: Organization of the RNA Editing Dataflow System (previous page) 
Flowchart describing the three-stage computational pipeline. For each stage a 
screen shot of the corresponding parameter options is shown. Stage I options 
include a matrix for selection of the type of discrepancies to search for and, 
because REDS translates all open reading frames, it is possible to search for 
exon/intron, non-coding/coding, and synonymous versus non-synonymous 
positions. In stage II all parameters annotated in dbSNP are selectable. Shown 
is an example that leads to the subtraction of any SNP sites that have been 
genomically validated. RNA secondary structure scores are computed in stage 
III according to the user-defined selection criteria. Candidate sites are ranked 
by structural score values in the output. Results from experimental analysis to 
validate bona fide editing events are annotated in REDS to flag known editing 
sites in future screens. Figure from Maas et al., 2011. 
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close proximity to, the editing site. Finally, the output candidate sites are ranked by an 
overall score. For further information about the REDS program see Appendix A. 
3.3.2 RNA and gDNA isolation from tissue 
All experiments conformed to the guidelines laid down by the Lehigh University 
Animal Welfare Committee, in accord with international guidelines on the ethical use of 
animals. Two 4 month old male mice were sacrificed and their brains dissected. Cortex 
was cleared from white tissue with scissors, halved and weighed. One half was placed in 
1ml of Trizol, the other minced and placed in 1ml of SNET (20mM Tris-HCl pH8, 5mM 
EDTA, 400mM NaCl, 1% SDS) for DNA extraction. Tissue in TRIZOL was 
homogenized and RNA isolated according to the manufacturer‟s protocol. 10g of RNA 
were treated three times with DNase I (NEB) and RNA integrity verified by running an 
aliquot on a standard 1.5% formaldehyde gel. Yield before DNase treatments were 54-
96g RNA from 50-100mg of mouse brain tissue. 
DNA was extracted by digesting tissue with 1mg/ml proteinase K at 55˚C 
overnight and subsequent RNaseA (1g/ml) treatment at 37˚C for 2h. Protein was 
removed by phenol-chloroform extraction. Traces of phenol were cleared from the 
aqueous phase and interphase with 1ml chloroform/isoamylalcohol. After centrifugation, 
DNA in the aqueous phase was precipitated with 1ml isopropanol, spooled, washed 
successively in 70% and 100% ethanol and allowed to dry at room temperature. The 
DNA was eluted over night in 100l Tris buffer. Yield from ~100mg tissue was 78-
105g of DNA.  
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3.3.3 RNA editing analysis 
Human total RNA and gDNA isolated from the same specimen (Biochain) were 
processed using standard protocols for reverse transcription and PCR. Gene-specific 
fragments of cDNA as well as genomic regions were amplified by PCR and subjected to 
dideoxy-sequencing as described previously (Athanasiadis et al., 2004; Gommans et al., 
2008). Primer information is given in Appendix B. Editing at the predicted positions was 
analyzed by inspecting the sequence traces for double peaks, with the ratio of the peak 
heights giving an indication of approximate editing levels. The occurrence of SNPs at 
candidate positions was excluded by analyzing the specimen-matched gDNA. 
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3.4 Results and Discussion 
3.4.1 Evidence for abundant, site-selective recoding A-to-I editing in human and 
mouse  
In eukaryotes, A-to-I RNA editing is the only known mechanism for generating 
inosine residues in RNA molecules. First we asked whether an excess of A/G 
discrepancies versus other types of base differences between cDNA and genomic DNA is 
detectable, even when excluding repetitive element mediated editing. Such a finding 
would support the hypothesis that many more editing sites within protein-coding 
sequences remain to be identified and may provide an estimate of the total number of 
existing sites. We aligned all sequences available in the human and mouse mRNA 
databases [from UCSC genome browser (Kuhn et al., 2007)] to their genomic 
counterparts and mapped the positions of A/G or other discrepancies between genomic 
and expressed sequence (Figure 10). Since there is no known mechanism for causing G/A 
or T/C transitions, we expect that such discrepancies are due to polymorphisms (SNPs) 
and/or sequencing errors and can therefore be considered background noise. 
The combined coding and non-coding regions of mRNA sequences contain more 
A/G-type differences in human than either G/A, C/T or T/C discrepancies (68,000 A/G 
versus 57,000 G/A; 58,000 C/T and 60,000 T/C). In mouse, the total numbers of 
discrepancies are slightly fewer and the excess of A/G discrepancies is less striking 
(62,000 A/G versus 56,000 G/A; 58,000 C/T and 55,000 T/C). This difference can 
probably be accounted for by the widespread Alu-repeat mediated editing in primates, as 
we and others have previously mapped thousands of such editing sites in non-coding 
human mRNA sequences (Athanasiadis et al., 2004; Levanon et al., 2004). 
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Figure 10: Distribution of mRNA/gDNA base-discrepancies in protein-coding 
sequences 
a) Comparison of A/G (blue), C/T (red), G/A (green), and T/C (purple) base 
discrepancies between human cDNA and DNA within coding and non-coding 
transcripts (# of all sites), only protein-coding sequences (coding), only at codon 
positions that predict a non-synonymous codon change (non-synon.), only non-
synonymous sites that are not annotated as genomic SNPs (non-synon. – SNP), and 
the number of distinct mRNAs with non-synonymous sites that are not gSNPs (# 
mRNAs). b) Same as in a) but for mouse. Part of the data is blown up to higher 
resolution on the right side of the figure. Figure adapted from Maas et al., 2011. 
b) Mouse 
a) Human 
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In contrast, rodents lack Alu-repeats and display only low levels of repeat element 
mediated editing. This conclusion is further supported when we exclude all discrepancies 
located within non-coding regions from our analysis (Figure 10). In both human and 
mouse, A/G discrepancies are still the most prominent type of discrepancy and the 
observed excess of A/G in human is comparable to that in the mouse dataset.  
We observe a very strong A/G-discrepancy bias when further restricting our 
analysis to non-synonymous codon changes (Figure 10). Editing at such sites changes the 
meaning of the codon and leads to amino acid substitutions in the resulting protein. There 
is a substantial overrepresentation of A/G discrepancies in both human and mouse (1.4-
2.1 fold in human and 1.3-2.0 fold in mouse) compared to all other types of transitions. 
When all known, genomically validated SNPs are subtracted from the list, the excess of 
A/G discrepancies further increases (1.6-2.2 fold in human and 1.4-2.1 fold in mouse). 
Moreover, when we count once sites identified multiple times in annotated RNA 
sequences (Figure 10; # of mRNAs), the excess of A/G discrepancies persists (1.5-2.0 
fold in human and 1.4-2.0 fold in mouse). Therefore, A/G discrepancy sites are 
distributed across many genes and not dominated by a small number of highly expressed 
genes that are overrepresented in the expression databases.  
Our analysis shows that even when just considering protein coding sequences, 
thereby eliminating the impact of repeat-mediated editing, there is still a substantial 
excess of A/G versus other transitions in the human and mouse transcriptomes. We see a 
surplus of ~4,700 (human) and 5,800 (mouse) unique sites compared to the average of all 
other types of changes. As many sites are edited to only a small extent or in a cell-type 
specific fashion in vivo, the number of discrepancies detected at this time may still be an 
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underestimate of the total number of editing sites in these species. Similarly, negative 
results from experimental evaluation of potential editing sites cannot rule out editing in 
another cell type or at another developmental time point. Alternatively, editing may occur 
to such a low level that the experimental assay is not sensitive enough for detection. In 
fact, two recent high-throughput sequencing studies suggest that the bulk of target sites 
may be edited to a low extent (Enstero et al., ; Li et al., 2009). Such a result is also 
predicted by the continuous probing (COP) hypothesis regarding the possible mechanism 
of how novel editing sites in the transcriptome emerge (Gommans et al., 2009). Due to 
the high accuracy sequence databases we utilized for the analysis (not including EST-
type sequences), we expect that almost half of the predicted ~10,000 potential sites may 
reflect real RNA editing events. Since A-to-I RNA editing is the only eukaryotic 
mechanism known to generate A/G-discrepancies, the excess over the background of 
SNPs and sequencing errors points to the potential existence of thousands of additional 
editing sites to be characterized.  
3.4.2 Synonymous versus non-synonymous changes 
One unresolved question is whether or not ADAR target sites occur 
predominantly at synonymous, or silent, positions. Or in other words, we are interested in 
whether transcript modifications elicited by editing are tolerated more at synonymous 
sites, increased at non-synonymous sites, or occur equally at synonymous and non-
synonymous sites. Until now, such an analysis was not possible due to limited 
information on the frequency of A-to-G discrepancies between genomic DNA and 
expressed sequences on a genome-wide scale. Such an analysis is also hampered by 
incomplete information on the prevalence of genomic SNPs. While still very difficult, the 
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information in Figure 10 allows an approximation of whether discrepancies between 
mRNA and gDNA lead to non-synonymous changes more or less frequently than would 
be expected by chance.  
The expected amounts of synonymous versus non-synonymous codon changes 
due to discrepancies between mRNA and gDNA will depend on at least two things: first, 
the number of possibilities of a synonymous versus non-synonymous change (i.e. how 
many codons change the meaning when A is changed to G, and how many do not?). 
Second, it depends on the codon usage bias (i.e. how frequent is a codon and can it 
contribute to the synonymous versus non-synonymous pool of possible changes?). Let us 
only consider A-to-G changes in human as an example. For simplicity, only single 
nucleotide changes for each codon are included in the calculation. Taking into account 
the codon usage bias in human (downloaded from the codon usage bias database), A-to-G 
changes would elicit a codon change in 78.8% of all cases, if the changes occurred by 
chance (Table 5). Based on the number of discrepancies found in coding sequence 
(Figure 10), i.e. 26,500 for A-to-G changes, and discounting all SNPs (synonymous and 
non-synonymous, obtained from SNPdb build 132), 15,636 A-to-G discrepancies in the 
coding sequence are not based on genomically validated SNPs. Of these, we observed 
about 10,200 discrepancies that lead to non-synonymous changes. However, we would 
expect there to be 12,278 changes if all synonymous and non- synonymous positions 
were targeted by chance alone. Accordingly, non-synonymous changes occur 17.25% 
less likely than would be expected. Calculations were performed for all four types of 
discrepancies discussed in Figure 10 (Table 5). This underrepresentation of non-
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 synonymous codon changes in the observed pool of discrepancies occurs in all 
categories analyzed and is statistically significant (T-test, p<0.05). Of course, in this pool 
of discrepancies we cannot distinguish between true genomic SNPs and editing, but 
assume that both SNPs and editing would affect synonymous vs. non-synonymous 
changes with a similar bias. 
This finding makes sense in an evolutionary context, as non-synonymous codon 
changes might be deleterious compared to synonymous ones. One may speculate that the 
higher reduction seen for C-to-T and T-to-C changes might be due to higher evolutionary 
pressure to conserve these latter ones, possibly because they lead to a higher proportion 
of deleterious non-conservative changes. Likewise, A-to-G and G-to-A changes are 
possibly allowed more because they grant a higher proportion of conservative changes 
such as K/R.  
This traditional view on neutral and conservative codon changes should not 
obscure more recent findings showing that synonymous changes can significantly impact 
Table 5: Observed and expected numbers of discrepancies 
Possible discrepancies in each category were examined with regard to type of change 
and codon bias. This allowed calculation of a hypothetical percentage of discrepancies 
leading to non-synonymous changes. The resulting percentage was used to calculate the 
expected number of non-synonymous discrepancies. In all categories, these were 
underrepresented by the indicated percentage.  
 Category A→G G→A C→T T→C 
# codons with synonymous changes 13 15 16 16 
# codons with non-synonymous changes 32 29 30 32 
% non-synonymous changes  79% 68% 57% 63% 
# discrepancies in coding sequence (observed) 26500 20000 21500 23000 
# discrepancies, coding w/o SNPs (estimate) 15636 10171 13342 13882 
# discrepancies, non-syn. w/o SNP (observed) 10200 5500 4600 6200 
# discrepancies, non-syn. w/o SNP (expected) 12326 6912 7608 8799 
% non-syn. changes underrepresented 17.2% 20.4% 39.5% 29.5% 
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both mRNA maturation and protein folding and function. For instance, it has been shown 
that a neutral SNP in the multi-drug resistance 1 gene results in an altered conformation 
of the protein (Kimchi-Sarfaty et al., 2007). This is probably due to the presence of a rare 
codon, marked by the silent SNP, which affects the timing of co-translational folding, 
altering the structure of the sites of substrate and inhibitor interaction. Indeed, both 
transcript structure and the frequency of codons can affect translation rate and protein 
folding (see Angov, 2011 and references therein). Furthermore, another neutral 
polymorphism has been shown to inactivate an exonic splice silencer site (ESS), 
conferring immunity to deleterious silent mutations in an exonic splice enhancer (ESE) 
that antagonizes the ESS (Nielsen et al., 2007). Therefore, silent codon changes can have 
dramatic context-dependent effects through their involvement in mechanistic and/or 
regulatory aspects of gene expression. More research is required to better understand the 
impact of synonymous codon changes, marked by either a neutral SNP or introduced on 
the transcript level, on protein expression.  
3.4.3 Experimental validation of novel editing sites in the human transcriptome  
High-scoring sites predicted by REDS that were obtained when applying stringent 
parameter settings (window1=500nt, window2=20nt, minimal base-pairs=11) were 
experimentally analyzed (Table 6, Table 7). Out of 32 known and validated A-to-I editing 
sites (considered the „true positives‟ for REDS analysis), 30 positions are detectable by 
REDS due to the presence of at least one mRNA sequence in the database that is of the 
edited variant (24 in case of mouse).  
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Editing for several genes after parallel analysis of cDNA and gDNA from human 
specimen was confirmed in vivo (Table 6). In addition, 10 sites recently experimentally 
validated by Li and co-workers (Li et al., 2009) as well as one site validated by Shah and 
colleagues (Shah et al., 2009) are also predicted as high-scoring targets by REDS, as are 
the other human validated RNA editing sites known at the time. Table 7 lists the top ten 
candidates in human and mouse based on a single, continuously base-paired segment. 
Table 6: Validated human A-to-I editing sites predicted by REDS 
Correctly predicted editing sites by REDS include 10 validated by Li et al., 2009, one 
by Shah et al., 2009 and 15 experimentally validated in our lab. This list does not 
include the 22 human validated RNA editing sites that were known before REDS. Table 
adapted from Maas et al., 2011. 
*All chromosomal positions are from human NCBI Build 36.1/hg18  
Gene Chr Position * Codon change % editing 
COPA 1 158568868 I/V 31 (this study) 
CDK13 7 39957073 Q/R 88 (this study) 
ATP6V0E2 7 149206502 K/E 30 (this study) 
 7 149206516 silent 29 (this study) 
 7 149206525 I/M 69 (this study) 
 7 149206589 R/G 59 (this study) 
 7 149206599 H/R 39 (this study) 
Unknown  
BC027448 
20 4071900, 4071955, 4071957, 
4071967, 4071987, 4071991, 
4072030, 4072068 
Unknown 
(reading frame 
unknown) 
5-95%  
(this study) 
HMCN1 1 184316976 K/E Li et al. 
CADPS 3 62398847 E/G Li et al. 
ATXN7 3 63942940 K/R Li et al. 
FBXL6 8 145550000 Stop/W Li et al. 
CRB2 9 125172441 T/A Li et al. 
RSU1 10 16898999 M/V Li et al. 
GANAB 11 62153917 Q/R Li et al. 
COG3 13 44988372 I/V 41 (Shah et al.) 
NEIL1 15 73433139 K/R Li et al. 
MEX3B 15 80123700 Q/R Li et al. 
ZNF70 22 22417185 Y/C Li et al. 
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Table 7: Candidate editing sites with extended continuous base-pairing in a) 
human and b) mouse 
All sites show A/G discrepancy between cDNA and gDNA, exonic region involved in 
base-pairing, non-synonymous codon position, no mismatches in structure. Only exonic 
sequences are shown. 
In vitro: edited in transfection experiments of minigene constructs into HeLa cells; in 
vivo: validated in human/mouse specimen; in silico: database evidence but in vivo 
editing level not above detection limit of ~5%; ND= not determined due to lack of 
amplification. *All chromosomal positions are from NCBI Build 36.1/hg18 (human) 
and NCBI Build 37/mm9 (mouse). 
 
a) Chr Position of 
discrepancy 
Gene Accession 
mRNA 
bp Editing 
evidence 
  hg18     
1 14 94155441 Serpin peptidase inhibitor A3 BC034554 90 In vitro 
2 7 149206502 ATPase, H+ transporting V0 
subunit 
AK094602 72 In vivo 
3 1 110057883 Glutathione S-transferase M5 AK127250 50 In silico 
4 8 133969994 Thyroglobulin X05615 46 In silico 
5 2 132622172 Hypothetical protein 
LOC554226 
BC045801 26 In silico 
6 20 4071869 unknown BC027448 23 In vivo 
7 21 33916232 Crystallin, zeta-like 1 BX648547 22 In silico 
8 16 57090613 SMAP-8 AK126729 22 ND 
9 11 1599513 Keratin-associated protein 5.4 AB126073 21 In silico 
10 11 70927021 Keratin-associated protein 5.8 AY360461 21 In silico 
       
b) Chr Position of 
discrepancy 
Gene Accession 
mRNA 
bp Editing 
evidence 
1 15 81961974 Coiled-coil domain protein 134 AK154557 36 In silico 
2 2 157383876 Blcap; bladder cancer assoc. 
protein 
AK018127 33 In vivo 
3 6 51538382 Sorting nexin 10 AK152825 26 In silico 
4 7 150745606 CARS, cysteinyl-tRNA 
synthetase 
AK033328 26 In silico 
5 2 83500344 Erythropoietin 4 AK217831 24 In silico 
6 7 149697247 18-day embryo whole body 
cDNA 
AK003147 24 In silico 
7 17 24511429 AT P-binding cassette, sub-
family A 
AK168428 24 In silico 
8 5 23958088 Centaurin gamma 3 AF459091 23 In silico 
9 9 59516903 Pyruvate kinase, muscle AK171106 22 In silico 
10 17 45797892 Transmembrane protein 63b AK217033 22 In silico 
 Table adapted from Maas et al., 2011. 
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Figures 11 and 12 show two novel human editing targets that harbor a total of 13 
newly validated editing sites. ATP6V0E2 is predicted to form an extended, highly base-
paired dsRNA structure with two neighboring segments of 72 and 68bp, respectively, 
which are not part of any repetitive-type element. Five prominent A-to-I RNA editing 
sites were experimentally validated, four of which lead to non-synonymous codon 
changes (Figure 11). Editing levels are between 30% and 70% and the codons are all 
located within the alternatively spliced exon 3. Based on in silico analysis, only about 
1.1% of transcripts (EST and mRNA sequences), all of which show evidence of multiple 
editing sites, contain the alternative exon, which appears to be brain-specific.  
 
Figure 11: Recoding editing in human ATP6V0E2  
Schematic of gene structure and predicted secondary structure of pre-mRNA 
with main base-paired segments indicated. Positions of editing sites are 
indicated with an asterisk and the base-pairing regions of exon 3, intron 3 and 
intron 4 are pointed out by arrows. The nucleotide and amino acid sequence 
with the five major editing sites (4 of them recoding) are given above the 
sequence traces for human brain cDNA (top) and gDNA (bottom). 
Figure adapted from Maas et al., 2011. 
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Figure 12 documents editing in transcripts of a gene (BC027448) of unknown 
function at a total of eight sites with efficiencies between 5 and 95%. It is not known 
whether the mRNA is translated in vivo, or what part of the sequence may constitute a 
functional open reading frame. The predicted RNA secondary structure forms a hairpin 
with adjacent segments of 23 and 15 continuous base-pairs entirely positioned within the 
same exon. 
Other members of the lab also identified the human coatomer protein complex 
subunit alpha (COPA) and cyclin dependent kinase CKD13 as novel editing targets. 
COPA was predicted as a candidate editing target from analysis of zebrafish databases 
and was experimentally validated (Maas et al., unpublished). With no edited version of 
COPA annotated in the human mRNA database, it would have evaded prediction by 
REDS, had we only screened the human database. Experimental analysis of human brain 
cDNA showed conserved editing at the equivalent position to that in zebrafish [31[±4]% 
individual 1; 16[±3]% individual 2; (Maas et al., 2011)]. The I-to-V substitution in COPA 
is positioned directly following one of its conserved WD-motifs. As editing of COPA 
transcripts is conserved in vertebrates from zebrafish to human, the COPA recoding event 
Figure 12: Editing in BC027448 
Schematic of pre-mRNA 
corresponding to human 
BC027448 around exon 3 with 
location of major base-pairing 
features (arrows) and relative 
location of the eight editing sites 
that were experimentally 
detected.  Figure adapted from Maas et al., 2011. 
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is likely to have substantial impact on protein function or regulation. COPA is part of the 
heptameric coatomer complex that defines COPI-type transport vesicles (Nickel et al., 
2002). These vesicles function mainly in the early secretory pathway, for instance in the 
retrograde transport of ER-specific luminal and membrane proteins from Golgi to ER (for 
review see Beck et al., 2009). COPA (or -COP) is a WD-repeat (WD40) protein which 
interacts not only with its coatomer complex partners, but also with signal motifs of 
proteins sorted into COPI vesicles. The conserved I-to-V amino acid substitution which 
results from editing occurs exactly adjacent to the C-terminal end of the second WD40 
domain and it will be interesting to investigate if coatomer complex formation or 
interaction of -COP with other protein ligands is impacted by this recoding event. 
Experimental evidence for site-specific recoding editing in the cyclin dependent 
kinase CDK13 was also obtained, where codon 103 within the ORF undergoes 88% 
editing in human brain changing a glutamine (Q) to an arginine (R) (Maas et al., 2011, 
data not shown). This high level of editing in CDK13 suggests a functional role for the 
predominant edited variant of the gene product. CDK13 has been implicated in splicing 
regulation based on its interaction with other splicing factors and its intracellular 
localization in speckles within the nucleoplasm (Even et al., 2006). Interestingly, the 
localization of CDK13 is dependent on the N-terminal sequence including an RS domain. 
The editing site maps to the N-terminus within a sequence immediately preceding the RS 
domain and may overlap with a monopartite nuclear localization sequence (Even et al., 
2006).  
77 
 
 
Within the human genome, by far the longest perfectly base-paired RNA structure 
(90bp) that involves protein-coding sequences is part of the SerpinA3 transcript (Figure 
13). Based on known RNA editing recoding targets in human and other organisms and 
the widespread editing of repetitive element induced RNA fold-back structures 
(Athanasiadis et al., 2004; Levanon et al., 2004), this extended double-stranded (ds)-
structure should constitute a strong binding platform for ADARs, such that multi-site, 
high-level editing activity is expected, similar to that seen in ATP6V0E2. Surprisingly, 
no evidence of editing could be detected in SerpinA3 amplified from human tissues 
(brain and spleen) at the position predicted by the computational screen, nor elsewhere 
within the exonic sequence forming part of the 90bp structure. However, preliminary 
results show that when segments of the SerpinA3 gene are expressed in a cell culture 
system, editing takes place both by endogenous ADAR and to a higher degree when co-
transfected with an ADAR2 expression plasmid. In vivo, editing may be prevented as a 
protective measure that ensures preservation of SerpinA3 function. Since the 90bp perfect 
Figure 13: Serpin peptidase inhibitor, clade A, member 3 (SerpinA3) 
Schematic of the SerpinA3 gene structure indicating the location of the two 
complementary sequence regions that yield a perfect 90bp RNA structure. A section 
that harbors an adenosine position predicted as editing site by REDS is enlarged. 
Figure 
adapted 
from 
Maas et 
al., 2011. 
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duplex would be heavily and promiscuously edited, the multiple amino acid changes and 
potential ORF disruptions would likely lead to a severely impaired or completely 
abolished function of SerpinA3. For analysis of SerpinA3 editing regulation see Chapter 
7.    
 
79 
 
3.5 Conclusion 
In light of our findings and recent results from a few high-throughput sequencing 
studies, the majority of the recoding A-to-I modification sites seem to be subject to low to 
very low editing (Li et al., 2009; Enstero et al., 2010). In fact, the complexity of the 
current human and mouse mRNA databases is sufficiently high to expect that any 
recoding editing event with high penetrance and wide tissue distribution should be readily 
detectable through a screen, such as REDS, that is based initially on mapping A-to-G 
discrepancies. Indeed, our computational screen predicts many of the known validated 
editing sites in human. Also, compared to a recent high-throughput sequencing analysis 
in mouse (Enstero et al., 2010), REDS detected all of those sites located within eight 
genes that were validated experimentally (Gabra3, Matr3, Ube1x, Xpo7) except those for 
which no edited sequence variant is represented in the mRNA database. In summary, we 
conclude that probably few high-level editing sites exist, most of which have now been 
identified, but a large number of low-level modification events as well as some tissue- or 
time-specific editing sites remain to be validated.  
Compared to previous algorithms used to identify novel A-to-I RNA recoding 
editing sites, REDS shows several advantages. First, unlike previous bioinformatics 
approaches, most known editing targets were present in the candidate list due to the 
greater sequence coverage and unbiased approach of the analysis. Second, user-defined 
parameter settings allow for optimization of the search algorithm, such that new insights 
of ADAR preferences can be immediately integrated. Third, REDS has expanded utility 
as it can also be used to analyze other nucleotide discrepancies.  
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While we were able to identify several previously unknown A-to-I RNA editing 
recoding sites, many of the tested candidates did not show evidence of editing in the 
human brain sample. Large-scale computational analyses such as REDS have recently 
been complemented by high-throughput sequencing methods in the laboratory. Analyses 
by REDS would benefit if combined with deep-sequencing analyses of several tissue 
specimens at different developmental time-points. As discussed previously, editing is 
regulated in a time- and tissue-specific manner and is amenable to external stimuli. 
Candidate editing sites with no evidence of editing in our analysis may be edited to a low 
degree or in a regulated manner, which would be detectable by deep-sequencing.  
Analysis of a single feature of ADAR preference, namely the presence of a 
double-stranded RNA structure, may be insufficient for a ranking method with high 
predictive force (i.e. where highly ranked candidates are likely to be true editing targets). 
Improvements of the program should include the analysis of nearest-neighbors and weigh 
certain sequence signatures that appear to surround edited adenosines as shown recently 
through the structural analysis of ADAR bound to RNA (Stefl et al., 2010). Other 
optional features that could strengthen the program are the analysis of sequence 
conservation around candidate sites and the simultaneous analysis of databases from 
different species. Additional data information will increase the likelihood of finding true 
editing sites that are conserved in the candidate list. One good example is COPA, which 
appeared as a high-ranking candidate in our analysis of the zebrafish but not in the human 
database. As our understanding of the A-to-I RNA editing mechanism increases together 
with ever more information in the databases, so will our ability to predict true editing 
sites.  
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4 Conserved recoding RNA editing of vertebrate C1q-
related factor C1QL1 
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4.1 Abstract 
Complement component 1, q subcomponent-like 1 (C1QL1) was a high-scoring 
candidate (rank 5) of our SNP-based search and filter strategy (Chapter 2). Here we show 
that C1QL1 undergoes RNA editing in vivo, causing non-synonymous amino acid 
substitutions in human, mouse, as well as zebrafish. Remarkably, although editing of 
C1QL1 occurs in different vertebrate species, the predicted RNA secondary structure 
mediating editing involves different regions in zebrafish versus mammals. However, the 
predicted RNA folds of X. tropicalis and M. domesticus (Opossum) resemble neither 
those of mammals nor zebrafish and are not edited. The editing site could thus have 
evolved separately in zebrafish and mammals, or editing may have been lost in some 
species.  
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4.2 Introduction 
Parts of this chapter have been published in Sie & Maas, 2009 (Sie & Maas, 
2009). Complement component 1, q subcomponent-like 1 (C1QL1) emerged as a high 
scoring candidate editing site in our SNP database screen (Chapter 2, Table 4). We 
experimentally analyzed editing in C1QL1 in a cDNA sample and analysis of single 
clones derived from the amplicon revealed that the predicted site was edited to 56%, 
changing a glutamine to an arginine codon (Q66R). In addition to the predicted site, a 
second site ten nucleotides upstream was also edited (18%, T63A). As we lacked the 
matching genomic DNA to this cDNA, we refrained from publishing these findings 
together with the other validated sites from our screen (Gommans et al., 2008). 
Unfortunately, standard PCR did not allow productive amplification of the human 
C1QL1 cDNA fragment from other templates, probably due to its high G/C content. The 
limited amounts of human RNA sample available prompted us to analyze C1QL1 in other 
species such as the mouse, which afforded us ample material to allow optimization of the 
PCR reaction conditions. 
Known editing sites are often conserved and edited in other species. Such 
conservation constrains the surrounding sequence, as it has to be maintained in order to 
facilitate editing by providing a double-stranded binding platform for ADARs. Indeed, 
bioinformatics screening methods often employ a conservation filter, with which highly 
conserved sequences surrounding a potential editing site are favored (Levanon et al., 
2005; Gommans et al., 2008). We therefore sought to analyze RNA from other species in 
order to confirm editing of C1QL1.  
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The sequence surrounding the C1QL1 editing site as well as the corresponding 
predicted RNA folds are highly conserved in mammals. Analysis of the predicted RNA 
fold of zebrafish C1QL1 also revealed a highly base-paired region that could potentially 
serve as editing target. However, the sequence and secondary structure are vastly 
different from those in mammals. We therefore experimentally analyzed zebrafish cDNA 
and gDNA and found that the site corresponding to the mammalian Q66R is edited to a 
high level. To further evaluate conservation of editing at this particular site, we also 
investigated editing in X. tropicalis and M. domesticus, two distant species. The predicted 
RNA folds of these differ from both that of mammals and zebrafish and appear not to be 
amenable for editing, and indeed experimental validation revealed no editing of C1QL1 
in these species. In summary, we show that C1QL1 undergoes A-to-I RNA editing within 
its open reading frame, leading to non-synonymous codon changes in human, mouse and 
zebrafish transcripts, but not in X. tropicalis and M. domesticus. 
 Even though the degree of conservation has been used as a filter-strategy to 
search for new editing sites, the way in which editing sites arise and evolve has been a 
vastly unexplored question in the field. For instance, differential editing occurs in 
potassium channels of octopus. RNA editing is regulated depending on the environment, 
specifically the temperature, where the octopus is living (Dr. J. Rosenthal, personal 
communication). The plastic nature of pre-mRNA secondary structure may allow 
continuous probing of potentially beneficial editing sites. Accordingly, an editing event 
would become engraved if it conferred an adaptive advantage under a given selection 
pressure, and only then would be edited at relatively high levels (Gommans et al., 2009).  
  
85 
 
4.3 Materials and Methods 
4.3.1 Databases and data analysis 
RNA secondary structures were predicted using the M-fold algorithm (Zuker, 
2003) and multiple sequence alignments were done with clustal W 1.8. Expressed 
sequence tag (EST) analysis for human, mouse and rat were performed using the NCBI 
BLAST server. 
4.3.2 cDNA and genomic DNA 
Human brain total RNA and gDNA isolated from the same specimen were 
obtained from Biochain, CA. For analysis of mouse C1QL1, total RNA and genomic 
DNA from cortex and cerebellum of two adult mice were prepared using standard 
procedures (Appendix A). Danio rerio gDNA and total RNA were isolated from adults 
and 4 day hatchlings using the same procedures (Appendix A). RNA was treated with 
DNase and processed using a standard protocol for reverse transcription (Appendix A). 
One specimen of X. tropicalis was sacrificed by hypothermia and dissected and gDNA 
and total RNA were isolated as before. M. domesticus tissue samples in RNAlater were 
kindly provided by Dr. Samollow, Texas A&M University, and processed to obtain 
gDNA and RNA with the same standard procedures as described.  
4.3.3 PCR 
For experimental validation, gene specific fragments of cDNA as well as genomic 
regions from the same specimen were amplified by PCR, gel-purified (QIAEXII Gel 
Extraction Kit, Qiagen) and subjected to dideoxy sequencing (Geneway Research) 
(Athanasiadis et al., 2004).  
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For amplification of part of the human C1QL1 comprising the putative editing 
site, the reaction mixes contained 400nM of each primers (Homo sapiens: C1Q14D and 
C1Q13U; Mus musculus: mC1Q7D and mC1Q8U ; Danio rerio: drC1Q15D and 
drC1Q16U, M. domesticus: mdC1Q17D and mdC1Q18U;  X. tropicalis: xtC1Q19D and 
xtC1Q20U; for primer sequences see Appendix B), 2l Phire™ Hot Start DNA 
Polymerase (NEB), 400nM dNTP mix, 3% DMSO (5% for Homo sapiens), 1l cDNA, 
and Phire polymerase buffer provided by the manufacturer in a total volume of 100l. 
The reactions were carried out in an Eppendorf Mastercycler. Cycling conditions 
included a 2 minute initial denaturation step followed by 35 cycles of:  
 H. sapiens M. musculus D. rerio M. domesticus X. tropicalis 
Denaturing 98°C, 10” 98°C, 10” 98°C, 10” 98°C, 10” 98°C, 10” 
Annealing 71°C, 5” 72°C, 5” 69°C, 5” 70°C, 5” 72°C, 5” 
Extension 72°C, 10” 72°C, 15” 72°C, 12” 72°C, 12” 72°C, 10” 
followed by a final extension step of 72°C for 1 minute. If yield was too low, a secondary 
PCR with the same conditions was performed, using 1l of the first PCR as template. The 
PCR products were purified by phenol-chloroform extraction, ethanol-precipitated, and 
subjected to DNA gel electrophoresis on a 2% agarose gel. The band of the expected size 
was excised and purified using the QIAEX II Gel Extraction Kit (QIAGEN). The purified 
products were sequenced. 
4.3.4 Subcloning 
For further analysis, PCR products were subcloned into pBluescript II 
(Stratagene) vector and individual DNA templates were purified and sequenced. Briefly, 
a PCR reaction using 400nM of each of the primers (human: C1Q14D-Eco and C1Q13U-
KpnI; mouse: mC1Q7D-Eco and mC1Q8U-KpnI; for primer sequences see Appendix B) 
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was performed on 2.5% of the purified amplicons, with PCR conditions as described 
above for human and mouse, respectively. The amplicons were restricted with 40U KpnI 
(NEB cat# R0142) for 3 hours at 37ºC, subsequently purified by phenol-chloroform 
extraction, ethanol-precipitated and restricted with 40U EcoRI (NEB) for 3 hours at 37ºC. 
Again, the cut fragments were purified by phenol-chloroform extraction and precipitated 
with ethanol, and then subjected to DNA gel electrophoresis on a 2.5% agarose gel. The 
bands of the expected size were excised, purified using the QIAEX II Gel Extraction Kit 
(QIAGEN) and then ligated into a pBluescript SK II vector also cut with EcoRI and KpnI 
and purified as described for the amplicon. The ligation reactions contained vector and 
insert in a 1:8 molar ratio and 0.5l T4 ligase (Invitrogen) in a total volume of 10l and 
was incubated at room temperature 4 hours to overnight. Z-competent DH5 cells were 
transformed with 5-10l of the ligation. Heat-shock was performed for 1.5min at 37ºC. 
The transformed cells were plated on LB containing ampicillin. Individual recombinant 
clones were used to inoculate liquid LB-amp and the purified plasmids (QIAprep Spin 
Miniprep Kit, QIAGEN) were sequenced.  
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4.4 Results and Discussion 
4.4.1 A-to-I RNA editing in mammalian C1QL1 is conserved 
Within the highest scoring group of predicted target sites derived from our study 
outlined in Chapter 2, we showed that three out of four positions are bona fide RNA 
editing recoding sites which affect two genes, splicing factor SRp25 and insulin-like 
growth factor binding protein IGFBP7 (Gommans et al., 2008). None of the lower 
scoring candidates that we evaluated experimentally (total of 68 sites) showed detectable 
RNA editing in human brain tissue. As standard PCR did not allow productive 
amplification of the human C1QL1 cDNA fragment, probably due to its high G/C 
content, we used abundant total mouse RNA to optimize reaction conditions for a RT-
PCR protocol that would allow RNA editing analysis. Not only is the mouse C1QL1 
cDNA highly conserved to the human sequence, but the predicted RNA secondary 
structures of mouse, rat and human exon 1 sequences are also the same (Figure 14). 
Therefore, we hypothesized that RNA editing at the projected position in human would 
be conserved in its mouse orthologue.  
Use of a DNA polymerase with high processivity, a buffer formulated to support 
amplification of GC-rich templates, and an optimized amplification protocol allowed us 
to obtain a specific amplicon for mouse C1QL1 cDNA. The analysis of purified cortex 
and cerebellum samples revealed three positions of RNA editing within the same exon of 
C1QL1, all of them effecting an amino acid substitution. The Q66R site had been 
predicted by our computational screen (Chapter 2, Table 4; Gommans et al., 2008), while 
the others alter a threonine (ACG) to an alanine (GCG) and a glutamine (CAG) to 
arginine (CGG) codon, respectively. Table 8 summarizes the editing levels measured at 
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the three sites within the two mice. Intriguingly, editing levels in cerebellum are 
substantially different from those in cortex, arguing for tissue-specific regulation of 
editing. The Q66R site is edited to 10% or 17% in cerebellum, whereas it is edited to only 
1-3% in cortex. Q69R only showed evidence of editing in cerebellum (3-7%) and the 
T63A site is modified at 1-2% in both cortex and cerebellum. Taken together, we 
confirmed that all three sites in mouse C1QL1 undergo RNA editing in vivo. 
Sample origin Number of clones 
analyzed 
T63A  
% editing 
Q66R  
% editing 
Q69R  
% editing 
Cortex mouse 1 66 1.5 1.5 - 
Cerebellum mouse 1 54 1.8* 17.0 3.6 
Cortex mouse 2 38 - 2.6 - 
Cerebellum mouse 2 40 2.5* 10.0 7.5 
 
We then moved to the analysis of several samples of human cDNA, applying the 
optimized protocol. As discussed in Chapter 2, one human brain cDNA showed high 
levels of modification at T63A (18%) and Q66R (56%), respectively (Figure 8). As in 
mouse, codon 63 was always edited concomitantly with codon 66. However, the genomic 
counterpart for this human specimen was not available. Subsequent subcloning analysis 
of additional specimens from human brain together with the corresponding genomic 
DNA confirmed the occurrence of RNA editing at the Q66R position, as the genomic 
Table 8: Analysis of C1QL1 RNA editing in mouse specimen by subcloning  
Amplicons from mouse cortex and cerebellum were subcloned into pBluescript 
vector. Sequencing of single clones shows differential editing at the Q66R site with 
10-17% editing in cerebellum and only low levels in cortex. T63A and Q69R are 
edited to a low extent and may not be edited at all in certain tissue samples (for 
example cortex mouse 2).  
*T63A is only edited together with Q66R site, which correlates with results from 
first analyzed human cDNA (Chapter 2). 
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samples displayed an adenosine (Figure 14). However, editing at the T63A site was not 
detectable in any of the samples (Table 9).  
 
 
Figure 14: Editing in mouse 
and human C1QL1 
a) Secondary structure 
predictions of human, mouse 
and rat C1QL1 encompassing 
the editing site. Putative editing 
sites are bold and underlined. 
Within the mouse sequence, 
bases that differ from human are 
shaded, and those that are 
different in rat are shown above 
the mouse sequence (shaded and 
boxed). 
b) Representative sequence tracks from single clones of C1QL1 from mouse 
cerebellum (top) and human brain specimen (bottom). Genomic sequences are shown 
above cDNA sequence tracks. Editing sites are boxed. 
a) 
b) 
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Sample number No. of clones  T63A site edited Q66R site edited 
unknown 45 18% 60% 
B105092 42 - 14% 
A802100 33 - - 
B105090 32 - - 
B105092 32 - 3% 
 
Although we cannot rule out that the T63A site represents a previously unknown 
recoding gSNP in human, our results from analysis in mouse, the complete conservation 
of the predicted RNA secondary structure surrounding the editing sites, as well as the 
observed coupling between major and minor editing sites argue that, like in mouse, the 
minor position is also an A-to-I target in human.  
The observed variation in editing levels at both the major and minor sites in 
human specimens may be due to regional and/or temporal regulation of C1QL1 editing, 
similar to what is observed for other recoding editing targets, such as glutamate receptor 
transcripts (Paschen & Djuricic, 1995). This assumption is supported by the tissue-
specific pattern of editing in mouse brain tissue described above. We also analyzed 
human spleen, lung, kidney, heart, and pancreas RNA samples for editing in C1QL1, but 
did not detect editing above the detection limit of 5% for sequence track analysis Figure 
15).  
Table 9: Analysis of C1QL1 RNA editing in human brain specimen by 
subcloning  
Amplicons from human brain samples were cloned into pBluescript vector. 
Sequencing of single clones confirms editing at the Q66R site with 3-14% editing 
in amplicons derived from one specific specimen (B105092). The other two 
analyzed samples displayed no editing in any of the sequenced clones (A802100 
and B105090).  
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4.4.2 A distinct RNA fold supports zebrafish C1QL1 editing  
The C1QL1 exon 1 sequence is strongly conserved between mammalian species 
(Figures 14 and 16) which suggests that in addition to the human and mouse gene, also 
the rat, cow and dog C1QL1 RNA is likely subject to editing. However, we noticed that 
the predicted secondary structure supporting editing in mammalian C1QL1 is not 
conserved within the zebrafish (Danio rerio) orthologue (Figure 16). The editing site 
complementary sequence (ECS) within human exon 1, located 50 nucleotides upstream 
of the recoding editing sites, is not conserved in any of the non-mammal sequences 
including zebrafish. However, in zebrafish, another RNA fold of similar strength is 
formed with sequences downstream of the recoding sites within exon 1. Indeed, when we 
analyze RNAs isolated from adult and four day post-fertilization zebrafish specimens, we 
readily detect editing at the Q74R site (equivalent to human Q66R) at about 50% in adult 
and 33% in hatchlings (Figure 16). The distinct RNA fold predicted for the zebrafish 
sequence is supported by the fact that two additional adenosines located on the opposite 
Spleen  
Lung    
Kidney   
Heart   
Pancreas  
Figure 15: C1QL1 
editing analysis of 
diverse tissues 
Sequence tracks (reverse 
shown) of C1QL1 
amplified from various 
human tissue samples. 
No evidence of editing is 
apparent from this 
analysis. 
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Figure 16: Clustal W (1.81) alignment of vertebrate C1QL1 sequences and RNA 
secondary structures that mediate editing  
a) Base-paired nucleotides in the mammalian structure are depicted in purple for the 
sequence surrounding the recoding editing sites and in yellow for the upstream, 
complementary region. Nucleotides involved in base-pairing in the zebrafish RNA 
structure are shown in purple (region around the recoding editing site) and green 
(downstream complementary region). Adenosines that were experimentally shown to 
be subject to editing are shown in red font with yellow shading. Nucleotides identical 
across all displayed species are indicated by a star below the alignment; base-
pairing nucleotides are further highlighted through bracket notation. b) Zebrafish 
RNA secondary prediction (Mfold). The edited adenosine corresponding to the Q66R 
site is highlighted in bold and underlined. Adenosines edited on the opposite strand 
of the duplex are highlighted in bold and gray shade. c) C1QL1 sequence tracks of 
cDNA derived from two adult (top) and 4-day old hatchlings (bottom) zebrafish. The 
edited adenosine corresponding to Q74R is boxed. gDNA sequence track showed 
absence of SNP at the corresponding position, validating it as a true editing site (not 
shown). Figure adapted from Sie & Maas, 2009. 
 
b) 
a) 
c) Adult 1 
Adult 2 
4-day hatchlings 
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site of the predicted duplex also undergo editing. In contrast, human C1QL1 does not 
show any evidence of editing at the downstream adenosines. 
4.4.3 C1QL1 editing is not conserved in other species 
While the predicted RNA folding patterns of most mammalian sequences are 
similar if not identical to each other, those of evolutionarily more distant species like X. 
tropicalis, Tetraodon nigroviridis, Takifugu rubripes (fugu), Gasterosteus aculeatus 
(stickleback), Oryzias latipes (medaka) and Danio rerio (zebrafish) differ considerably 
from that of mammals and amongst each other (comparison of sequence homology 
between different species and homo sapiens C1QL1 see Table 10). 
These differences can partly be explained by sequence insertions of up to 15 
nucleotides upstream of the editing target site in addition to sequence diversification (see 
as example fugu and zebrafish in sequence alignment of Figure 16). Of the 10 
mammalian sequences analyzed by Mfold, only the predicted structure of opossum 
differs considerably from that of human. We analyzed C1QL1 from various tissues of 
both M. domesticus and X. tropicalis, whose secondary structure predictions are different 
from both human and zebrafish (Figure 17a), and found that none of the sequence tracks 
showed detectable editing levels (Figure 17b). 
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5’- CUCCGCCUUCCA--CUCUGGUGC 
    ||||||||||||  ||||||||| 
3’- ggggugggaggu  gagactatg 
                ac         ……… 
 
       AA      CAAG-  AAAG    A 
5’- GGUUC  GGUCCU     GC    CUGG C 
    |||||  ||||||     ||    ||||  G 
3’- CCAAG  GGCCCA     GC    GACC U 
                 AAAAA  ----  
 
Figure 17: Analysis of X. 
tropicalis and M. domesticus 
C1QL1 editing 
a) Predicted secondary structures 
of X. tropicalis and M. domesticus 
encompassing the homologous 
region that is edited in mammals 
and zebrafish.  
b) Representative sequence tracks 
of X. tropicalis and M. domesticus 
shows no evidence of editing of 
C1QL1 in these species. 
a)     X. tropicalis 
M. domesticus (two 
alternative structures shown) 
X. tropicalis 
M. domesticus 
b)       
% Identity to Homo sapiens aa level 
nt level (coding 
sequence exon1) 
nt level (coding 
sequence only) 
Macaca mulatta 99% 98% 98% 
Mus musculus 98% 97% 93% 
Rattus norvegicus 98% 97% 92% 
Bos Taurus 98% 94% 93% 
Canis famiiaris 98% 94% 94% 
Sus scrofa 96% 94% 94% 
Monodelphis domestica 93% 84% 84% 
Xenopus tropicalis 82% 71% 73% 
Tetraodon nigroviridis 79% ND* ND* 
Danio rerio 75% 75% 74% 
 
Table 10: Identity of C1QL1 sequences among species 
Identity of amino acid and nucleotide sequences, respectively, of C1QL1 in ten 
species compared to homo sapiens C1QL1.  
*ND = not determined due to lack of nucleotide sequence 
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4.5 Conclusions 
Our findings validating mammalian C1QL1 as a bona fide A-to-I RNA editing 
target further highlights the effectiveness of our bioinformatics search strategy as applied 
to the subset of human mRNAs with non-synonymous A-to-G discrepancies chosen from 
the SNP database. Four of the top five highest scoring sites prove to be in vivo editing 
targets, whereas none of the tested sites with lower scores (an additional 64 positions 
tested) show detectable editing.  
Editing of C1QL1 occurs in human, mouse and zebrafish, where it is facilitated 
by a different RNA fold. Editing may also occur in other mammalian species, due to a 
conserved RNA fold. However, editing in this target probably does not extend throughout 
the animal kingdom, as analysis of C1QL1 of opossum and Xenopus has shown. Further 
investigation of additional species would be interesting, in particular those with similar 
RNA secondary structures to that of zebrafish. However, the limited number of species 
with annotated C1QL1 sequences currently prevents such an undertaking. 
The family of C1Q-domain proteins includes important signaling molecules with 
roles in inflammation, adaptive immunity and energy homeostasis (Ghai et al., 2007). 
The physiological function of C1QL1 has not been elucidated, but it is expressed highest 
within the brain, particularly in the brainstem parts of the cerebellum (Iijima et al., 2010), 
and was suggested to be especially important for neurons involved in coordination and 
regulation of motor control (Berube et al., 1999). Furthermore, it may be part of a 
neuroprotective immune response and is expressed from glia cells (Glanzer et al., 2007). 
One study revealed upregulation of C1QL1 in response to kainic acid induced seizures 
(Hunsberger et al., 2005). All four C1QL family members are secreted, form homo- and 
B 
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heteromers and oligomerize to hexamers and high-molecular weight complexes (Iijima et 
al., 2010). Members of the closely related Cbln family were shown to act as trans-
neuronal regulators of synaptic integrity by stabilizing synaptic contacts and controlling 
functional synaptic plasticity by regulating the postsynaptic endocytosis pathway of 
AMPA receptors (Yuzaki, 2008). Reminiscent of such a role, the C1QL family members 
may also act as neuronal cytokines. It is speculated that the degree of multimerization and 
heteromer formation may allow for the activation of different receptors and functions 
(Iijima et al., 2010). The T63A and Q66R amino acid substitutions may impact protein 
oligomerization as they are situated immediately prior to a collagen-like trimerization 
domain (Figure 8). In other C1Q-domain proteins, such as the hormone adiponectin, this 
also coincides with a region of protease-mediated processing (Waki et al., 2005). Future 
studies will show if the amino acid substitutions caused by RNA editing may alter post-
translational processing of C1QL1, or if it affects other properties of the protein in vivo.  
It remains to be elucidated why editing of C1QL1 occurs to such a high level in 
zebrafish. High levels of editing often point toward a functional consequence for the 
ensuing protein variants. It is especially intriguing that the same codon in mammals and 
zebrafish is targeted by ADARs, yet the double-stranded structures that support editing 
are vastly different from each other. This suggests that the editing sites evolved 
independently of each other, which again strongly implies a functional impact on the 
encoded protein. Due to the current incomplete picture of C1QL1 function, possible 
consequences will have to be assessed at a later date.  
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5 Consequences of RNA editing on FLNA-protein 
interactions  
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5.1 Abstract 
Filamin A (FLNA) organizes cytoskeletal F-actin into crosslinked networks and 
tethers them to the cell membrane. It is indispensable for maintaining and remodeling the 
cytoskeleton to effect changes in cell shape and migration, whereby it serves as a 
molecular scaffold by interacting with various proteins. FLNA has a N-terminal actin-
binding domain followed by 24 Immunoglobulin (Ig)-like repeats. The 24
th
 repeat serves 
as a dimerization domain. FLNA is edited in its 22
nd
 C-terminal repeat, The codon 
change alters an uncharged Glutamine (Q) to a positively charged, bulkier Arginine (R). 
The two protein isoforms (FLNA and FLNA-Q/R, respectively) are produced in one cell 
from the same allele. Editing in FLNA is highly conserved and regulated in a tissue-
specific manner, suggesting that the amino acid change produces a functionally distinct 
protein isoform. Here we tested the ability of the two isoforms to bind known interaction 
partners in a yeast-two-hybrid assay to determine if editing alters binding affinity to any 
of them. 
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5.2 Introduction 
Filamins were discovered as a family of non-muscle actin-binding proteins in the 
1970s. The filamin family encodes three isoforms in mammals, Filamin A, B and C 
(FLNA, FLNB and FLNC). They consist of an amino-terminal actin-binding domain 
(ABD) composed of two tandem calponin homology domains (CHD1 and CHD2), 
followed by a long rod of 24 repeated, anti-parallel -strands that adopt an 
immunoglobulin-like fold (Nakamura et al., 2007). The long rod is interrupted by two 
flexible hinges between repeats 15 and 16 and 23 and 24, respectively (Feng & Walsh, 
2004). Dimerization occurs through the last carboxyl-terminal repeat, mediating the 
formation of a V-shaped structure. These high-molecular weight cytoplasmic dimers 
serve as structural proteins that link cortical actin filaments into a dynamic three-
dimensional structure (Nakamura et al., 2007). The actin cytoskeleton is not only 
essential for the maintenance of cell shape and motility, but also for the integration of cell 
signals that initiate and propagate alterations in the cytoskeleton. FLNA has been found 
to interact with a multiplicity of transmembrane and peripheral membrane proteins, of 
which more than 30 have been identified (Ohta et al., 1999; Robertson, 2005; Ohta et al., 
2006; Zhu et al., 2007). Furthermore, either as a full-length protein or in its cleaved form, 
it has also been shown to colocalize with transcription factors and nuclear receptors 
(Popowicz et al., 2006).  
Genetic mutations in FLNA and FLNB have been shown to cause a wide range of 
human X-linked diseases. Null-mutations cause dysfunctional neuronal migration, which 
manifest themselves as periventricular heterotopias characterized by a partial failure of 
neuronal migration into the cerebral cortex with consequent formation of ectopically 
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placed neuronal nodules in the ventricular and subventricular zones (Guerrini & 
Carrozzo, 2001; Sheen et al., 2002; Sheen et al., 2005; Sarkisian et al., 2008). Missense-
mutations in FLNA are connected with the spectrum disorder otopalatodigital syndrome 
which includes otopalatodigital syndromes types 1 and 2, frontometaphyseal dysplasia, 
and Melnick-Needles syndrome (Robertson, 2005). The disorders are a phenotypically 
heterogeneous group of conditions characterized by a skeletal dysplasia and variable 
anomalies in the brain, craniofacial structures, cardiac, genitourinary and gastrointestinal 
systems (Robertson, 2005). More recently, some mutations in FLNA have also been 
associated with the connective tissue disorder Ehlers-Danlos syndrome, in which affected 
individuals present joint and skin hyperextensibility and vascular problems (Sheen et al., 
2005).  
The ~96 amino acid long repeats forming the antiparallel, partially overlapping -
strands are highly homologous. However, -strands 16-24 have been shown to pack more 
tightly than those in the N-terminal portion of the protein (Nakamura et al., 2007), some 
of them apparently folding onto neighboring repeats in a way that may regulate binding 
to other proteins (Lad et al., 2007). FLNA mRNA was shown to be subjected to A-to-I 
RNA editing, changing a glutamine to an arginine codon (Q2341R) in its repeat 22 at 
amino acid 2341 (Levanon et al., 2005). No functional consequences of this amino acid 
change have yet been reported. Several proteins are known to interact with the C-
terminus of FLNA (Feng & Walsh, 2004) (Figure 18), shown either by a yeast-two-
hybrid or similar protein binding assay. Here we assessed whether the altered amino acid 
in FLNA impacts its interaction with one or more of its known binding partners. We 
selected proteins for analysis based on reports in the literature that indicate that repeat 22  
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of FLNA might be required for that specific interaction. Since FLNA acts as a molecular 
scaffold, we expect that alterations in its binding capability will have significant impact 
on the functional capacity of the resulting signaling complexes. To test this hypothesis, 
proteins that interact with fragments of FLNA that include repeat 22 were chosen for 
analysis in the Matchmaker
TM
 GAL4 Two-Hybrid System 3 (Clontech). The reported 
interaction proteins were genetically fused to the GAL4-DNA binding domain as bait, 
and FLNA or FLNA-Q/R was fused to the GAL4-activation domain as prey. Interaction 
between the fusion proteins was assessed using -galactosidase assays. 
  
C 
Figure 18: FLNA domain structure and binding proteins 
Each subunit of the FLNA homodimer has a C-terminal actin-binding 
domain composed of two CHD domains followed by 24 antiparallel 
-sheets interrupted by two hinge-regions. The N-terminal 24th repeat 
mediates dimerization. FLNA was shown to interact with more than 
30 proteins (Feng & Walsh, 2004). 
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5.3 Materials and Methods 
5.3.1 Cloning Procedures 
Cloning procedures are outlined in Appendix A, primer sequences can be found in 
Appendix B. Briefly, the following gene fragments were ligated into the corresponding 
restriction enzyme sites of the indicated vectors: 
Gene Vector 
5’ restriction 
site 
3’ restriction 
site 
Expressed 
fragment 
FLNA pGADT7 Sfi1 Xho1 C-term. 476 aa 
Integrin1 pGBKT7 BamH1 Pst1 C-term. 47 aa 
Presinilin pGBKT7 BamH1 Pst1 aa 259-407 
mGluR5a pGBKT7 BamH1 Pst1 aa 827-933 
mGluR7b pGBKT7 BamH1 Pst1 aa 900-922 
mGluR8a pGBKT7 BamH1 Pst1 aa 855-908 
P73a pGBKT7 Nde1 EcoR1 aa 464-636 
P2Y2 pGBKT7 BamH1 Pst1 aa 318-362 
Calcitonin 
Receptor 
pGBKT7 BamH1 EcoR1 aa 390-474 
BRCA2 pGBKT7 BamH1 Pst1 aa 187-354 
Smad5 pGBKT7 Nde1 BamH1 
Insertion 
mutation, non-
functional 
SEK1 pGBKT7 Nde1 BamH1 
Cloning not 
successful 
FLNA Q/R pGADT7 Retrieved by site-directed mutagenesis of FLNA 
Integrin1-
Y788E 
pGBKT7 Retrieved by site-directed mutagenesis of Integrin1 
5.3.2 Yeast Transformation 
2x50ml of YPDA was inoculated with three ~3mm large colonies each and 
incubated at 30˚C for 18 hours, shaking, to OD>1.2. The overnight cultures were diluted 
to OD 0.25 into 150-250ml YPDA and incubated at 30˚C for 3 hr, shaking, to OD ~0.5. 
The cell suspension was distributed into 50ml falcon tubes and centrifuged at 1000g for 5 
minutes at room temperature. The supernatant was discarded and cells were pooled and 
resuspended in 2x25ml sterile TE. Cells were centrifuged again for 5 minutes at 1000g, 
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the supernatant decanted, and the pellet resuspended in 2x1.5ml sterile 1xTE/LiAc 
solution. In 1.5ml eppendorf tubes, 200ng of pGBKT7-bait plasmid was mixed with 
100ng pGADT7-fusion protein plasmid and 100g herring testes carrier DNA. 100l 
yeast competent cells and 600l sterile PEG/LiAc solution were added and vortexed to 
mix. The cells were incubated at 30˚C for 30 minutes. 70l DMSO was added and mixed 
by inversion, followed by a 15 minute heat-shock at 42˚C. Cells were chilled on ice for 2 
minutes, centrifuged briefly, the supernatant removed, and resuspended in 500l 1xTE. 
100–200l transformed cells were plated on SD –Leu/-Trp plates and incubated at 30˚C 
for 2-3 days. 
5.3.3 -Galactosidase Colony Lift Assay 
Single colonies from the transformation were streaked out on selection medium 
(SD –Leu/-Trp). The plates were incubated at 30°C for 2-3 days. Whatman filter paper 
was placed onto the plates and carefully flattened to pick up yeast patches, removed and 
submerged into LN2 for 10 seconds to break open the cells. With the cells facing upward, 
the paper was then placed onto a filter paper pre-soaked in Z-buffer/X-Gal solution. 
Color was allowed to develop for 4 hours. Frequent photographs were taken to monitor 
color development over time. 
5.3.4 ONPG Assay 
Fresh (<3 weeks old) colonies of single-colony purified yeast transformants were 
submerged into 1ml SD-Trp/-Leu selection medium, vigorously vortexed to disperse the 
cells and transferred to a 5ml culture. Cultures were incubated at 30°C for 16-20 hours on 
a rotating wheel. 1ml of overnight culture was transferred to 4ml YPD medium and 
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incubated for 3-5 h at 30°C until cells were in mid-log phase (OD600 = 0.5-0.8). All 
FLNA-expressing yeast cells had slowed growth and were thus used directly at OD600 = 
0.5-0.8 from the overnight culture. OD of each culture was recorded before harvest. 
3x1.5ml of cultures were centrifuged at maximum speed for 30 seconds. Supernatants 
were removed and cells resuspended in 1.5ml Z buffer. After centrifugation, pellets were 
resuspended in 200l Z buffer (concentration factor is 1.5/0.2 = 7.5 fold). 3x62.5l of 
cell suspension was distributed to fresh microcentrifuge tubes. Cells were lysed by three 
freeze/thaw cycles of 5-10 minutes at -150°C followed by 2 minutes at 37°C. 437.5l Z-
buffer/-mercaptoethanol was added to reactions and blanks, which contained 62.5l Z-
buffer. Time was recorded and 100l ONPG in Z buffer was added to each reaction and 
blank. The reaction was allowed to proceed at 30°C until yellow color developed, 
anywhere between 30 minutes and 4 h. To stop the reaction, 250l 1M Na2CO3 was 
added. Elapsed time for each reaction was recorded. Tubes were centrifuged for 10 
minutes at maximum speed to pellet cell debris and supernatants were transferred to 
cuvettes. The spectrophotometer was calibrated against the blank at A420 and OD420 of 
samples were measured relative to the blank. -galactosidase units were calculated 
according to the Yeast Protocols Handbook (Clontech): 
-galactosidase units  =  1,000 x OD420 / (t x V x OD600) 
 t =  elapsed time in minutes until reaction was stopped 
 V = 0.0625 ml x 7.5 (concentraction factor) 
 OD600 = A600 of 1ml culture (input) 
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5.4 Results and Discussion 
5.4.1 Colony-lift assay 
To assess differences in binding between FLNA and FLNA-Q/R protein variants 
we used the Matchmaker
TM
 GAL4 Two-Hybrid System 3 of Clontech according to the 
manufacturer‟s instructions. Briefly, the phenotype of S. cerevisiae strain Y187 
(phenotype: Mat, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4, met-, 
gal80, URA3::GAL1UAS-GAL1TATA-lacZ) was verified by assessing growth on 
selection plates (-Ura, -His, -Leu, -Trp, -Leu/-Trp) before using them for transformation. 
As a control, each plasmid was transformed together with an empty vector contributing 
either Trp or Leu resistance, respectively, so that all transformants could be selected on 
SD –Leu/-Trp plates. These controls were necessary to determine if the single fusion 
proteins were able to activate expression of the reporter gene by themselves. Additional 
controls included a vector that constitutively expresses LacZ (pCL1) and can thus be used 
for verification of the -Galactosidase assay, as well as GAL4 fusion proteins that show 
interaction and activate lacZ transcription when co-expressed (pGADT7/T-antigen and 
pGBKT7/p53) or fusion proteins that do not interact and are used as negative controls 
(pGADT7/T-antigen and pGBKT7/Lam). A table of the plasmid combinations for the co-
transformations is outlined in Appendix A.  
All transformants that express the FLNA fusion protein or its edited variant 
showed considerably slower growth than other transformants. This reduced growth 
resulted in noticeably smaller colonies on the transformation plates. On every plate with 
such small colonies, several (<1%) larger colonies also appeared. To test whether these 
larger colonies represented transformants that had lost expression of the Gal4-AD-FLNA 
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fusion protein, a subset of them were also single-colony purified and tested in the colony-
lift assay (see below), namely mGluR5a, mGluR8a, p73a, P2Y2, BRCA2, and CTR, co-
transformed with either Gal4-AD-FLNA or Gal4-AD-FLNA-Q/R, respectively. The yeast 
transformants originating from these larger colonies were unable to activate the reporter 
gene, in contrast to the transformants purified from small colonies. The large colonies 
therefore represent revertants that may have lost the ability to express the FLNA fusion 
proteins, which would be consistent with the lack of reporter gene activation. Forthwith, 
all subsequent transformants were single-colony purified from small colonies for testing 
in yeast-two-hybrid assays. However, the finding that some cells may be able to lose the 
ability to express the FLNA fusion proteins was noted. 
A -galactosidase colony-lift assay was used to assess activation of the reporter 
gene lacZ. On every plate, all three controls (pCL1, pGADT7-T-antigen + pGBKT7-p53, 
and pGADT7-T-antigen + pGBKT7-Lam) were present at least once, and each 
experiment was done in triplicate. Colonies of double transformants spread out in 1cm
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patches did not grow at comparable rates; FLNA co-transformation slowed yeast growth 
considerably, and thus these strains had to be incubated 1-1.5 days longer to attain a 
similarly dense cell lawn.  
The positive controls provided with the kit developed a strong signal every time, 
while the negative controls did not, indicating lack of interaction between Lam and T-
antigen. Most control transformations with one fusion protein and a complementing 
empty vector also showed no signal development, indicating that the fusion-proteins by 
themselves are unable to activate gene transcription of the reporter gene. However, the 
negative controls expressing only pGADT7-FLNA or pGADT7-FLNA-Q/R alone 
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showed color development, indicating that these fusion proteins are able to activate 
transcription on their own, without interacting with a pGBKT7-bait fusion protein. 
Interestingly, background activation as seen by pGADT7-FLNA or pGADT7-FLNA-Q/R 
is almost entirely abrogated when a GAL4-DNA-binding fusion protein that does not 
interact with FLNA is co-expressed (i.e. pGBKT7-Integrin1-Y788E, mutant form of 
integrin that cannot bind FLNA). It seems that the BD/fusion protein outcompetes 
binding to the promoter region that AD/FLNA may bind to and so eliminates background 
activation of gene expression.  
All ten interaction partners that were tested in this manner activated the reporter 
gene to a similar extent when expressed with either pGADT7-FLNA or pGADT7-FLNA 
Q/R, indicating that the proteins interact with both edited and unedited versions of 
FLNA. However, the colony-lift assay can only be used as a qualitative measure of 
protein-protein interactions and does not provide a quantitative assessment of binding 
strength. In order to detect more subtle differences in binding, quanitative assays such as 
the liquid ONPG assay or pull-down experiments have to be applied. We therefore 
decided to assess protein-protein binding strength using the ONPG assay with the yeast 
transformants already at hand. 
5.4.2 Liquid ONPG assay 
Growth of FLNA-expressing yeast in liquid culture was slowed from a doubling 
time of approximately 2h (controls) to 4-5h, consistent with slower growth of colonies on 
agar plates. The cause for this growth reduction is unknown. Due to this slowed growth, 
such cultures were used directly from overnight incubation, while all others were re-
inoculated in the morning into fresh medium (1:5 dilution, see “5.3.4: ONPG Assay”). 
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Typically, an amount of cells corresponding to an OD600 of 1 was used as input (in 
triplicates), except for the provided positive controls, which were used at OD600 of 0.25 
(pCL1) and 0.5 (p53 and T-antigen), respectively. For most experiments, a total of 9 data-
points per transformant were obtained (three time-points in triplicates), which allowed us 
to assess the statistical significance of the results.  
As expected, the positive control reactions pCL1 and p53:T-antigen elicited a 
strong signal, whereas the negative control reactions Lam:T-antigen and 
FLNA:IntegrinY788E showed no color development at all (not shown). The negative 
control reactions with one fusion protein alone also did not activate reporter gene 
expression, with the exception that both FLNA and FLNA-Q/R alone again gave positive 
signal, correlating with the findings of the colony-lift assay.  
The -galactosidase units produced by the transformants were calculated 
according to the manufacturer‟s instructions. To analyze whether FLNA Q/R interactions 
varied from those of FLNA, we calculated the ratio of -galactosidase units produced by 
the interaction between FLNA-Q/R and a test protein over units produced by the 
interaction between FLNA and the same test protein: 
 -galactosidase units (FLNA-Q/R:test protein) 
  -galactosidase units (FLNA:test protein) 
All tested interaction partners elicited a stronger signal when interacting with 
FLNA-Q/R compared to FLNA (Figure 19). Most importantly, FLNA-Q/R alone also 
elicited a stronger signal than its unedited variant, a finding, though intriguing, that 
renders analysis of the results virtually impossible (see “5.5: Conclusions”). This stronger  
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reporter gene activation in FLNA-Q/R expressing cells is statistically significant (t-test, p 
= 0.001).  
The ONPG assay is prone to a lot of variability that results in high standard 
deviations within the same experiment and renders inter-experimental comparison 
difficult. As previously mentioned, FLNA-expressing cells grow much more slowly than 
any of the other transformants, which necessitated adjustments in the experimental 
outline. Since yeast cells grow slowly in the presence of the GAL4-AD-FLNA fusion 
protein, it is conceivable that they may produce less of this protein, for example by 
inactivating FLNA expression (which may have occurred in several of the large colony 
revertants, as discussed above). Secondly, loss of cell material during the numerous 
Figure 19: Ratio of binding affinity between test proteins and FLNA-Q/R over 
FLNA, respectively  
Shown are the ratios of -galactosidase units produced by interaction of a test 
protein with FLNA-Q/R and FLNA, respectively, with standard error bars. Note 
higher reporter gene activation in FLNA-Q/R expressing cells alone.  
*only one experiment was performed. 
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centrifugation and resuspension steps is very likely. Furthermore, cells may not 
completely lyse during the freeze-thaw cycles. These factors most likely all contribute to 
the high standard-deviation seen in the ONPG assay.  
A one-sample t-test was performed to compare the experimental samples to the 
FLNA-only control (n=5, mean=1.3729, standard deviation = 0.2768). Two test proteins 
elicited a significantly lower signal than the control, namely mGluR7b (p = 0.004) and 
the calcitonin receptor (p = 0.01), and two elicited a significantly higher signal than the 
negative control, i.e. p73alpha (p = 0.023) and Integrin (p = 0.009) (Table 11).  
  Test protein N Mean Standard 
deviation 
Standard 
error mean 
t-value p-value 
mGluR5a 3 1.1555 0.1556 0.8983 -2.42 0.137 
mGluR7b 9 1.2648 0.8233 0.0274 -3.937 0.004 
mGluR8a 10 1.4343 0.0948 0.0299 2.051 0.071 
CTR 8 1.1804 0.1549 0.0548 -3.515 0.01 
BRCA2 8 1.2788 0.2886 0.0667 -1.411 0.201 
p73alpha 4 1.8409 0.2155 0.1078 4.343 0.023 
P2Y2 2 1.3381 0.1075 0.076 -.458 0.727 
Integrin 3 1.7852 0.0667 0.0385 10.71 0.009 
Table 11: Statistical significance of results (one-sample t-test) 
Ratios of signal intensities elicited by interaction of test proteins with FLNA-Q/R 
over FLNA were compared to signal elicited by FLNA-Q/R over FLNA alone. Test 
proteins with significantly lower and higher values are highlighted in red and green, 
respectively. Confidence level ≥95%. 
112 
 
5.5 Conclusions 
The 24 Ig-like repeats of FLNA show high sequence homology, and one could 
expect that a single amino acid change in a single repeat might not significantly impact 
protein function. For many interaction partners of FLNA it remains to be elucidated 
whether the binding is restricted to a specific part or repeat of FLNA. However, binding 
was shown to occur in a specific manner with individual repeats in certain cases (for 
example Lad et al., 2008). Furthermore, specific repeats have been shown regulate 
binding of proteins by competitive interaction with neighboring repeats (Lad et al., 2007), 
and missense mutations in FLNA can cause otopalatodigital spectrum disorders 
(Robertson et al., 2003). We thus expect that single amino acid changes can interrupt or 
increase specific binding to interaction partners. Consequently, the yeast-two-hybrid 
method to assess differences in interaction between FLNA and FLNA-Q/R and selected 
proteins was a valid experimental approach, considering our current knowledge on FLNA 
function. 
None of the tested proteins show evidence of dramatic alterations of binding to 
the edited FLNA. This does not exclude the possibility that interactions are in fact altered 
in vivo. The apparent weaker color development in FLNA and FLNA-Q/R transformants 
compared to the positive controls may be due to either weaker interaction between the 
fusion proteins and/or the fact that FLNA and FLNA-Q/R reduce growth of the yeast 
cells, resulting in smaller colonies and thus reduced absolute lacZ expression.  
Four of the tested proteins show significantly different alterations in -
galactosidase production when compared to the ratio of signal elicited by the negative 
controls. The fact that the negative controls themselves activate reporter gene 
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transcription and do so differentially (i.e. FLNA-Q/R elicits stronger signal than unedited 
FLNA) renders proper experimental evaluation and a reliable conclusion difficult. The 
underlying cause of the reporter gene activation by FLNA alone is unknown. If we 
assumed that this background activation was negated by the presence of a tested 
interaction partner, the results would mean that all test proteins interact more strongly 
with the edited version of FLNA. This assumption is supported by the fact that co-
expression of the mutated Integrin (mutated at a single amino acid that abrogates 
binding to FLNA) abolishes reporter gene activation completely (data not shown). On the 
other hand, why should all binding proteins interact more strongly with FLNA-Q/R than 
FLNA?  
The answer may not lie with the tested proteins, but instead with the assay system 
that was used. If FLNA were to generally increase transcription or translation by, for 
example, interacting with a yeast protein, we could partially resolve these apparently 
irreconcilable differences. Expression of one or several genes would be increased by the 
presence of FLNA and FLNA-Q/R, respectively, but lack of reporter gene transcription in 
conjunction with the mutated integrin-Y788E would remain silent. However, FLNA and 
FLNA-Q/R alone also increase reporter gene activation, and therefore must directly 
impact the GAL4 promoter, possibly by direct DNA binding. Therefore, reporter gene 
activation with the test proteins may be influenced by several factors: reporter gene 
activation by FLNA or FLNA-Q/R alone („background‟), boosting of transcription or 
translation through an unknown factor, and finally the interaction between test proteins 
and FLNA isoforms. Consequently, it is impossible to use the yeast-two-hybrid system to 
test whether proteins interact more or less strongly with the edited FLNA. However, the 
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finding that FLNA-Q/R is able to elicit reporter gene activation more strongly than 
FLNA is interesting in itself. Whether or not the assumed underlying interaction with a 
host factor is physiologically relevant for higher organisms is another question.  
While the yeast-two-hybrid method is excellent for analyzing protein-protein 
interactions, the chosen approach is limited by the subset of potential interaction partners 
that are analyzed. An alternative, unbiased method is the expression of TAP (Tandem 
Affinity Purification)-tagged FLNA and edited FLNA in FLNA-deficient cells, 
purification of the FLNA isoforms together with the respective protein binding partners 
using tandem affinity purification and subsequent analysis of the purified protein 
complexes by silver-staining and mass-spectrometry. Such an approach allows probing of 
the protein binding landscape of the two FLNA isoforms without restriction to known 
interaction partners. To that end, appropriate cloning vectors (pCeMM-NTAP(GS) and 
pCeMM-CTAP(GS)), specifically designed for TAP from mammalian cells 
(Burckstummer et al., 2006), were selected for cloning of the C-termini of FLNA and 
edited FLNA. FLNA-deficient mammalian cells were generously provided by Dr. Stossel 
(Brigham & Women‟s Hospital, Harvard Medical School). The vectors and cells were 
shared with Dr. M. Jantsch (University of Vienna, Austria) for use in his investigations. 
The results would be able to answer our question of whether editing of FLNA modifies 
its protein binding ability. 
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6 Consequences of RNA editing on IGFBP7 function 
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6.1 Abstract 
Recoding of protein-coding sequences quite often has critical consequences on 
protein stability, localization, and/or functional properties. In fact, it is necessary for the 
proper development and physiological functions of higher eukaryotes, underscoring the 
importance of editing in higher organisms. The production of several protein isoforms in 
the same cell increases proteome diversity from a limited number of genes. After 
identifying previously unknown A-to-I RNA recoding events in the first part of my 
dissertation, my goal was to analyze functional impacts of editing on the alternative 
protein variants. In Chapter 2, we validated two A-to-I RNA editing sites in the Insulin-
like growth factor binding protein 7 (IGFBP7) gene, both leading to amino acid changes 
when edited. IGFBP7 encodes a secreted protein that modulates the interactions of a cell 
with its surroundings. Its expression is silenced in several cancers; notably, the 
restoration of transcription and IGFBP7 protein synthesis in melanoma cells triggers 
apoptosis. However, IGFBP7 can also promote angiogenesis and stimulate proliferation 
of fibroblast cells. Besides these, IGFBP7 is important for other cellular functions as 
well, as it is elevated in the blood of insulin-resistant diabetes patients and inhibits 
estrogen production in granulose cells, diversifying its biological functions further. Such 
complexity may be explained at least in part by RNA editing. Here we characterize 
IGFPB7 editing patterns in different tissues and investigate possible consequences that 
editing may have on IGFBP7 function.  
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6.2 Introduction 
Differential editing of multiple sites within the same target has been shown to 
regulate protein function as well as RNA splicing, protein trafficking, and stability (Burns 
et al., 1997). Importantly, characterized cases of recoding events revealed that editing 
usually affects highly conserved amino acid residues and dramatically alters protein 
function. It is thus of interest to get better insight into the editing patterns of the two sites 
in IGFBP7, especially since both seem to be edited in a significant proportion of mRNA 
sequences. We hypothesized that editing at either site or at both sites together produce 
protein variants with distinct properties. For the same reason, we were interested in 
elucidating the patterns of editing in different tissues to investigate the possibility of cell-
type specific editing, as shown for other editing targets (He et al., 2011). In addition, we 
sought to determine if editing also occurs in mouse tissue, and thus may be conserved in 
mammals. We analyzed a number of specimens to characterize editing at the two sites in 
IGFBP7. To reveal editing patterns, individual clones of amplicons of different origin 
were sequenced as described previously. This strategy allowed us to determine whether 
or not editing in IGFBP7 is tissue-specific and subject to coordinated or differential 
regulation. 
One distinguishing feature of IGFPB7 is its apparent versatility. It has been 
isolated on multiple occasions due to one of many characteristic properties and bears 
several names. IGFBP7 was initially identified as a gene downregulated in meningiomas, 
and named meningioma-associated cDNA (Mac25) (Murphy et al., 1993). The secreted 
protein was later independently purified from the human bladder carcinoma cell line EJ-1 
and tentatively termed tumor-derived adhesion factor (TAF) (Akaogi et al., 1994), as well 
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as from cultured fibroblast cells as prostacyclin-stimulating factor (PSF) (Yamauchi et 
al., 1994). It was later proposed to be renamed angiomodulin (AGM) for its involvement 
in the formation of new capillary vessels by vascular endothelial cells (Akaogi et al., 
1996a).  
Since the early days of its characterization, IGFBP7 has been implicated in 
various forms of cancers, often as a putative tumor suppressor (Chen et al., 2007; Lin et 
al., 2007) with functions in apoptosis and senescence (Sprenger et al., 2002; Wilson et al., 
2002; Mutaguchi et al., 2003; Ruan et al., 2007; Wajapeyee et al., 2008), yet also as a 
promoter (Adachi et al., 2001; van Beijnum et al., 2006; Pen et al., 2008) or blocker 
(Tamura et al., 2009) of angiogenesis, and it is overexpressed in circulating endothelial 
cells (CECs) of metastatic cancer patients (Smirnov et al., 2006). Conflicting reports on 
its growth stimulatory (Akaogi et al., 1996b) and inhibitory (Wilson et al., 2002) 
functions underline its complexity. Furthermore, increased levels of IGFBP7 have been 
detected in the blood of insulin resistant diabetic patients (Lopez-Bermejo et al., 2006) 
and it interacts with chemokines (Nagakubo et al., 2003). Recently, it was also shown to 
inhibit estrogen production in granulosa cells (Tamura et al., 2007). Thus, IGFBP7 is 
involved in a multitude of functions, and we hypothesized this vast functional range may 
in part be facilitated by editing, which allows the production of four protein isoforms 
from the same allele.  
Similarities between other IGFBPs (IGFBP1 to 6) and IGFPB7 are restricted to 
the N-terminal cysteine-rich domain (CRD), which is contained within a single exon 
(Collet & Candy, 1998). IGFBP7 shares only ~20% identity in the CRD with most of the 
12 cysteine residues conserved. However, no significant sequence similarity is observed 
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outside of this domain. CRDs can be found in various proteins associated with the 
extracellular matrix (ECM), with vastly different functions. The CRD probably arose 
from exon shuffling, while the other domains of IGFBP7 have distinct structures which 
are unrelated to those of the rest of the IGFBP family members (Collet & Candy, 1998).  
Beside the N-terminal CRD, IGFPB7 has a Kazal-type trypsin inhibitor domain, 
and a single copy of an Immunoglobulin-like type C repeat in its C-terminal half (Collet 
& Candy, 1998). The two editing sites change the codons at positions R78 and K95 of the 
full-length protein, changing R to G and K to R, respectively, and are contained within 
the CRD. Interestingly, IGFBP7 is proteolytically cleaved after K97, which results in a 
two-chain form comprised of amino acids 27-97 (8kDa) and 98-282 (25kDa) that are 
 
Figure 20: IGFBP7 editing and cleavage sites 
Schematic representation of IGFBP7 protein with signal sequence (ss), editing sites, 
heparin binding site (HBS) and cleavage site indicated. Part of the protein sequence 
bound by heparin and cleaved by MT-SP1 is enlarged. Consequences of cleavage 
are shown. 
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cross-linked by disulfide bridges (Sato et al., 1999; Ahmed et al., 2003; Ahmed et al., 
2006). Amino acids 1-26 are a signal sequence that is cleaved during post-translational 
processing. Proteolytic processing of IGFBP7 modulates its biological activity: intact 
IGFBP7 stimulates growth of DLD-1 colon carcinoma cells in synergy with insulin/IGF-
I, but cleaved IGFBP7 completely abolishes the synergistic growth-stimulatory activity, 
possibly due to the loss of its insulin/IGF-I binding activity (Ahmed et al., 2003) (Figure 
20). At the same time, the heparin-binding activity of IGFBP7 is decreased by 
proteolysis. Cleaved IGFBP7 appears to bind to syndecan-1 more efficiently than the 
intact protein (Ahmed et al., 2003). It is supposed that the cleavage induces a 
conformational change that masks the heparin-binding sequence, while exposing a 
different binding site to syndecan-1. Thus, the intact and cleaved forms of IGFBP7 have 
different biological activities. As editing occurs directly within this biologically relevant 
site, we hypothesized that editing has functional consequences for the ensuing protein 
isoforms, specifically with regard to proteolytic processing and/or heparin binding 
affinity. While the elicited amino acid change may seem conservative, other recoding 
events of the same nature such as in NEIL1 have been shown to dramatically alter protein 
function (Yeo et al., 2010). 
The type II transmembrane protein MT-SP1 (membrane-type serine proteinase 
matriptase) was identified as the specific protease for IGFBP7 in ovarian clear cell 
adenocarcinoma (OVISE) and gastric carcinoma (MKN-45) cells, which produce the 
cleaved IGFBP7 at high levels (Ahmed et al., 2006). MT-SP1 contains an extracellular 
protease domain with a preferred cleavage sequence [P4-(Arg/Lys) P3-(X) P2-(Ser) P1-
(Arg) P1‟-(Ala)] and [P4-(X) P3-(Arg/Lys) P2-(Ser) P1-(Arg) P1‟-(Ala)] (Takeuchi et al., 
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2000). In comparison, IGFBP7 contains amino acids RKGKA (RRGKA in edited 
proteins) at positions P4 through P1‟ (Figure 20). A-to-I RNA editing at the second 
position results in an amino acid change from K to R at P3 of the cleavage recognition 
site – a conservative change which seems to be readily accepted by the matriptase, i.e. 
both sequences should be cleaved by MT-SP1. However, direct comparison of the protein 
isoforms might reveal a preferential proteolysis of one versus the other. 
While a substantial body of research has accumulated over the past years about 
IGFBP7, due to its significance in cancer and disease, no one has specifically compared 
the functional roles of the different protein isoforms created by RNA editing. However, 
editing in this target may directly contribute to the large functional repertoire that 
IGFBP7 seems to possess. Elucidating the effects editing might have on proteolytic 
processing of the resulting protein variants directly addresses this question as evidence 
reported in the literature suggests distinct biological activities of cleaved and uncleaved 
IGFBP7.   
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6.3 Materials and Methods 
6.3.1 PCR analysis 
The reaction mixes contained 400nM of each of the primers (human: IGF7D and 
IGF2U (cDNA) or IGF7D and gIGFU (gDNA); mouse: mIGF12D and mIGF13U 
(cDNA) or mIGF12D and gIGFU (gDNA), primer sequences see Appendix B), 2l 
Phire™ Hot Start DNA Polymerase (NEB), 0.4mM dNTP mix (Invitrogen), 1l cDNA, 
and Phire polymerase buffer provided by the manufacturer in a total volume of 100l 
(2x50l). The reactions were carried out in an Eppendorf Mastercycler. Human: 98˚C for 
2 minutes followed by 35 cycles of 98˚C for 10s, 71˚C for 5s, and 72˚C for 10s, followed 
by a final step of 72°C for 1 minute. Mouse: 98˚C for 2 minutes followed by 35 cycles of 
98˚C for 10s, and 72˚C for 15s (12s for amplification of genomic DNA), followed by a 
final step of 72°C for 1 minute. Reaction products were analyzed on a 2% agarose gel. 
6.3.2 Subcloning 
IGFBP7 amplicons from select tissues were re-amplified using primers IGF8D-
Eco and IGF9U-Kpn (Appendix B). The amplicons were restricted with 40U KpnI (NEB) 
for 3 hours at 37ºC, subsequently purified by phenol-chloroform extraction, ethanol-
precipitated and restricted with 40U EcoRI (NEB) for 3 hours at 37ºC. Again, the cut 
fragments were purified by phenol-chloroform extraction and precipitated with ethanol, 
and then subjected to DNA gel electrophoresis on a 2.5% agarose gel. The bands of the 
expected size were excised, purified using the QIAEX II Gel Extraction Kit (QIAGEN) 
and then ligated into a pBluescript SK II vector also cut with EcoRI and KpnI and 
purified as described for the amplicons. The ligation reactions contained vector and insert 
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in a 1:8 molar ratio and 0.5l T4 ligase (Invitrogen) in a total volume of 10l and was 
incubated at room temperature 4 hours to over-night. Z-competent DH5 cells were 
transformed with 5-10l of the ligation (Appendix A). The transformed cells were plated 
on LB containing ampicillin. Individual recombinant clones were used to inoculate liquid 
LB-Amp and the purified plasmids (QIAprep Spin Miniprep Kit, QIAGEN) were 
sequenced (Geneway, CA).  
6.3.3 Cell culture 
HEK293 cells were maintained in 1xMEM (Cellgro) containing 10% FCS and 1x 
antibiotic/antimycotic solution. Cells were passaged at least twice a week. 
6.3.4 Cloning of IGFBP7 
Full-length IGFBP7 coding sequence in the pCMV6-XL4 expression vector was 
purchased from Origene. Three pre-edited isoforms were created by site-directed 
mutagenesis, changing codon 78 from arginine (AGG) to glycine (GGG) and/or codon 95 
from lysine (AAG) to arginine (AGG). IGFBP7 coding sequences of the four editing 
isoforms were C-terminally tagged with the HA sequence by PCR amplification and 
corresponding primer sequences (Appendix B), digested with XhoI and XbaI and ligated 
into the XhoI/XbaI sites of a pCI-neo vector. DNA sequencing analysis confirmed the 
fidelity of the constructs. For primer sequences see Appendix B. 
6.3.5 Stable cell lines 
Transfection of the four IGFBP7 isoforms in pCI-neo into HEK293 cells was 
performd using XtremeGene 9 transfection reagent from Roche according to the 
manufacturer‟s instructions. Reagent to DNA ratio was 9:1. Control cells were produced 
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by transfecting cells with an empty pCI-neo vector. Stable transfectants were obtained 
after selection in 500g/ml G418 for 3 weeks and were maintained in 300g/ml G418 
thereafter.  
6.3.6 IGFBP7 protein purification 
Culture medium of HEK293 cell lines stably expressing IGFBP7 isoforms was 
collected, 1/20V 20xTBS and 1/250V EZview Red Anti-HA Affinity Gel (corresponding 
to 1/500V of bead volume) (Sigma) was added and incubated on a rotating wheel for 1h 
at 4°C. Beads were washed three times with excess cold 1xTBS. Bound IGFBP7 protein 
was eluted with elution buffer (1xTBS, 0.05% SDS, 100g/ml HA peptide) using 5 times 
the bead volume at 38.5°C for 2h with frequent vortexing. Eluates were diluted 1:5 with 
adjustment buffer (56.875mM Tris, 28.75mM NaCl, 0.01% tween 20, pH9) to convert the 
elution buffer into the MT-SP1 assay buffer. Diluted samples were ultrafiltrated using 
Amicon Ultra-0.5 Centrifugal filters (Millipore) in a table top centrifuge for 15 minutes at 
14‟000g at 4°C. 
6.3.7 MT-SP1 proteolytic cleavage assay 
Recombinant human matriptase (MT-SP1, MW = 26kDa) encoded by the ST14 
gene was purchased from R&D systems. 100ng/l stock solutions were prepared in 
sterile 50mM Tris, 10% glycerol, pH 8.0 and stored at -20°C. Relative concentrations of 
the purified IGFBP7 isoforms were estimated from Western blots and input for the 
proteolysis reactions were approximated accordingly. Total reaction volume was adjusted 
to 39l with 1x assay buffer (50mM Tris, 50mM NaCL, 0.01% Tween 20, pH9.0). 10% 
were removed as negative controls before adding 0.9l 0.5ng/l MT-SP1 (final 
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concentration = 12.5pg/l or 325nM). Proteolysis reactions took place in 200l tubes at 
25°C. At indicated timepoints, 4l aliquots were removed, mixed with SDS sample 
buffer and boiled for 5 minutes at 90°C to stop the reaction. Rate of proteolytic cleavage 
was assessed via SDS PAGE (12% gel, standard protocol, Sambrook laboratory manual) 
and Western Blotting analysis. 
6.3.8 Western blot 
Standard protocols were used to separate proteins according to their molecular 
weight on a 12% SDS polyacrylamide gel and transfer them onto 0.2m nitrocellulose 
membranes. Membranes were blocked for two hours at room temperature in 2% milk in 
PBS/0.05% Tween 20. Primary antibody (rabbit anti-HA, Clontech) was diluted 1:300 in 
blocking buffer and incubated with the membrane over night at 4°C. Blots were washed 
with PBS/0.05% Tween 20 and incubated with the secondary HR-conjugated anti-rabbit 
antibody at 1:25,000. Blots were washed again before application of ECL Plus 
(Amersham) and exposure to film for 5-30 minutes. 
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6.4 Results and Discussion 
6.4.1 Editing of IGFBP7 is conserved in mammals 
Editing of IGFBP7 was analyzed in mouse cortex and cerebellum. Editing at both 
sites occur to a much higher degree than was found in human: 95% at the R78G site and 
85% at the K95R site. The reason for these high editing levels in mouse brain tissue is 
unknown, but could reflect species-specific editing of this target. Unlike in the editing 
target C1QL1, editing occurred to comparable levels in both cortex and cerebellum 
(Table 12). Analysis of the genomic DNA did not reveal occurrence of a SNP at either 
site. 
 
6.4.2 Tissue-specific editing patterns of IGFBP7 
The editing levels at the two sites of IGFBP7 were estimated from sequence 
tracks of 8 different human tissues. The wide range of editing from 6-57% for R78G and 
30-85% for K95R is a strong indication of tissue-specific regulation of editing in IGFBP7 
(Figure 21). Since each sample is derived from a different donor, this variability could 
also be due to inter-personal differences rather than tissue-specificity. However, Li et al. 
determined IGFBP7 editing levels by deep sequencing, obtaining the same results for 
Table 12: Editing levels in mouse IGFBP7 
Levels were estimated from sequence tracks obtained from cortex 
and cerebellum of two adult mice. Sequence tracks not shown. 
Sample ID Tissue R78G  
% editing 
K95R  
% editing 
Mouse 1 Cortex 95 85 
Mouse 1 Cerebellum 90 85 
Mouse 2 Cortex 90 85 
Mouse 2 Cerebellum 90 85 
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kidney samples (7% at R78G, 30% at K95R). Editing at K95R is almost always higher 
than editing at R78G, with the exception of the heart tissue. The differences do not 
correlate with observed expression levels of IGFBP7 (GNF expression atlas, not shown).  
6.4.3 Tissue-specific, site-independent editing in IGFBP7 
To determine the distribution of the four possible transcript versions that can arise 
due to editing, we subcloned the amplicons from brain, heart and spleen and sequenced at 
least 94 individual clones per sample. As shown in Figure 22, editing leads to a distinct 
distribution of transcript variants in the three tissues. Chi-square analysis of the data 
using a two-way classification reveals no significant difference between the editing levels 
of the two brain samples. Conversely, when comparing the data from brain with heart or 
spleen, respectively, editing levels are significantly different (brain: p<0.01; spleen: 
p<0.025). Comparison between heart and spleen also shows significantly different editing 
levels, with a p-value <0.001. These results therefore point toward a tissue-specific 
K95R 
R78G 
Figure 21: Editing at R78G and K95R across different human tissues 
Editing levels were estimated from sequence tracks. Red bars (front): editing at 
R78G, green bars (back): K95R. Editing percentages are indicated above bars. 
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regulation of editing in IGFBP7, which could enable a cell to perform specialized 
functions associated with its specific environment. 
  
Enstero et al. showed that adenosines located on the same side of a RNA double 
helix are often edited together, which is referred to as coupling (Enstero et al., 2009). 
Since RNA double helices contain about 10-12 nucleotides per turn, the R78G and K95R 
sites, which are distanced from each other by 51 nucleotides, may therefore be coupled. 
To test this, a Pearson chi-square analysis was performed on the data. Even though the 
R78G site is edited almost exclusively together with the K95R site, coupling between the 
two sites is statistically significant only in the first brain (p<0.01) and the heart samples 
(p<< 0.001). For the second brain and the spleen sample, the percentage of transcripts 
edited at both positions simultaneously is due to chance (p>>0.05). This is not surprising, 
Figure 22: Distribution of transcript variants determined from different tissues 
PCR products obtained from the indicated tissues were cloned and single clones 
isolated and sequenced, allowing detailed analysis of transcript versions present in 
different tissues. Exact percentages of editing are indicated on bars. 
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as coupling is generally disrupted by bulges in the RNA helix, of which there are five 
between R78G and K95R. Therefore, the two sites are edited independently of each 
other. An unknown mechanism may ensure mainly production of transcripts edited at 
both sites rather than R78G alone, which would explain the statistically significant 
coupling seen in the first brain and the heart samples. 
6.4.4 Proteolytic cleavage of IGFBP7 isoforms 
Initially, we used in vitro transcription and translation and radioactive labeling 
with 
35
S-Met of IGFBP7 (TNT system, Promega) to produce the respective protein 
isoforms with an apparent mass of 33kDa. Proteolytic cleavage with MT-SP1 (R&D) 
yielded the expected fragment of 8kDa (N-terminus, labeled portion). Low signal-to-
noise ratio made quantification of the band intensities over a time-course of incubation 
with MT-SP1 difficult, but these initial experiments indicated that the K95R form seems 
to be cleaved at a slower rate (not shown). To circumvent the low labeling problem 
(IGFBP7 only contains 3 methionines at the N-terminus) which results in a high 
background, we instead decided to tag the protein isoforms with the hemagglutinin (HA) 
peptide sequence. Expression of these HA-tagged isoforms in cells enabled us to purify 
them with an anti-HA matrix and analyze them via Western blotting using an anti-HA 
antibody. 
Expression of proteins in cell culture has both advantages and disadvantages over 
expression in vitro. For example, post-translational modifications of the proteins such as 
glycosylation and phosphorylation occur in vivo. On the other hand, the editing 
competent secondary structure of IGFBP7 is formed entirely by exon 1 and, 
consequently, transcription of the open reading frame of IGFBP7 also produces RNA 
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structures amenable to editing. This could result in mixed populations of IGFPB7 
isoforms, even with only one type of expression plasmid present in a specific stable cell 
line. We therefore assessed editing levels in the transcripts of the recombinant isoforms 
using a plasmid-specific forward primer located in the 5‟-UTR that spans an intron and 
an IGFBP7-specific reverse primer. Even though HEK293 cells typically show low 
ADAR activity, some editing (up to 20%) occurs in the originally unedited and single 
edited versions of IGFBP7 (data not shown). The editing levels were not negligible, but 
low enough to proceed with the proteolysis assay, keeping in mind that the IGFBP7 
isoforms thus assessed are not entirely pure.  
In vitro proteolysis of IGFBP7-HA isoforms by MT-SP1 results in two cleavage 
products, a 27kDa C-terminal and 8kDa N-terminal part, respectively. Only the 27kDa 
product can be detected with the anti-HA antibody on a Western blot, as the HA-tag is C-
terminal. The bands of cleaved and uncleaved protein were quantified using ImageJ 
software. For analysis of cleavage efficiency, the ratios of signal from cleaved (27kDa) 
versus uncleaved (35kDa) product were plotted against time and linear regression 
analysis was executed (Figure 23). The cleavage efficiencies of the unedited („wild-type‟, 
or wt) and the R78G isoforms appear to be similar, but in most experiments are markedly 
different from those of the K95R and double edited variants, respectively. The amino 
acid change elicited by editing at the K95R position lies directly within the protease 
recognition site, and in all experiments, this K95R isoform is cleaved less efficiently than 
the others. The double-edited version (with amino acid changes at both positions 78 and 
95) seems to be cleaved at a rate somewhere in between that of K95R and the other two.  
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Figure 23: Proteolysis of IGFBP7 isoforms 
Four independent experiments are shown, corresponding Western blots on the right.  
Graphs display the ratio of 27kDa over the 37kDa IGFPB7 for each isoform. 
n
eg
 
1
 
2
 
3
 
5
 
7
.5
 
1
0
 
1
2
.5
 
1
5
 
wt 
R78G 
K95R 
double 
n
eg
 
1
 
2
 
3
 
5
 
7
.5
 
1
0
 
1
2
.5
 
1
5
 
wt 
R78G 
K95R 
 double 
n
eg
 
1
 
2
 
3
 
5
 
7
.5
 
1
0
 
1
2
.5
 
1
5
 
3
0
 
wt 
R78G 
K95R 
 double 
n
eg
 
1
 
2
 
3
 
5
 
7
.5
 
1
0
 
1
2
.5
 
1
5
 
3
0
 
wt 
R78G 
K95R 
 double 
wt 
R78G 
K95R 
double 
132 
 
 
The slopes of linear regression curves are indicators of cleavage efficiency (Table 
13), which is a function of substrate and protease quantity. Due to the small amount of 
material used for these experiments, substrate input could not be standardized between 
experiments, as it is below the detection limit of regular protein quantification methods. 
Substrate input was instead estimated from the relative signal intensities from Western 
blots with different substrate loading volumes of each IGFBP7 isoform. Therefore, they 
varied with every experiment, leading to different cleavage efficiencies each time. 
Furthermore, very dark bands may be saturated with signal and can thus lead to 
underestimation of actual quantity. 
This last detriment is mitigated to 
some degree by taking the ratio of 
two bands of different intensities, 
one of them usually not being 
saturated. To better account for 
 Experiment 1 Experiment 2 Experiment 3 Experiment 4 
Wild-
type 
0.0702x + 0.0904 
(0.9152) 
0.0454x + 0.2544 
(0.9027) 
0.0629x + 0.1574 
(0.8995) 
0.0269x + 0.0835 
(0.9287) 
R78G 0.0883x + 0.0333 
(0.952) 
0.0526x + 0.0485 
(0.9446) 
0.0704x + 0.0347 
(0.9782) 
0.0283x + 0.0176 
(0.9558) 
K95R 0.0381x + 0.0538 
(0.9696) 
0.0099x + 0.0105 
(0.086) 
0.0085x  
(0.7327) 
0.0033x + 0.0103 
(0.5936) 
double 0.0664x + 0.1223 
(0.9181) 
0.0239 + 0.2002 
(0.8521) 
0.024x + 0.0364 
(0.9616) 
0.0188 + 0.0002 
(0.9913) 
 
Table 13: Linear regression analysis 
Equations of the linear regression analysis of four IGFBP7 proteolysis reactions. 
Equations are given in the form of y = mx + q (R
2
), m=slope, q=y-axis intersection. 
R
2
=correlation coefficient.  
 
 1 2 3 4 
R78G 74% 116% 110% 87% 
K95R 73% 97% 89% 92% 
double 54% 112% 82% 108% 
Table 14: Substrate input 
Substrate input levels relative to wild-type, 
estimated from Western blot signals (ImageJ). 
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differences in substrate input within one experiment, the signal intensities per lane were 
averaged for each isoform to serve as estimate of relative input compared to the wild 
type. Taking the average is preferable than basing the analysis on single lanes due to local 
irregularities that occur around each band from background signal or disparities in protein 
transfer during blotting. Lanes with very high background or where one band was not 
blotted properly were excluded. Such analysis shows that in experiment 1, substrate input 
of R78G and K95R was about 73%, and input of the double-edited isoform only 54% of 
that of wild-type. Less substrate with equal amounts of protease would result in faster 
cleavage. Therefore, the discrepancy in input material may be the cause for a cleavage 
rate of the double-edited IGFBP7 equal to that of wild-type. Input levels of isoforms 
compared to wild-type for all experiments are shown in Table 14. 
The differences in input levels were mostly minor and within the range of +/-18%, 
with the exception of experiment 1 as discussed above. The fact that the R78G variant is 
cleaved at a rate comparable to that of wild-type in all four experiments, yet shows 
variability of input levels akin to the other two isoforms, validates the differences in 
cleavage rate we observe for both the K95R and the double-edited variant. However, 
reduction of input by 50% seems to have the noticeable effect as seen for the double-
edited variant in experiment 1.  
The results of the proteolytic cleavage assay show that editing at the K95R codon 
has a significant effect on cleavage efficiency of the resulting protein isoform. Cleavage 
rate of the edited K95R variant is reduced at least two-fold compared to that of the 
unedited and R78G edited variants. In vivo, this reduction in cleavage could have a major 
impact on the function of IGFPB7.   
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6.5 Conclusions 
IGFBP7 has been shown to be involved in diverse biological functions, from 
apoptosis, to inhibition or stimulation of growth and angiogenesis, to stimulation of 
prostacyclin production in endothelial cells and diabetes. It can associate with type IV 
collagen (Akaogi et al., 1996a; Akaogi et al., 1996b) and bind IGFs and insulin (Akaogi 
et al., 1996b; Yamanaka et al., 1997). There is only one modification known to date, the 
N-glycosylation of asparagine 171 (Oh et al., 1996), and thus regulation of its many 
activities through post-translational modification seems limited. Five alternative splice 
variants are suggested by sequence annotations, but the functionality of these variants 
remains to be evaluated. Besides alternative splicing, transcript modification by A-to-I 
RNA editing leading to recoding might allow expanded functionality of this transcript. 
Our analysis of editing patterns in samples of human origin shows a tissue-
specific distribution (Figure 21). The obtained editing levels correspond well to those 
found by a recent deep-sequencing analysis (Li et al., 2009). Detailed analysis of 
transcript variants by cloning of amplicons and sequencing of single clones revealed that 
the predominant variant in brain and heart is the unedited version, followed by the K95R 
and double-edited variants. In spleen, IGFBP7 transcripts are mainly edited at the K95R 
position, followed by the unedited version and the double-edited variant, respectively 
(Figure 22). There is therefore a tissue-specific distribution of transcript variants, which 
possibly gives rise to a tissue-specific distribution of the corresponding protein isoforms. 
Such tissue-specificity is indicative of regulated editing, especially as editing levels in 
spleen and lung significantly surpass those seen in brain, which displays the highest 
levels of editing in known and characterized targets. The nature of this regulation remains 
135 
 
to be investigated. As editing appears to be regulated, it is likely that the resulting 
transcript variants occupy different functions, which might support the functional 
diversity of the IGFBP7 protein. 
Proteolytic cleavage at K97 of the full-length IGFBP7 results in a two-chain form 
with modulated biological functions (Ahmed et al., 2003). The cleaved form binds more 
strongly to cell surfaces and induces cell attachment, and also shows decreased binding to 
IGF and insulin and reduced growth stimulation of fibroblasts. Editing changes a lysine 
(K) to an arginine (R) codon at codon 95. Even though K/R represents a conservative 
amino acid change, it was shown that the same change dramatically impacts lesion 
specificity of a DNA repair enzyme (Yeo et al., 2010). Our results show that editing at 
the K95R site results in significant reduction of cleavage efficiency by the specific MT-
SP1 protease. Such a reduction might be even more relevant in vivo, where other 
interactions might compete with recognition and cleavage of IGFBP7 by MT-SP1, for 
example binding to heparin (see below), chemokines, and/or IGFs or insulin. Decreased 
affinity of the K95R IGFBP7 isoform for MT-SP1 might strongly favor binding to these 
or other factors and thus shift its biological activity. Different tissues may require a 
specific distribution of IGFBP7 isoforms to fulfill distinct functions, hence the tissue-
specific editing patterns.  
The intermediate cleavage efficiency displayed by the double-edited isoform is 
unexpected, as a behavior similar to that of K95R would have been expected. There is 
only limited protein structure information available, as only the structure of IGFBP5 has 
been elucidated (Kalus et al., 1998; Zeslawski et al., 2001). The N-terminal domain 
(which includes both R78G and K95R) of IGFBP7 is only 57% similar (20% identical) to  
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that of IGFBP1 to 6, which has to be taken into account when aligning IGFBP7 to the 
structure of IGFBP5. Alignment of the homologous regions of IGFBP7 to this structure 
shows that both R78G and K95R are in loop-regions, separated by a -strand (Figure 24). 
Interestingly, IGFBP5 binds IGF-I with a domain homologous to one close to the K95R 
site in IGFBP7 (Zeslawski et al., 2001). Cleavage has been shown to change affinity of 
IGFPB7 for IGF-I and insulin, but it is unknown whether the amino acid change at K95R 
has an effect on binding affinity, in either cleaved or intact form. Since R78G and K95R 
are presumably in distinct regions of the protein, both in loop-regions, it is unclear how 
the amino acid change at R78G in double-edited isoforms could increase MT-SP1 affinity 
to its recognition site and thus alleviate the reduced proteolytic cleavage seen in K95R 
single-edited isoforms. It has been shown that the sequence of a gene can tune the speed 
of translation, which is important for protein folding (Cannarozzi et al., 2010; Fredrick & 
Ibba, 2010). It is possible that the nucleotide change at codon 78 might alter translation 
efficiency, which in turn might modify protein folding. A change in protein folding could 
Figure 24: Structure of IGFBP5 
The structure prediction of the N-terminus of 
IGFBP5 is shown. The loop between amino 
acid 50 and 54 corresponds to the 
homologous part containing R78G in 
IGFBP7. The loop between amino acid 62 
and Leu70 in IGFBP5 corresponds to the 
homologous region containing K95R in 
IGFPB7. Figure adapted from (Kalus et al., 
1998). 
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impact the local IGFBP7 domain structure such as to change the proteolytic cleavage rate 
occurring in a loop opposite to the R78G site. In this manner the distant editing sites at 
codon R78G might be able to reduce the effect of the K95R amino acid substitution on 
proteolytic cleavage efficiency. 
Additional experiments that are likely to provide important insights include 
assessing other possible consequences of editing on IGFBP7 function. Heparin and 
heparan sulfates on cell surfaces bind to growth factors, cytokines, enzymes, and 
inhibitors, thereby modulating their biological activities. It was observed that cell 
adhesion activities of IGFBP7 are inhibited by heparin (Akaogi et al., 1996a) and 
K89SRKRRKGK97 was identified as the heparin binding site on IGFBP7 (Sato et al., 
1999). Thus, the cell binding capacity of IGFBP7 seems to be attributable to a heparin-
binding site. IGFBP7 was shown to bind to IGF-I and IGF-II, albeit with lower affinity 
(5-6 and 20-25-fold lower, respectively) than other IGFBPs, such as IGFBP3 (Oh et al., 
1996). However, IGFBP7, IGF, and insulin synergistically stimulate the growth of mouse 
fibroblasts, indicating that the interaction between IGFBP7, IGF and insulin is 
biologically relevant (Akaogi et al., 1996b). Both binding of IGFBP7 to cell surfaces and 
IGFs and insulin could be affected by the amino acid changes introduced by editing. 
Investigaing this possibility in experiments will assess the binding of IGFBP7 isoforms in 
cleaved and uncleaved form to cell surfaces. Addition of heparin to the IGFBP7 isoforms 
will determine whether this cell attachment is dependent on the heparin binding site or 
not. Finally, edited IGFBP7 isoforms in conjunction with cleavage might have altered 
interaction with IGF and insulin, which subsequently might lead to changes in 
stimulation of cell proliferation.   
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7 Regulation of editing in a highly predicted ADAR 
target 
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7.1 Abstract 
SerpinA3 emerged as highest-scoring candidate in the biocomputational screening 
using the REDS program due to a predicted 90bp double-stranded RNA structure 
(Chapter 3). Since double-stranded RNA structures of 50bp or more have been shown to 
be promiscuously edited, the lack of editing in this transcript suggests the existence of a 
novel form of editing regulation. Using minigene constructs comprising parts of the 
SerpinA3 gene we investigated the effects of splicing and the presence of putative splice-
enhancer binding sites on editing efficiency. We show that editing occurs in pre-mRNA, 
but is absent in fully processed mRNA. Our results further show that the inosines, and 
neither the strong double-stranded RNA fold nor the A-to-G changes, are responsible for 
degrading or otherwise obscuring the edited transcripts from detection by our system. 
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7.2 Introduction 
The serine protease inhibitor alpha-1 antichymotrypsin (SerpinA3) has been 
implicated in the pathology of a number of human diseases including chronic obstructive 
pulmonary disease, Parkinson‟s and Alzheimer‟s diseases, stroke, cystic fibrosis, cerebral 
haemorrhage and multiple system atrophy (for review see Ye & Goldsmith, 2001; Devlin 
& Bottomley, 2005; Baker et al., 2007) . SerpinA3 is a secreted acute phase protein and is 
upregulated by cytokines. At sites of inflammation it binds to and controls target 
proteinases. Its structure consists of three -sheets, eight alpha helices and a 23 amino 
acid long active center loop (RCL), which presents itself as a pseudosubstrate for the 
target proteinase. After binding, the protease cleaves the P1-P1‟ peptide bond in the RCL, 
and a dramatic conformational transition of the serpin protein results in the irreversible 
insertion of the loop into a -sheet, which inactivates the protease. The altered 
conformation of SerpinA3 bound to its target is then recognized by hepatic receptors and 
cleared from the circulation.  
The activity of SerpinA3 relies on its metastability in the native conformation, 
which allows a dramatic conformational change upon binding to the cognate protease and 
formation of a stable complex. This metastability depends on a kinetically trapped 
intermediate fold of the native SerpinA3, which is vulnerable to dysfunction by 
mutations. Mutations can cause aberrant conformational transitions that bring about the 
detention of the serpin within the cell, resulting in serpinopathies that manifest 
themselves in gain of function due to intracellular accumulation or loss of function due to 
lack of circulating serpin (for review see Lomas, 2005; Davies & Lomas, 2008). 
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SerpinA3 has been detected in senile plaques and surrounding astrocytes, and in complex 
with toxic beta-amyloid peptide in brains of Alzheimer‟s patients (Baker et al., 2007).  
SerpinA3 emerged as the highest scoring candidate in the REDS ranked list of 
putative editing targets (Chapter 3, Table 7a). The pre-mRNA earns its high rank due to a 
predicted 90 bp completely complementary foldback structure surrounding the putative 
editing site. In fact, double-stranded structures of 50bp in length or more are often 
promiscuously edited (Polson & Bass, 1994; Bass, 2002) and the longest completely 
complementary dsRNA of known site-specific editing targets is 17bp in the case of 
GluR-B. However, editing of SerpinA3 could not be detected in RNA analyzed from 
human brain or spleen (Chapter 4). Although the complementary sequences of SerpinA3 
transcripts are separated by ~900 nucleotides, editing at other known recoding sites 
requires folding of sequences even further apart from each other: the Q/R recoding sites 
of GluR-5 and GluR-6 involve an intronic ECS that is ~1700 nucleotides away from their 
exonic complementary sequences (Herb et al., 1996). The distance between the editing 
site and the ECS is thus not likely to be the only reason for the lack or low level of 
editing in SerpinA3.  
To assess whether lack of editing in brain and spleen was due to tissue-specific 
editing as reported for other targets (He et al., 2011), relevant parts of SerpinA3 
transcripts were analyzed in six human tissues (heart, pancreas, liver, lung, kidney and 
testis). No editing was observed in any of these sequence tracks, providing a unique 
opportunity to extend our knowledge of editing regulation.  
The intronic ECS is embedded in a L2 element. Interestingly, the ECS is present 
only in human and chimpanzee, but not in other primates such as marmoset, orangutan or 
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 rhesus, and its insertion must thus be a recent evolutionary event (Figure 25). At the time 
of the experiments, another L2 element located further downstream in intron 3 was 
annotated in the UCSC genome browser (human genome build hg18, March 2006). Since 
its orientation was opposite to that reported for the L2 element surrounding the ECS, it 
Figure 25: Genetic elements in SerpinA3 
a) Predicted RNA secondary structure formed between putative exonic target and 
intronic ECS (Zuker, 2003; Costa, 2010). b) A schematic representation of the 
SerpinA3 gene structure with repeat elements indicated at the bottom. c) 
Magnification of ECS and adjoining L2 element (L2a_l and L2a_r, forming the left 
and right arms of one L2 element) with conservation in chimpanzee but not 
orangutan, rhesus and marmoset, as evidenced by the gap in the alignment. The 
sequence aligned by the program in the opposite orientation is the exonic target 
sequence. b and c are snapshots taken from the UCSC Genome Browser (Forster & 
Symons, 1987; Kent et al., 2002).    
a) 
b)
v 
c) 
SerpinA3 
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seemed prudent to investigate whether these elements prevent formation of the editing 
competent structure by folding onto each other and favoring a competitive RNA fold. 
(Note that this second oppositely oriented L2 element is not annotated in the latest human 
genome build hg19 from February 2009). We analyzed whether such sequence elements 
could possibly prevent editing of the predicted 90bp region in vivo using a number of 
minigene expression constructs. These minigenes consist of parts of the SerpinA3 gene 
including the 90 nucleotide target sequence and the ECS. They were co-transfected with 
an ADAR-expression construct into HeLa cells. Specific genetic elements, such as splice 
and putative splice enhancer sites, were further manipulated to analyze whether editing 
and splicing compete with each other for the same target, which may prevent editing. 
Lack of editing in SerpinA3 provides us with an opportunity to dissect how 
editing is regulated, a vastly unexplored area of research. Even though editing of specific 
targets has been shown to be regulated temporally and spatially, as well as by certain 
environmental stimuli, it has never been shown that editing is actively prevented from 
taking place in putative targets. Such a finding would substantially add to our 
comprehension of regulation of editing. Surprisingly, we show that SerpinA3 pre-mRNA 
is promiscuously edited, even though the spliced mRNA product does not show evidence 
of editing. Using the minigene constructs we show that the strong double-stranded 
structure formed between the 90 nucleotide target sequence and the ECS is not 
responsible for removing the edited transcripts. Our results demonstrate that possible 
deleterious promiscuous editing of the SerpinA3 transcript is detected and eliminated, 
possibly through a yet unidentified surveillance mechanism.  
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7.3 Materials and Methods 
7.3.1 SerpinA3 minigene construct  
All sequence elements from the SerpinA3 gene were amplified using Hot Start 
Pfu Polymerase (Invitrogen) according to the manufacturer‟s instructions. Restriction 
enzyme recognition sites were added to primer sequences as indicated and the resulting 
amplicons were subjected to restriction digestion according to the manufacturer‟s 
instructions (restriction enzymes from NEB). For a graphic illustration of construct 
variants, refer to Figure 26. For primer sequences see Appendix B. 
 Amplification of SerpinA3 sequences for the full-length wild-type construct 
occurred in several steps. Initially, the first half, between exon 3 and about 300 
nucleotides into intron 3, was amplified with SPI5D-EcoR1 and SPI8U-Nsi1 and primers 
SPI7D-Nsi1 and SPI6U-Kpn1 were used to amplify the rest of the sequence through the 
end of the 90 bp editing site complementary sequence (ECS). The two restricted 
amplicons were ligated into pCI vector cleaved with EcoR1 and Kpn1 in a three-way 
ligation, yielding construct SPI_02. Primers SPI13D and SPI14U-Xma1 were then used 
to amplify the rest of intron 3 and exon 4 and ligated into SPI_02 restricted with Stu1 and 
Xma1, yielding construct SPI_04. An internal Stu1 restriction site about 50 nucleotides 
upstream of the 90 nucleotide intronic ECS facilitated this strategy. SPI14U-Xma1 
anneals with exon 4.  
To replace parts of intron 3 in the vectors with unrelated sequences, sections of 
the upstream intron 2 were used. Primers SPI15DmutDAge1 and SPI16UmutUAge1 
enabled introduction of an Age1 restriction site 55 nucleotides into intron 3 in construct 
SPI_02 via site-directed mutagenesis. Vector SPI_02 thus mutated was cut with Age1 
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and PvuII. An internal PvuII restriction site immediately 5‟ to the ECS allowed precise 
replacement of intronic sequence between exon 3 and ECS. A part of intron 2 was 
amplified with primers SPI17D-Age1 and SPI30U-PvuII and inserted into the restricted 
vector, yielding construct SPI_03, which have intronic sequence disparate from wildtype 
between exon 3 and the ECS.  
Construct SPI_05 required addition of the rest of intron 3 and exon 4 to SPI_03. 
The PvuII restriction site located before the ECS was mutated to SacII (primers SPI43D-
mutPvu-Sac and SPI44U-mutPvu-Sac) in construct SPI_03, as the intronic sequence 
between the ECS and exon4 contains three additional PvuII sites and makes use of this 
enzyme impossible. The mutated construct and the amplicon derived with SPI5-SacII and 
SPI14U-XmaI were cut with the enzymes and ligated to yield SPI_05.  
For construct SPI_06, the sequence between the ECS and exon 4 was exchanged 
using primers SPI25D-KpnI and SPI26U-Sal1 to amplify parts of intron 2, and SPI27D-
Sal1 and SPI14U-Xma1 to amplify the 3‟-end of intron 3 (including branch-point) and 
parts of exon 4. The two amplicons were restricted with the respective enzymes and 
ligated into vector SPI_02 cut with KpnI and XmaI in a three-way ligation.  
Similarly, to exchange the part of the L2 element directly downstream of the ECS, 
intron 2 sequence was amplified using primers SPI25D-Kpn1 and SPI31U-Sal1. Parts of 
intron 3 and exon 4 were amplified with SPI32D-Sal1 and SPI14U-Xma1. Both 
amplicons were restricted with the respective enzymes and ligated into vector SPI_02 
cleaved with KpnI and XmaI in a three-way ligation to yield SPI_07. 
Construct SPI_08 was generated in two steps to exchange only the L2 element 
located in the 3‟-half of intron 3 (annotated as L2 on the negative strand in hg18, March 
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2006). First, SPI34D-Kpn1 and SPI26U-Sal1 were used to amplify part of intron 2, 
SPI27D-Sal1 and SPI14U-Xma1 to amplify part of intron 3 and exon 4. These amplicons 
were ligated into SPI_02 in a three-way ligation. The resulting construct was cleaved 
with KpnI and StuI, which cuts directly before the ECS, and an amplicon containing 
sequence from the ECS to the downstream L2 (using primers SPI13D and SPI33U-Kpn1) 
was inserted.  
Finally, a short construct was generated as positive control (SPI_01), whereby 
exonic sequence amplified with SPI3D-Nhe1 and SPI4U-EcoR1 as well as the ECS 
amplified with SPI5D-EcoR1 and SPI6U-Kpn1 were cloned into the pCI vector. This 
constructs lacks most of the sequence separating exonic target and intronic ECS, leaving 
less than 50 nucleotides in between. 
7.3.2 SerpinA3 minigene site-directed mutagenesis 
7.3.2.1 Splice-site mutants 
For mutation primers see Appendix B. Splice sites were mutated in two rounds. 
First, primers SPI35D-mut5‟(2) and SPI36U-mut5‟(2) were used to mutate the „Gg‟ (last 
nucleotide of exon, first nucleotide of intron) to a „TA‟ dinucleotide. Splice acceptor sites 
were mutated using primers SPI37D-mut3‟ and SPI38U-mut3‟. Since the first mutations 
did not eliminate splicing completely (not shown), the splice sites were further mutated. 
SPI47D-mut5‟(3) and SPI48U-mut5‟(3) changed two additional nucleotides, the 
canonical intronic T and a G of a „GT‟ dinucleotide in the exon that could serve as 
alternative splice site (see Figure 28, page 153). Similarly, primers SPI39D-mut3‟(2) and 
SPI40U-mut3‟(2) mutated the 3‟-splice acceptor sites, changing a total of four guanosines 
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at the splice-acceptor present in the canonical „AG‟ dinucleotide conformation (Figure 
28).  
7.3.2.2 Splice-enhancer mutants 
Splice-enhancers may bind to the 90 nucleotide target sequence and prevent 
formation of the 90bp dsRNA. Putative splice-enhancer sites were determined as outlined 
in “7.4.4: Splice-enhancers” (Figure 29). The two most promising potential recognition 
sites were subsequently mutated. Due to possible annealing of the mutagenesis primers to 
both exonic target and ECS in the SPI_04 construct, primers were designed according to 
a protocol by Liu and Naismith that facilitates multi-site mutagenesis (Liu & Naismith, 
2008). The protocol allows newly synthesized DNA to be used as template, thus greatly 
enhancing the efficiency of the site-directed mutagenesis reaction and increasing the 
probability of mutated clones. Briefly, the two primers annealing to one target site are 
only partially overlapping, which facilitates their reannealing to newly amplified DNA by 
allowing them to bridge the nick. According to Liu and Naismith, the non-overlapping 
sequence of the primers are designed to have an annealing temperature 5-10˚C higher 
than either of the overlapping (complementary) primer sequences. 12 amplification 
cycles consisted of 95°C for 1 minute, Tm (non-overlapping) -5°C for 1 minute and 68°C 
for 14 minutes. The PCR cycles were finished with an annealing step at Tm 
(complementary) -5˚C for 1 minute and an extension step at 72°C for 30 minutes. Primer 
sequences SPI51D-mutSRp40.1, SPI52U-mutSRp40.1 (mutagenesis of first SRp40 
binding site) and SPI53D-mutSRp40.2, SPI54U-mutSRp40.2 and SPI55D-mutSRp40.2-
ECS (mutagenesis of second SRp40 binding site) are given in Appendix B. 
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7.3.2.3 ECS mutants 
To destroy the 90bp double-stranded structure, the ECS was mutated at a total of 
11 nucleotides. Four rounds of site-directed mutagenesis were required, primer sequences 
can be found in Appendix B and a graphic depiction of the engineered mutants are shown 
in Figure 31, page 160. 
7.3.2.4 A-to-G mutants 
Adenosines subjected to A-to-I RNA editing in the 90 nucleotide target sequence 
were mutated to guanosines to mimic editing (Figure 32). Twelve adenosines were shown 
to be edited to a substantial amount. Since simultaneous mutations in the complementary 
ECS were not desired, I used two previously generated plasmids that were mutated in the 
ECS (Figure 31a, mutants 2 and 3) to specifically target the mutagenesis primers only to 
the exonic 90 nucleotide sequence. Four sequential mutagenesis reactions were necessary 
to mutagenize 12 adenosines in total.  
7.3.3 Co-transfection experiments 
HeLa cells were transfected with expression plasmids using SuperFect (Qiagen) 
or X-treme Gene HP (Roche) as described by the manufacturers. The SerpinA3 
expression constructs were either co-transfected with an ADAR2 expression vector or 
with an empty pCI vector as control. RNA was extracted from transfected cells using 
Trizol reagent (Invitrogen) as suggested by the manufacturer. RNA was treated up to 
three times with DNase to remove residual plasmid DNA. To this end, RNA was 
dissolved in 24 l DEPC-treated water, supplemented with 3l 10xDNase buffer, 2l 
DNase I (4U, NEB) and 1l RNasin (40U, Invitrogen) and incubated for 1 hour at 37˚C. 
DNase-treated RNA was phenol-chloroform extracted and precipitated with ethanol in 
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between treatments. Purified DNase-treated RNA was then reverse transcribed using 
Superscript III Reverse Transcriptase (Invitrogen) and specific reverse primers SP14U 
and SP16U at a concentration 50nM each. PCR was performed on the cDNA using 
construct-specific primers and the amplicons were purified as described previously and 
sequenced (Geneway).  
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7.4 Results and Discussion 
7.4.1 Genetic elements of SerpinA3 
To assess the impact of certain genetic elements on editing in SerpinA3, we 
cloned parts of the gene into an expression vector. We focused on exon 3, intron 3, and 
exon 4 for the experiments, as the intron contains both the ECS and genetic elements that 
have the potential to interfere with the predicted folding of the SerpinA3 transcript. Three 
partial repeat elements belonging to the LINE family were annotated for this intron. Two 
L2 elements flank the putative ECS and are located on the negative strand, and a third 
partial L2 element is located about 200 nucleotides upstream of exon 4 on the positive 
Figure 26: SerpinA3 constructs 
Part of the SerpinA3 gene between exons 3 and 4 with genetic elements indicated 
and the 8 different constructs derived from the wild-type sequence. Constructs are 
color coded like genetic elements, green parts indicate exchange of sequence with 
unrelated sequence derived from intron 2 from same gene.  
 
SPI_01 
SPI_02 
SPI_03 
SPI_04 
SPI_05 
SPI_06 
SPI_07 
SPI_08 
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strand (Figure 26). This third L2 element was removed from the sequence in a newer 
version of the database (hg19, release date February 2009). All three L2 elements are 
incomplete fragments that do not correspond to the same part of the consensus L2 
sequence and alignment using blastn did not reveal sufficient sequence similarity to 
suggest formation of a strong secondary structure between these elements. In fact, the 
two L2 elements flanking the ECS are one contiguous partial L2 element interrupted by 
the insertion of the ECS in recent evolutionary history (see Figure 26 and “7.2: 
Introduction”). Nevertheless, we decided to analyze whether these elements or any other 
sequence present in intron 3 may preclude editing by, for example, preventing the 
formation of the 90bp double-stranded structure. To that end, constructs SPI_01-SPI_08 
were cloned, with intronic information exchanged with unrelated sequence of equal 
length and GC-content, derived from intron 2 of SerpinA3 (Figure 26).  
7.4.2 SerpinA3 short transcripts are edited 
 Parts of the SerpinA3 sequence from exon 3 to exon 4 were expressed in a cell-
based system (Figure 26). Even with simultaneous overexpression of ADAR2, mRNA 
was not edited at detectable levels in the target sequence using Sanger sequencing (Figure 
27, threshold set at 10%). Exchanging parts of the intron with unrelated sequences of 
equal lengths also did not increase editing to a detectable level. However, transcripts 
from shortened vectors comprising only sequence from exon 3 to the ECS were edited at 
multiple adenosines to high levels (Figure 27). Indeed, editing levels in the „short‟ 
transcripts are comparable to those seen in promiscuously edited Alu repeat elements 
(Athanasiadis et al., 2004). It has been shown that editing and splicing are coordinated in 
some editing targets with intronic ECSs such that editing occurs before splicing 
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(Laurencikiene et al., 2006; Ryman et al., 2007). It remains to be shown whether this 
coordination occurs on a more global scale. It is possible that in the case of SerpinA3, or 
indeed during transcription of most genes, such coordination does not occur and splicing 
removes the intron before the RNA forms a secondary structure amenable to editing. We 
therefore decided to destroy the splice sites through site-directed mutagenesis in order to 
prevent splicing in transcripts SPI_04-SPI_08.  
7.4.3 Splice-inefficient transcripts are edited to a low extent 
Expression vectors SPI_04 to SPI_08 were mutated at splice-donor and acceptor 
sites as shown in Figure 28a. Splice inefficiency was shown by PCR amplification of 
Figure 27: Editing in SerpinA3 transcripts derived from eight expression 
constructs 
Editing in transcripts from eight expression constructs outlined in Figure 26 was 
evaluated at the first 9 adenosines of the exonic target sequence (adenosines within 
red box of 90bp dsRNA shown above graph). Evaluation of the rest of the sequence 
was difficult for the highly edited constructs SPI_01 - _03 due to shifted sequence 
peaks. No editing above a 10% threshold was detected for the other transcripts 
further downstream. Dotted line = 10% threshold. 
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spliced transcripts across exon/exon boundaries, using the appropriate primers (Figure 
28b). As can be seen in the gel electrophoresis, splice mutants still exhibit some degree of 
a) 
b) 
Figure 28: Editing in SerpinA3 transcripts and splice-site mutants  
a) Splice sites were mutated in constructs SPI_04 to SPI_08 through site-directed 
mutagenesis as indicated below graphic (upper sequence = wild-type, lower 
sequence = mutants). b) Reduction of splice-efficiency was verified by PCR 
amplification across exon/exon boundaries using primers SPI23D and SPI14U. 
 c) Editing in transcripts from eight expression constructs outlined in Figure 26 
and their corresponding splice-site mutants was evaluated at the 5
th
 adenosine of 
the exonic target sequence. Dotted line = 10% threshold. 
c) 
1kb 
500bp 
- 
- 
X X 
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splicing, despite the substantial mutagenesis at four positions at each splice site. Some 
amplicons appear to differ in size from those derived from the corresponding non-
mutated parent constructs. Sequencing revealed the use of alternative splice donor and 
acceptor sites, possibly facilitated by the minor spliceosome, which uses recognition sites 
different from that of the major spliceosome (Will & Luhrmann, 2005). Nevertheless, 
splicing is at least greatly reduced or almost undetectable in the splice mutants. Yet, when 
we analyzed editing levels in splice-deficient mutants, only the fifth adenosine in the 
target sequence showed editing levels reaching up to 25% (SPI_06 mutated at both 5‟-
donor -and 3‟-acceptor sites, Figure 28).  
7.4.4 Splice-enhancers 
Splicing in SerpinA3 appears to be extraordinarily efficient. Four point-mutations 
at each splice-site did not suffice to abolish splicing in most constructs. The majority of 
splice-sites require the action of splice-enhancers for an efficient reaction together with 
SR-proteins that bind to the RNA at recognition sites and promote assembly of the 
spliceosome at the splice site (Long & Caceres, 2009). If splice-enhancers were to bind to 
the exonic target sequence, formation of the 90bp double-stranded RNA structure could 
be prevented. The recognition sites of splice enhancers are relatively short and ill-defined 
(Chasin, 2007). Still, web-based algorithms allow the search for putative splice-enhancer 
on a given sequence (Cartegni et al., 2003; Smith et al., 2006; Desmet et al., 2009). 
Additionally, SR-proteins bind single-stranded RNA, and thus their binding sequences 
must be displayed on single-stranded RNA loops (Shepard & Hertel, 2009). In order to 
predict true splice-enhancer sites within the exonic target sequence, web-derived 
potential splice-enhancer sites were aligned to the probability that a particular nucleotide 
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be single-stranded (ss-count), as predicted by Mfold (Zuker, 2003). Mfold determines this 
probability based on folding of up to 50 lowest-energy secondary structures of a given 
RNA sequence (Zuker, 2003). Since human and chimpanzee both have very low or zero 
probability of single-stranded nucleotides within the 90 nucleotide target sequence, 
SerpinA3 sequences from orangutan and macaque, as well as human RNA sequence 
Figure 29: Putative splice-enhancer sites  
The ss-count (Mfold) for each nucleotide of SerpinA3 sequences from four species 
were aligned and color-coded (white = 0%, dark red = 100%). The human sequence 
without ECS was also analyzed in this manner (H. w/o ECS). Ss-counts were 
averaged across the three sequences without ECS (H. w/o ECS, orangutan, macaque) 
or the two with ECS (human and chimp) and likewise color-coded. The nucleotides 
which are likely to be single-stranded are therefore orange to red. The human 
sequence shown was then submitted to the ESE Finder 3.0 and Human Splicing 
Finder Version 2.4.1 (Cartegni et al., 2003). The sites were aligned to the sequence 
and strong ESE candidates overlapping with single-stranded areas were selected for 
analysis (blue boxes). Nucleotides in green were mutated to sequence in blue.  
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lacking the ECS (i.e. with the two L2-arms joined together) were analyzed, assuming that 
SR-protein binding sites in primates are relatively conserved. Figure 29 shows a heat-
map of the percentage of RNA folds in which a given nucleotide is in single-stranded 
configuration from 0% (white) to 100% (dark red) of the five analyzed sequences. 
Binning calculated the average of single-strandedness along 5 nucleotides of the two 
sequences with ECS (human and chimp) or the three sequences without ECS (H. w/o 
ECS, macaque, orangutan). Color-coding highlights the nucleotides which are more 
likely to be single-stranded in these closely related species. The human SerpinA3 
sequence was then submitted to ESEfinder 3.0 (Cartegni et al., 2003; Smith et al., 2006), 
and Human Splicing Finder Version 2.4.1 (Desmet et al., 2009), web-based tools that 
predict potential exonic splice enhancer sites and score them according to their strength. 
Two strong ESE candidate sites that overlap with areas that are likely to be single-
stranded were chosen for analysis. They were mutated in a way as to destroy their 
consensus binding sites for the SRp40 and SF2/ASF splice-enhancer proteins.  
Sequence track analysis of amplified transcripts derived from these constructs did 
not show evidence of editing in the 90 nucleotide target sequence (data not shown). 
Additionally, splicing was not inhibited as estimated from the PCR amplification (data 
not shown). Despite careful analysis and computational predictions it is possible that the 
predicted and mutated ESE recognition sites may not represent true ESE binding sites.  
7.4.5 Pre-messenger RNA is edited promiscuously 
For amplification of transcripts from splice-mutant minigene constructs, a reverse 
primer annealing to the 3‟-end of exon 3 was used, and thus both spliced and unspliced 
transcripts were amplified. The forward primer, spanning a plasmid-specific intron, 
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ensures that only transcripts from expression constructs were amplified. We hypothesized 
that differences in editing in spliced and unspliced transcripts could explain the findings 
obtained thus far. If editing levels were higher in unspliced transcripts, slightly higher 
levels of editing in splice-deficient transcripts could be expected, as pre-mRNA may 
accumulate more than from splice-competent transcripts. To address this question, we 
amplified pre-mRNA specific sequences using a reverse primer annealing to the intron of 
transcripts from select constructs and their corresponding splice-inefficient variants 
(Figure 30a). To our surprise, all transcripts, regardless of expression construct, were 
edited to a high level at multiple adenosines within the 90 nucleotide exonic target 
sequence. The high percentage of edited pre-mRNA obscured the sequence track 
SPI_02 
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SPI_06 
Figure 30: Editing in pre-mRNA 
a) Constructs and primers used for analysis of editing in pre-mRNA.  
b) Portion of 90 nucleotide target sequence analyzed for editing in pre-mRNA. Bars 
indicate range of editing observed at the specific adenosine.  
 
 
a) 
b) 
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analysis. The bars in Figure 30b depict the range of editing levels in the pre-mRNA 
variants at a specific adenosine in the 90 nucleotide target sequence. Editing extents are 
independent of the transcript variant (i.e. the original construct).  
While pre-mRNAs of SerpinA3 transcripts from expression plasmids are 
promiscuously edited, mature mRNAs show low to no evidence of editing. Several 
possible scenarios could explain this observation. First, edited pre-mRNA and/or mRNA 
may be degraded or otherwise made unavailable for amplification. Tudor-SN is an RNase 
that specifically recognizes and cleaves inosine-containing RNA and has been shown to 
associate with the U5 snRNP of the spliceosome (Yang et al., 2007). It is tempting to 
speculate that Tudor-SN recognizes and cleaves edited SerpinA3 RNA, leading to its 
directed destruction. Only unedited transcripts and/or those with few inosines would 
persist. Alternatively, formation of the strong 90bp double-stranded structure could 
trigger removal of such folded transcripts from the system. If the last scenario were true, 
one would expect to see no editing at all in any mRNA. However, editing levels of up to 
10% and 25% were observed in certain SerpinA3 transcript variants and splice-inefficient 
mutants, respectively. Consequently, a double-stranded structure must have been present 
for these transcripts to be edited. Still, it is important to determine whether edited 
transcripts are cleared form the detectable pool of transcripts due to editing or due to a 
strong double-stranded secondary structure.  
7.4.6 Editing, not double-strandedness, causes transcripts to be cleared 
To determine whether double-stranded structures degrade or otherwise make 
SerpinA3 pre-mRNA undetectable, the intronic ECS was mutated at eleven positions to 
disrupt the perfect complementarity between it and its target sequence. Four sequential 
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site-directed mutagenesis reactions were performed on plasmid SPI_04, yielding 
expression constructs with consecutively smaller extents of complete complementarity 
(Figure 31a). While editing levels are lower than in SPI_04-transcripts, as expected due 
to the successively smaller sections of complementarity, editing is detected in pre-mRNA 
(Figure 31b) but not in processed mRNA (not shown) of these ECS mutants. We 
conclude that the strong double-stranded structure by itself is not required for reducing 
the pool of edited pre-mRNA.  
7.4.7 Editing triggers degradation of pre-mRNA 
As can be deduced from the editing levels seen in pre-mRNA, most pre-mRNAs 
are edited (the fifth adenosine is edited up to 75%). However, editing levels are low to 
undetectable in PCR products amplified with a primer that amplifies both mRNA and 
pre-mRNA alike. This observation is significant in so far as it implies that the edited pre-
mRNA pool is substantially smaller than the corresponding unedited spliced mRNA pool. 
Therefore, two fates exist for a pre-mRNA: either it gets edited and rapidly degraded, or 
it remains unedited, matures and is relatively stable.  
There are two possibilities for how the edited pre-mRNA is recognized: either by 
recognition of A-to-G changes or by recognition of inosines. To distinguish between 
these possibilities, adenosines that are highly edited in pre-mRNA were mutated to 
guanosines in expression constructs (Figure 32b). Since mutagenesis primers could 
anneal to two identical sequences in the wild-type minigene (SPI_04), we chose instead 
to mutate the ECS mutants 1 and 2. This provided for some sequence specificity of the 
primers, which were used to mutate 12 adenosines in four sequential mutagenesis 
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reactions. If the inosines were specifically recognized, these mutants should be immune 
to the mechanism that rids the system of edited pre-mRNA and therefore accumulate 
mature RNA faster than editing-competent transcripts (Figure 32a). If, on the other hand, 
the sequence changes from A to G trigger such a mechanism, the mRNA of the A/G 
SPI_04 
ECS 
mut 1 
ECS 
mut 2 
ECS 
mut 3 
a) 
b) 
Figure 31: Editing in ECS mutants 
a) Double-stranded structures predicted for the transcripts of SPI_04 and three ECS 
mutants with successively reduced complementarity.  
b) Adenosines 4 -18 of 90 nucleotide target sequence analyzed for editing in pre-
mRNA. All ECS mutants display promiscuous editing with slightly reduced levels 
compared to transcripts of the SPI_04 construct. No editing was detected in spliced 
mRNA of any of the ECS mutants (not shown). 
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mutants would be targeted for destruction just like the edited portion of pre-mRNA in 
editing-competent transcripts. Indeed, there may be no accumulation of mRNA from A/G 
mutants in that case.  
The qRT-PCR analysis planned initially to quantify pre-mRNA and mRNA levels 
proved to be problematic, possibly due to an inhibitory effect of the strong double-
stranded structure that can form between exon and ECS. Similarly, residual pre-mRNA in 
the cDNA preparation might also anneal to the 90 nucleotide target sequence. 
Additionally, such annealing might result in fluorescence to give a false-positive signal. 
A semi-quantitative PCR reaction was performed instead of the qRT-PCR. Preliminary 
results showed no signficiant differences in amplification among wild-type (SPI_04), 
ECS mutant and corresponding A/G mutant, neither in unspliced nor spliced transcripts. 
It is interesting that A/G mutant mature mRNA can be amplified, indicating that the 
nucleotide changes do not appear to influence pre-mRNA processing. While these 
preliminary results are not conclusive, they at least show that splicing is not inhibited by 
the presence of guanosines in place of adenosines in the 90 nucleotide target sequence. 
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Figure 32: A/G mutants 
a) Model demonstrating how editing, splicing and elimination of edited pre-mRNA 
might alter the equilibrium of unspliced and mature mRNA. Top of the schematic 
shows that wild-type pre-mRNA is primarily edited and thus somehow eliminated. At 
the bottom, this equilibrium might be changed in A/G mutants with no editing in pre-
mRNA and thus a higher rate of splicing. 
 b) ECS mutants 1 and 2 were mutated in the 90 nucleotide target sequence at 
adenosines that are highly edited in the cell culture experiments. Sequence changes 
are highlighted in red.  
 
 
a) 
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Therefore, it is likely that the inosines themselves are responsible for triggering the 
elimination of edited pre-mRNA. Tudor-SN is an inosine-specific RNase and was shown 
to target edited pri- and pre-miRNAs for degradation. We hypothesize that Tudor-SN, 
which is associated with the U5 snRNP and functions in spliceosome assembly and pre-
mRNA splicing, recognizes hyper-edited SerpinA3 pre-mRNA and initiates its 
degradation. Inhibition of Tudor-SN in vivo with the specific inhibitor Thymidine 3‟,5‟-
diphosphate would lead to the accumulation of edited pre-mRNA if Tudor-SN was 
indeed involved in the degradation of edited SerpinA3 pre-mRNA. This could be assess 
by determining the editing levels in amplicons obtained using an exon3-specific reverse 
primer, which leads to amplification of both pre-mRNA and mRNA.  
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7.5 Conclusions 
SerpinA3 inhibits cognate proteases by the insertion of a reactive center loop into 
their active sites and the formation of an irreversible, stable complex (Devlin & 
Bottomley, 2005). This activity requires a metastable native conformation, which allows 
it to undergo a large conformational change upon binding. Such metastability is easily 
disrupted by mutations, which manifest themselves as devastating diseases termed 
serpinopathies (Crowther et al., 2004; Lomas, 2005; Davies & Lomas, 2008).  
SerpinA3 pre-mRNA is predicted to form a 90bp completely complementary 
structure between a 90 nucleotide exonic sequence and an intronic ECS. For this reason, 
the REDS program listed SerpinA3 as highest-ranking candidate. Its lack of editing in 
mRNA from several human tissues led us to question the reasons why this presumably 
„perfect‟ ADAR target is not edited. We show here that while fully mature mRNA does 
not have detectable levels of editing, SerpinA3 pre-mRNA is indeed promiscuously 
edited. A mechanism that we hypothesize to involve Tudor-SN appears to ensure that 
edited SerpinA3 pre-mRNA does not mature into functional mRNA. The potential 
existence of a surveillance mechanism in this transcript is not surprising, considering the 
devastating effect promiscuous editing and thus a host of recoding events would have on 
the functionality of SerpinA3. The nature of this surveillance mechanism and whether it 
acts on a more global scale remains to be elucidated. The insertion of the ECS into the L2 
element appears to be a recent event in evolutionary terms, as it is present in human and 
chimpanzee, but not in macaque and orangutan. This mechanism must have been in place 
when this insertion happened, in order to prevent promiscuous editing, and allow the 
insertion to persist. 
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When highly edited adenosines were mutated to guanosines in minigene 
constructs, transcripts were still processed to fully mature mRNA. This indicates that the 
surveillance mechanism specifically recognizes inosines, and not the nucleotide changes. 
Tudor-SN is a RNase that specifically recognizes and cleaves inosine-containing RNA. It 
has been shown to associate with the U5 snRNP of the spliceosome. We hypothesize that 
Tudor-SN is involved in recognition and degradation of promiscuously edited pre-mRNA 
as part of this surveillance system. This mechanism might act in a manner similar to the 
one shown to function in the miRNA pathway (see Chapter 1 and Yang et al., 2006). 
Indeed this mechanism might act in several instances where promiscuous editing occurs 
in exonic sequences, as evidence of editing is absent in many of the high-ranking 
candidates predicted by the REDS program. 
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8 Conclusions 
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8.1 Bioinformatics prediction of A-to-I RNA editing recoding sites in 
the era of RNA deep-sequencing 
Recent technological advances have made in-depth analyses of transcriptomes 
available to a larger research community through relatively affordable high-throughput 
sequencing. Will the brute force of vast amounts of sequence data reduce the need for 
bioinformatics-driven predictive models? Recent deep-sequencing analyses successfully 
identified many more editing targets than previously known (Li et al., 2009; Enstero et 
al., 2010). High-throughput analyses today usually only allow sequencing of short 
stretches of transcripts, limiting their efficacy to specific sites within in the transcriptome. 
Thus, analyses to date rely on computational screening methods to arrive at a candidate 
list of putative editing targets. Therefore, at least for the moment, computational 
screening and high-throughput sequencing go hand-in-hand. Consequently, the 
experimental data can only be as good as the initial bioinformatics screening.  
Due to the increasing information content in publicly available sequence 
databases, recoding editing events with high penetrance and wide tissue distribution 
should be readily detectable through a screen such as REDS. Recent bioinformatics-
driven screens from us and others, and a few deep-sequencing analyses, indicate that few 
high-level editing sites exist, most of which have now been identified. However, it is 
increasingly clear that editing is regulated in a target-, tissue-, time-, and/or stimuli-
dependent manner. The challenge now is to identify recoding editing sites that are of 
consequence and possibly highly regulated. Again, a bioinformatics approach with high 
predictive force is indispensable to pinpoint such elusive targets. A program with a high 
data flow-rate, that allows analysis of several databases within a short period of time, 
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adjustment of user-defined screening settings, and integration of new insights into ADAR 
target preferences in combination with high-throughput sequencing could potentially 
enable the ambitious search for targets that are edited only intermittently. The 
incorporation of nearest-neighbor analysis, optional analysis of the degree of 
conservation, and information about the tissue-specificity of mRNAs with annotated G-
discrepancy might be sufficient refinements of the REDS algorithm to support such an 
endeavor.  
8.2 Consequences of editing on protein function 
Functional analysis of the effects of recoding events on the affected protein 
variants is an important part of assessing the impact of editing on transcriptome and 
proteome diversity. The need to characterize consequences of editing on protein function 
is growing with the discovery of more targets such as C1QL1, IGFBP7, FLNA, CDK13, 
and COPA, to name a few. In order to conceive valid assays that test relevant functions, 
each target requires a streamlined study that integrates knowledge of protein function, 
domains, interaction partners, post-translational modifications and processing. Integration 
of available information can enable a well-informed experimental approach to allow 
testing the functionality of the different protein isoforms. Another way to elucidate the 
impact of editing on protein function is the creation of transgenic animals that are either 
incompetent in editing a certain target (by removal of the ECS for example), or that can 
only express the edited variant. This allows analyzing effects in an organismal context, 
enabling researchers to assess effects on various tissues and at different developmental 
time-points. While successful in some cases (for example for the GluR-B Q/R site), it is 
expensive and time-consuming and does not guarantee success in determining the 
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underlying molecular bases of observations. In conclusion, analysis of functional 
consequences for the ensuing protein variants upon editing may require vastly different 
experimental analysis methods, rationalized upon the distinct features of the affected 
protein. Much research is needed on this aspect of A-to-I RNA editing. 
8.3 Unexplored RNA world 
Much of the A-to-I RNA editing field has so far focused on the identification and 
characterization of recoding events. Due to the increasing awareness of the importance of 
non-coding RNAs in the past few years, new efforts have been made in trying to 
elucidate the consequences of editing on non-coding RNAs such as miRNAs. Indeed, 
functional RNAs are not, as long presumed, the solitary remnants of the primordial RNA 
world in which self-replicating, catalytic RNA reigned. Instead, RNA has continued to 
play a central role throughout evolution. In fact, non-protein coding portions of genomes, 
the majority of which is pervasively transcribed from yeast to human (Kapranov et al., 
2002; Miura et al., 2006; Kapranov et al., 2007), increase with increasing complexity of 
organisms, while the quantity of sequences coding for proteins remains comparatively 
similar (Lander et al., 2001; Stein et al., 2003; International Human Genome Sequencing 
Consortium, 2004). Although co-transcriptional modifications such as editing and 
alternative splicing considerably expand proteome diversity from a limited number of 
genes, they can only partially explain the elaborateness of metabolic, developmental, 
architectural, and cognitive systems in higher organisms. The true force underlying 
organismal complexity may be more related to the sophistication of regulatory networks 
encrypted in non-coding sequences. Therefore, it has been proposed that the complexity 
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of higher organisms is directly related to the information stored in the non-protein coding 
part of a genome (Taft et al., 2007).  
Even though ncRNAs are starting to receive the attention they deserve only of 
late, their involvement in many regulatory networks is already apparent, such as 
regulating the epigenetic state of a cell and controlling gene expression on transcriptional 
and translational levels in both cis and trans (Costa, 2010; Mattick, 2010; Tsai et al., 
2010). The combinatorial control of complex networks governed largely by regulatory 
RNAs seems to be particularly important for the highly complex human nervous system. 
Consequently, ncRNAs are now subject of intense research efforts, aimed at trying to 
elucidate their various roles in cellular functions. A critical aspect of how a cell controls 
the actions of such ncRNAs is its ability to modulate and regulate them both on a 
transcriptional level and through posttranscriptional regulation and modification. RNA 
interacting partners in general and RNA modifying enzymes in particular may assume the 
critical responsibility of directing and modulating functional RNAs. ADARs have been 
shown to edit and as a result profoundly impact the regulation and function of miRNAs, 
but we are just beginning to explore their regulatory power on other RNAs. Alu elements 
appear to be evolutionarily important for primates, especially in conjunction with A-to-I 
RNA editing (Eisenberg et al., 2005b). This notion has been supported by the finding that 
editing can lead to the exonization of an Alu element by changing an AA dinucleotide 
into an AG 3‟ acceptor splice site (Lev-Maor et al., 2007). The sophisticated regulation of 
neurons mediated by RNAs may in part explain the difference between human and other 
species. Incidentally, inosine-levels are highest in brain (Paul & Bass, 1998). In order to 
comprehend how regulatory RNAs exert their functions, it is important to elucidate how 
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these RNAs are governed by their own superimposed regulatory networks – attacking this 
uncharted territory promises to break new ground in a young research field.  
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9 Appendix A 
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9.1 Computational methods 
9.1.1 Databases and Bioinformatics procedure for scoring and ranking candidates 
for RNA editing, SNP study 
Annotations for human SNPs from the dbSNP database build 125 (Sherry et al. 
2001) were downloaded using the UCSC genome table browser (Kuhn et al. 2007). For 
subsequent analysis of candidate genes the UCSC human genome browser (assembly 
May 2004) was used.  
Cross-species conservation was analyzed on two levels. Initially, conservation 
was evaluated for all 554 candidate genes using the UCSC genome browser conservation 
track, which is based on the phastCons program designed to identify conserved elements 
in multiple aligned sequences (Siepel et al. 2005). PhastCons is based on a phylogenetic 
hidden Markov model (phylo-HMM), a type of statistical model that considers both the 
process by which nucleotide substitutions occur at each site in a genome and how this 
process changes from one site to the next (Siepel et al. 2005). PhastCons produces a 
continuous valued „„conservation score‟‟ for each base of the reference genome. The 
conservation score at each base in the reference genome is defined as the posterior 
probability that the corresponding alignment column was generated by the conserved 
state (rather than the nonconserved state) of the phylo-HMM, given the model parameters 
and the multiple alignment. Therefore, the scores range between 0 and 1, corresponding 
to 0%– 100% conservation. 
All 554 candidate genes were grouped into five bins according to the PhastCons 
score covering the region of 15 nucleotides (nt) upstream of and 15 nt downstream from 
each candidate site for editing. The bins were: high (H), for conservation of higher than 
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90%; high-medium (HM) for conservation between 75% and 90%; medium (M) for 
conservation of 50%–75%; medium-low (ML) for conservation of 25%–50%; and low 
(L) for conservation <25%. Only candidates from the H and HM bins were used for 
further analysis. 
The second level of cross-species conservation taken into consideration was the 
conservation of the potentially edited adenosine. Candidates where only human and 
mouse homologous carry an adenosine at the predicted editing position, but not the rat 
counterpart (and/or chicken if available for the gene), were eliminated from further 
analysis even if previously grouped into the H or HM bin. This two-step evaluation of 
cross-species conservation is based on the data from known editing sites where the 
sequence surrounding the editing site as well as the edited adenosine itself are conserved 
to a higher degree than the general conservation of exonic, coding sequences, since in 
addition to encoding amino acids, the sequences also participate in forming a functional 
RNA structure. 
293 of the 554 candidate sites remained for further analysis, whereas 261 entries 
were filtered out at this step. Next, evidence for in silico editing was analyzed for each of 
the 293 sites using the BLASTN program (NCBI). To this end 30nt upstream of and 30 nt 
downstream from the predicted sites were successively blasted against the nr (NCBI) and 
the human EST databases (NCBI) and the percentage of sequences that carry a G instead 
of an A at the predicted site was recorded. For 204 candidates in silico editing was equal 
to or higher than 1%, whereas for 89 entries no evidence of editing was detected in silico. 
The possibility of a RNA fold-back structure was then investigated for each of the 
204 remaining candidate genes. In known cases of RNA editing, the RNA fold-back 
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structure usually involves the exonic sequence immediately surrounding the edited 
adenosine and an editing site complementary sequence (ECS), which is often located in 
the downstream intron in mammalian targets. For fold-back analysis we used the 
MFOLD program (Zuker 2003) in the batch mode, which allows for the folding of up to 
800 nt of RNA sequence. Initially, 700 nt upstream of and 100 nt downstream from, or 
100 nt upstream of and 700 nt downstream from, the predicted editing site were run and 
the resulting secondary structures were inspected for fold-back substructures that 
included the immediate region surrounding the predicted site. If no distinctive structure 
was found, additional sequences were folded using MFOLD by selecting z100 nt 
upstream of and downstream from the predicted site together with up to 600 nt of 
sequences from another region within the gene and < 2.5 kb upstream of or downstream 
from the predicted site. This selection is based on known edited genes, where the ECS 
was found to be located in intronic regions up to a few kilobases away from the exonic 
editing site. Only those sequences were selected that showed a high degree of 
conservation according to the PhastCon track of the UCSC human genome browser. 
The substructure or substructures covering the sequence region around the 
predicted editing site that showed the highest doublestranded character for each candidate 
were then grouped into bins 1–5 based on a calculated structural score (STR). The 
structural score STR was obtained from values for three different features determined for 
each evaluated candidate. First, the base-pairing (BP) score was calculated, which 
corresponds to the number of base pairs present in the structure multiplied by the fraction 
of nonbase-paired nucleotides [BP = bp(1-bp/nt)]. The value for this feature reflects the 
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fraction of nucleotides that are base paired in the structure, and also accounts for the total 
lengths of the structure including base-paired as well as nonbase-paired nucleotides. 
Second, the GC content of the base pairs was analyzed (the GC score) by 
determining the sum of base pair values using a value of 3 for a G/C base pair and a value 
of 2 for an A/T or a G/T base pair. 
Third, a penalty value (IS score) was determined for the length of intervening 
sequence between the two base-paired regions, as our previous study of intramolecular 
folding and editing of Alu-element-containing sequences showed that the level of editing 
decreases with an increasing size of the intervening sequence. The individual IS score 
bins were: Intervening sequence of >100 nt: penalty reducing score by 10%; >500 nt: 
18%; >750 nt: 23%; >1000 nt: 30%; >1250 nt: 38%; >1500 nt: 45%; >1750 nt: 51%; 
>2000 nt: 60%; and >2500 nt: 80%. 
The overall structural score STR follows as: 
STR = BP3GC – IS. 
Candidate structures with a STR score <100 were placed in bin 5; scores between 
100 and 300 in bin 4; scores between 300 and 900 in bin 3; scores between 900 and 1800 
in bin 2 and scores >1800 in bin 1. 
Our scoring of fold-back structures is uniquely tailored to identify folds that are 
more likely functional in supporting RNA editing and does not simply select the most 
thermodynamically stable structures. This is, for example, reflected in that the penalty for 
intervening sequences between the base-pairing regions is based on the known and 
characterized editing targets 
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For each of the molecular features analyzed (identity of -1 and +1 nucleotide; 
conservation; structure, as described in the Results section) we then computed a 
comparative score. For each feature I with a value xi we calculated a log-odds score: 
 
 
 
based on a relative entropy approach (Lim et al. 2003). fi(xi) corresponds to the 
frequency of the parameter value xi in the reference set of known edited exons, and gi(xi) 
being the frequency of xi among the sample set of all pre-mRNA sequences in our 
prefiltered database. Finally, a combined score for each candidate editing site is derived 
from the sum of the log-odds scores for each analyzed parameter: 
 
9.1.2 Computational Methods and Databases used for the REDS study 
Human, mouse and zebrafish genomic DNA sequences, mRNA data files, SNP 
data, as well as table annotations were retrieved using the UCSC genome browser ftp site 
(assembly March 2006) (Kuhn et al., 2007). REDS consists of three consecutive 
computational stages (Supplemental Fig. S1). Stage 1 aligns expressed sequences (UCSC 
mRNA database) from a given species to the corresponding genomic sequence. Coding 
sequences are translated, allowing for determination of non-synonymous codon positions 
within ORFs. According to user specifications (type of base difference, coding versus 
non-coding, synonymous versus non-synonymous), specific types of base discrepancies 
are mapped and output with chromosome location and position, mRNA accession and 
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position, gene ID and description and affected amino acid. Previously known RNA 
editing site are flagged. Stage 2 compares the list of base discrepancies to the species-
specific SNP database (Sherry et al., 2001) and all positions that correspond to 
genomically validated SNPs are filtered out. 
The third stage of the computational pipeline evaluates RNA folding 
characteristics for each of the remaining sites. The user defines several parameters: a first 
sequence window determines how much of the genomic sequence upstream and 
downstream of the putative editing site will be analyzed. A second sequence window 
selects a small gene section surrounding the candidate site, for which the algorithm 
generates the reverse complement sequence with which to scan window 1 for matches 
(including G-T wobble base pairs and allowing for single, symmetric mismatches). 
Furthermore, the cut-off value for how many consecutive base pair matches within the 
RNA secondary structure are required to pass the filter and finally a minimum value for 
the length of the intervening sequence between the base-pairing sections are determined. 
A multi-segment heuristic combines pairs of base-pairing segments within the 
sequence that may be part of one composite RNA secondary structure. A score is 
assigned to this composite structure, whereby base-pairs involving nucleotides within the 
inner window 2 are weighted more strongly according to a user-defined value. This 
biases the search for bona fide editing targets since base-paired segments of an RNA fold 
that supports editing include, or are in close vicinity to, the editing site. Finally, the 
output list of candidate sites is ranked by an overall score. For further information about 
REDS see Supplementary Documents.  
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9.2 Molecular Biology materials and methods 
9.2.1 RNA isolation from adherent cell culture  
Cells grown in monolayer were lysed directly in the dish by adding 100l TRIzol 
reagent/cm
2
 surface, passing the cells multiple times through a pipette and incubating the 
samples 5 minutes at RT. 200l chloroform per 1ml TRIzol were added and tubes shaken 
vigorously for 15 seconds. After incubation for 3 minutes at RT, samples were 
centrifuged for 15 minutes at 12,000g at 4°C. The upper aqueous phase was mixed with 
0.5ml isopropanol per 1ml TRIzol used and incubated 20 minutes at RT to precipitate 
RNA. RNA was pelleted by centrifugation for 10 minutes at 12,000g at 4°C. The RNA 
pellet was washed once with 75% ethanol, centrifuged for 5 minutes at 7,500g at 4°C, air 
dried and dissolved in DEPC-treated ddH2O. 
9.2.2 Phenol/chloroform extraction and ethanol precipitation of nucleic acids 
Phenol/chloroform extraction was performed to purify nucleic acids from protein 
contaminations after e.g. DNase treatment. An equal volume of phenol/chloroform/ 
isoamylalcohol (PCI, Invitrogen) was added to the aqueous nucleic acid solution, 
vortexed for 10 seconds and centrifuged at maximum speed for 5 minutes at RT. The 
upped aqueous phase was transferred to a fresh tube, mixed with an equal volume of 
chloroform/isoamylalcohol (24:1), and centrifuged at maximum speed for 5 minutes at 
RT. The upper aqueous phase was again transferred to a fresh tube and nucleic acid was 
precipitated by adding 1/10 volume 3M NaOAc, pH 3, and 2.5V 100% EtOH. Usually, 
nucleic acids were allowed to precipitate for 20 minutes to over night at -20°C. 
Precipitates were pelleted by centrifugation for 30 minutes at maximum speed at RT in a 
180 
 
tabletop centrifuge. Pellets were washed once with 75% EtOH, centrifuged 5 minutes at 
maximum speed, the supernatant removed and air dried before being dissolved in ddH2O 
(DEPC-treated for RNA).   
9.2.3 DNase treatment 
To remove contaminating traces of DNA from RNA isolates, RNA samples were 
treated multiple times with either 3-5 units RQ1 RNase-free DNase (Promega) or 6 units 
TURBO DNase (Ambion) according to the protocols provided by the manufacturers. The 
reactions were stopped by Phenol/Chloroform extraction and Ethanol precipitation. 
9.2.4 RT-PCR 
Tissue specific total RNA was reverse transcribed in a reaction containing 2-10g 
of RNA, 250ng random primers, 1mM dNTPs, 10mM DTT, Rnasin, first strand buffer 
and 150U SuperScript III Reverse Transcriptase (Invitrogen) in 20l final volume. When 
later amplification by PCR was expected to be difficult, specific reverse primers were 
added to the mix at a concentration of 100nM (e.g. for C1QL1 amplifications: homo 
sapiens C1Q13U; mus musculus: mC1Q8U; danio rerio: drC1Q16U)  
For subsequent amplification of any of the other targets, addition of a reverse 
primer during reverse transcription was not necessary. The reaction was incubated at 
55°C for 30 minutes, another 150U reverse transcriptase was added, and the reaction was 
allowed to proceed for another 30 minutes before it was stopped by incubation at 70°C 
for 15 minutes. 
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9.2.5 RNA editing analysis  
Human total RNA and gDNA isolated from the same specimen (Biochain) were 
processed using standard protocols for reverse transcription and PCR. Gene-specific 
fragments of cDNA as well as genomic regions were amplified by PCR and subjected to 
dideoxy-sequencing as described previously (Athanasiadis et al., 2004; Gommans et al., 
2008). Editing at the predicted positions was analyzed by inspecting the sequence traces 
for double peaks, with the ratio of the peak heights giving an indication of approximate 
editing levels. The occurrence of SNPs at candidate positions was excluded by analyzing 
the specimen-matched gDNA. 
9.2.6 Site-directed mutagenesis 
Site-specific mutations (up to 5 point mutations at once) were introduced into 
cloning vectors through site-directed mutagenesis using HotStart PfuTurbo polymerase 
(Invitrogen) and specific mutagenesis primers (forward and reverse), which generally 
consisted of approximately 20 nucleotides flanking (the) desired nucleotide change(s) on 
either side. Reactions contained 1x Pfu reaction buffer, up to 200ng dsDNA template 
(vector), 300nM of forward and reverse primer each, 200M dNTP mix, and 2.5U of 
PfuTurbo DNA polymerase in a total volume of 50l. Reactions were overlayed with 
30l mineral oil to prevent evaporation. An initial denaturation step at 95°C for 30 
seconds was followed by 12-18 cycles of 95°C for 30 seconds, 55°C annealing for 1 
minute, and 68°C extension for 1 minute/kb of plasmid length. A final extension occurred 
at 72°C for 15 minutes. Methylated, non-mutated parental DNA was digested with 10 
units DpnI at 37°C for one hour. Products were purified with phenol/chloroform 
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extraction and precipitated with ethanol. Typically, half or all of the mutagenesis reaction 
was used to transform Z-competent E. coli cells (see below).  
9.2.7 Z-competent cells 
Z-competent E. coli were prepared using the Z-Competent E. coli Transformation 
Buffer Set™ (Zymo Research) according to the manufacturer‟s instructions, aliquoted at 
150l and stored at -80°C. 
9.2.8 Transformation 
Z-competent cells were thawed on ice, DNA to be transformed was added, the 
tubes briefly flicked and incubated on ice for 20 minutes. After a heat shock at 42°C for 
45 seconds (alternatively, 37°C for 90 seconds was also successfully used), cells were 
placed on ice for 2 minutes before addition of 250l SOC medium. Cells were allowed to 
recover for one hour at 37°C under gentle agitation before plating up to 200l of 
transformants onto LB selection plates (containing either ampicillin or kanamycin). 
9.3 Protein biology 
9.3.1 Co-transfection experiments 
Plasmids were used for transfection of HeLa cells using SuperFect (Qiagen) as 
described by the manufacturer. The construct was either co-transfected with an ADAR2 
expression vector or with an empty pCI vector as control. RNA was extracted from 
transfected cells using Trizol reagent (Invitrogen) as suggested by the manufacturer. 
RNA was treated up to three times with DNase to remove residual plasmid DNA. To this 
end, RNA was dissolved in 24 l DEPC-treated water, supplemented with 3l 
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10xDNase buffer, 2l DNase I (4U, NEB) and 1l RNasin (40U, Invitrogen) and 
incubated for 1 hour at 37˚C. DNase-treated RNA was Phenol-Chloroform extracted and 
precipitated with ethanol in between treatments. Purified DNase-treated RNA was then 
reverse transcribed using Superscript III Reverse Transcriptase (Invitrogen) and specific 
reverse primers SP14U and SP16U at a concentration of 0.8 M each. PCR was performed 
on the cDNA using construct-specific primers and the amplicons were purified as 
described previously and sequenced (Geneway).  
9.4 Cell biology 
9.4.1 Cell culture 
HeLa and HEK293 cells were maintained in 1xMEM (Cellgro) containing 10% 
FCS and 1x antibiotic/antimycotic solution. Cells were trypsinized at least twice a week 
and never allowed to grow over-confluent. 
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10.1 Media, buffers and solutions  
10.1.1 HeLa and HEK293 cell culture medium 
500ml 1xMEM (Cellgro) 
5.5ml  Antibiotic/Antimycotic solution (Cellgro) 
50ml Fetal Calf Serum (HyClone) 
Assembled under sterile conditions, stored at 4°C. 
To select for stably transfected HEK293 cells that express the neomycin 
resistance gene encoded on the pCI-neo vector, 500g/ml G418 (from 100mg/ml in 
40mM Hepes frozen stock) was added to the medium immediately prior to use. Stable 
transfectants were subsequently maintained in 300g/ml G418. 
10.1.2 LB Medium 
10g Tryptone (BD) 
5g Yeast extract (BD) 
10g NaCl  
15g Bacto Agar (for plates only) (BD) 
ddH2O to 950ml 
pH to 7.0 with ~200l 5N NaOH, ddH2O to 1l and autoclaved for 20 min., 15 psi, 
121°C 
10.1.3 LB Ampicillin or Kanamycin 
1000x Ampicillin stock solutions were prepared at 50mg/ml in ddH2O and stored 
in 1ml aliquots at -20°C. 1000x Kanamycin stock solutions were prepared at 30mg/ml in 
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ddH2O and stored in 1ml aliquots at -20°C. Appropriate volumes of Ampicillin and 
Kanamycin were added fresh to either LB broth or melted LB agar (T<70°C) before use. 
10.1.4 SOB Medium 
20g Tryptone (BD) 
5g Yeast extract (BD) 
500mg NaCl  
ddH2O to 950ml 
10ml 250mM KCl 
pH to 7.0 with ~200l 5N NaOH 
ddH2O to 1l and autoclaved for 20 minutes at 15 psi, 121°C 
10.1.5 SOC Medium 
Assembled under sterile conditions: 
10ml sterile SOB medium 
200l sterile 1M glucose 
100l 1M MgCl2 
10.1.6 40% Glucose 
40g Glucose 
ddH2O to 100ml and sterile filtered 
10.1.7 YPDA Medium 
20g/l Difco peptone (BD) 
10g/l  Yeast extract (BD) 
20g/l  Bacto agar (for plates only) (BD) 
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15ml/l 0.2% adenine hemisulfate 
ddH2O to 950ml and autoclaved for 20 minutes at 15 psi, 121°C 
50ml  sterile 40% glucose solution added under sterile conditions 
10.1.8 Synthetic Dextrose –Trp-Leu dropout medium (SD-Trp-Leu) 
26.7g Minimal SD Base (Clontech) 
640mg -Leu/-Trp DO Supplement (Clontech) 
20g/l Agar (for plates only) (BD) 
ddH2O to 950ml and autoclaved for 20 minutes at 15 psi, 121°C 
50ml  sterile 40% glucose solution added under sterile conditions  
10.2 Solutions yeast two-hybrid  
10.2.1 10x TE buffer 
100mM  Tris-HCl 
10mM  EDTA 
pH adjusted to 7.5 and autoclaved for 20 minutes at 15 psi, 121°C 
10.2.2 10x LiAc 
1M LiAc 
pH adjusted to 7.5 with dilute acetic acid and autoclaved for 20 minutes at 15 psi, 
121°C 
10.2.3 X-gal 
20mg/ml in Dimethylformamide, stored at -20°C in the dark 
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10.2.4 50% PEG  
Prepared with sterile ddH2O, warmed to 50°C for 30 minutes to dissolve PEG. 
10.2.5 Z buffer 
16.1g/l Na2HPO4·7H2O 
5.5g/l NaH2PO4·H2O 
750mg/l KCl 
246mg/l MgSO4·7H2O 
pH adjusted to 7.0 and autoclaved for 20 minutes at 15 psi, 121°C 
10.2.6 Z buffer/X-gal solution 
100ml Z buffer 
270l -mercaptoethanol 
1.67ml X-gal stock solution 
10.2.7 Z buffer with -mercaptoethanol 
100ml Z buffer 
270l -mercaptoethanol 
10.2.8 ONPG (o-nitrophenyl -D-galactopyranoside) 
ONPG was prepared fresh by dissolving 4mg/ml in Z buffer 1-2h before use, pH 
was adjusted to 7.0 
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10.3 Primer sequences 
Length = length of primer in number of nucleotides 
% GC = GC content of primer sequence 
Tm [°C] = melting temperature, based on nearest neighbor 
Tm F. [°C] = melting temperature, according to Finnzyme Tm calculator (for use with 
Phire polymerase) 
Nucleotides in bold and italic = restriction enzyme recognition sites 
Nucleotides underlined = mutagenesis (site-directed nucleotide exchanges or insertions) 
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Overview of Qualifications 
 Experienced in a broad range of laboratory research techniques:  
o Cellular biology (cell culture of HeLa, HEK293, primary chondrocytes; 
histocytochemistry; transfections) and tissue engineering (human and ovine articular 
cartilage) 
o Molecular biology (PCR, cloning, mutagenesis) 
o Bioinformatics analysis (UCSC Genome browser, BLAST, Mfold) 
o Protein biochemistry (expression in cell culture, purification, SDS PAGE, Western 
blotting, in vitro proteolysis, in vitro transcription/translation, radioblotting) 
 Managed high-risk project in start-up biotech company 
 Demonstrated effective prioritization of several research projects while efficiently managing 
numerous other responsibilities in research, teaching, and services 
 Accustomed to be accountable for the planning, preparation and completion of projects with a 
budget 
 Experienced working in interdisciplinary, international, and collaborative settings 
Education 
Ph.D., Molecular Biology, Lehigh University, Bethlehem, PA, USA, defended September 30
th
 
2011, accepted October 28
th
 2011, expected graduation January 2012 
M.Sc., Biological Sciences, Swiss Federal Institute of Technology Zurich (ETH), Zurich, 
Switzerland, 2002 
Employment and Work Experience 
Research Assistant, Lehigh University, Bethlehem, PA, USA 2007 – 2011 
 Planned and supervised six undergraduate research projects over the past four years 
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 Mentored undergraduates to develop hypotheses, plan experiments, and present research 
Teaching Assistant, Lehigh University, Bethlehem, PA, USA 2007 – 2011 
 Research lab course (Science Education Alliance program, HHMI) 
 Graduate student research fellow to BDSI, an interdisciplinary research initiative by 
HHMI 
 Recitation courses (Genetics, Cellular and Molecular Biology) 
Management Assistant, AIM International AG, Lucerne, Switzerland 2006 
 Administrative work, travel and meeting arrangements, implementation of filing system 
Project Manager (R&D), Millenium Biologix AG, Schlieren, Switzerland 2003 –2005 
 Tissue engineering of articular cartilage for the generation of implants for joint defects 
 Planned and managed pilot animal trial (sheep) 
 Part of interdisciplinary/international team to develop an automated cell culture system 
(ACTES) 
Intern, Veterinary Research Institute (VUVEL), Brno, Czech Republic 2002 –2003  
 Identification of Mycobacteria in animals with Tuberculosis and Crohn‟s patients 
(multiplex PCR) 
Tutorial Assistant, Swiss Federal Institute of Technology, Switzerland „01 –„02  
 Part-time assistant at the Institutes of Plant Physiology and Microbiology 
Publications 
Godfried Sie, C.P., Kuchka, M. RNA editing adds flavor to complexity. Biochemistry (Moscow) 
2011; 76(8): 869-881. 
Maas, S., Godfried Sie, C.P., Loev, I., et al. Genome-wide evaluation and discovery of 
vertebrate A-to-I RNA editing sites. Biochemical Biophysical Research Communications 
2011; 412(3): 407-12. 
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Sie, C.P. and Maas, S. Conserved recoding RNA editing of vertebrate C1q-related factor C1QL1. 
FEBS Letters 2009; 583: 1171-1174.  
Gommans, W.M., Tatalias, N.E., Sie, C.P. et al. Screening of human SNP database identifies 
recoding sites of A-to-I RNA editing. RNA 2008; 14(10): 1-12.  
Skibbens, R.V., Sie, C.P., Eastman, L. Role of chromosome segregation genes in BRCA1-
dependent lethality. Cell Cycle 2008; 7(13): 2071-2. 
Francioli, S.-E., Martin, I., Sie, C.P., et al. Growth Factors for Clinical-Scale Expansion of 
Human Articular Chondrocytes: Relevance for Automated Bioreactor Systems. Tissue Eng. 
2007; 13(6): 1227-1234.  
Invited Talks and Seminars 
Godfried Sie, C.P. Understanding the lack of A-to-I RNA editing in a highly predicted ADAR 
target. 
 Department of Biological Sciences Seminar, Lehigh University, PA, April 2011 
Godfried Sie, C.P., Kuchka, M. and Maas, S. Anatomy of a perfect ADAR target that is not 
edited in vivo. 
 Gordon Research Conference on RNA Editing, Galveston, TX, January 2011 
Godfried Sie, C.P. Identification and Characterization of A-to-I RNA Editing Targets.  
 Department of Biological Sciences Seminar, Lehigh University, PA, March 2010 
Sie, C.P. The Cellular Cytoskeleton.  
 Guest Speaker “Cellular and Molecular Biology, Core I”, Lehigh University, PA, March 
2008 
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Conferences and Meetings 
Gordon Research Conference on RNA Editing, Galveston, TX Jan. 2011 
 Editing and Modification of RNA and DNA. Invited talk and poster presentation. 
American Society of Cell Biology 50
th
 Annual Meeting, Philadelphia, PA Dec.2010 
RNA Biology, Philadelphia RNA Club, Philadelphia, PA  Mar. 2009 
Gordon Research Conference on RNA Editing, Galveston, TX Jan. 2009 
 Roles of RNA and DNA editing and Modification in Cellular Function. Poster presentation. 
The Biology of Small RNA, Newark, DE  Apr. 2008 
American Society of Cell Biology 46
th
 Annual Meeting, San Diego, CA Dec. 2006 
Bioimaging and Engineered Biosystems, Bethlehem, PA  Sept. 2006 
Regenerative Medicine Showcase, Ann Arbor, MI  May 2005 
Strategies in Tissue Engineering, Würzburg, Germany  June 2004 
Awards and Funding 
Fellowships and Funding: 
 Sigma Delta Epsilon-Graduate Women in Science (GWIS) fellowship 2011 
 Sigma Xi Grants in Aid of Research (GIAR) 2011 
 Nemes Fellowship, Department of Biological Sciences, Lehigh University 2009 and 2011 
 Lehigh University Forum Student Research Grant  2010 
 CAS Graduate Research Fund, Lehigh University 2010 
 Datatel Scholars Foundation Scholarship  2007/08 and 2009/10 
 Biosystems Dynamics Summer Institute Research Fellowship  2008 
 Medicus Scholarship, Swiss Benevolent Society NY  2007-2008 
 Lehigh University Fellowship award  2006-2007 
Awards: 
 Graduate Student Merit Award, Alumni Association of Lehigh University 2011 
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Other Skills and Interests 
Computer skills: 
 Microsoft Office, basic level Photoshop, EndNote 
 Leadership Programs and Workshops: 
Iacocca Institute Workshops, Iacocca Institute, Bethlehem PA 2009/2010 
Teacher Development Program, Lehigh University, Bethlehem PA 2009/2010 
Competence in Project Management, Zurich, Switzerland 2005 
Languages:  
 Fluent in German and English, conversation level French and Spanish, basic level Italian 
Services 
Student Services Committee to the graduate student body of Lehigh University, Bethlehem, PA, 
2011-2012 
Graduate Liaison Officer to the Graduate Student Committee at the Department of Biological 
Sciences, Lehigh University, Bethlehem, PA, 2011 
Representative of the Graduate Students of Biological Sciences at the Graduate Student Senate, 
Lehigh University, Bethlehem, PA, 2010 
Founder of the Lehigh Valley German Speaking Group (weekly meetings, special events), June 
2009 
PJAS Judge at the Pennsylvania Junior Academy of Science regional competition in Easton, PA, 
2009/2010/2011 
Volunteer for the Lehigh River and Stream Clean-up, Bethlehem, PA, spring 2009 
Participant of the Relay for Life Fundraiser, Bethlehem, PA, 2008 
 
